Solubility for target compounds

ABSTRACT

The present disclosure relates to compounds having an improved solubility thereby increasing their bioavailability, lower dosages, etc. The target compounds, may include but are not limited to, macrophage migration inhibitory factor (MIF) inhibitors, epidermal growth factor receptor (EGRF) inhibitors, kinase inhibitors and prodrugs of alpha4 beta1 and alpha4 beta7 integrin antagonists. An illustrative compound is shown below:

CLAIM OF PRIORITY

This application claims priority to U.S. application Ser. No. 15/250,336filed on Aug. 29, 2016 which claims priority to U.S. Application62/214,519 filed on Sep. 4, 2015, the contents of which are herein fullyincorporated by reference in its entirety.

FIELD OF THE EMBODIMENTS

The field of the embodiments of the present invention relate tocompounds having improved solubility thereby increasing theirbioavailability. In particular, the present invention relates to thesynthesis and applications of such target compounds.

BACKGROUND OF THE EMBODIMENTS

Isosorbide is a heterocyclic compound derived from glucose. Isosorbidehas two isomers, namely two diastereomers, isomannide and isoidide,which belong to a class of compounds called 1,4;3,6-dianhydrohexitols.Isosorbide is essentially two fused tetrahydrofuran rings having acis-arrangement at the ring junction, providing for a wedge-shapedmolecule. The compound bears two hydroxyl groups, one at C₆ having anexo-orientation with respect to the wedge-shaped molecule, and the otherat C₃ having the endo-orientation. This spatial relationship is whatfacilitates the intramolecular hydrogen bonding with the oxygen atom ofthe neighboring tetrahydrofuran ring (see below).

Overall, and in part to its derivation from starches, isosorbide ishighly stable, non-toxic, inexpensive, and commercially available inlarge quantities. Moreover, it bears two hydroxyl groups, whichdescribed below, allow further chemical modification of the isosorbidecore. Isosorbide is thus an attractive and versatile chemical platformfor many in academia and industry research.

Isosorbide and its derivatives have been utilized in polymer materialsfor, amongst others, the synthesis of biodegradable polymers,plasticizers, solvents, and surfactants. In other more limited usages,isosorbide and use of its derivatives have been reported in the medicalfield with the exception of isosorbide mononitrate, which has seenprominence in the pharmaceutical industry. Some of the other morelimited medical applications include, but are not limited to, uses as adiuretic and in treating glaucoma. Other medications derived fromisosorbide, include isosorbide dinitrate which, along with isosorbidemononitrate, are used to treat angina pectoris. Other isosorbide-basedmedicines are used as osmotic diuretics and for treatment of esophagealvarices. Further, isosorbide dinitrate and hydralazine are the twocomponents of the anti-hypertensive drug isosorbidedinitrate/hydralazine.

Notwithstanding the above, many derivatives of isosorbide (Isoidide,3-exo and 6-exo substitution) are very difficult to make usingconventional approaches. In practice, one use the disparate reactivityof the two hydroxyl groups (endo and exo) of isosorbide, to selectivelyreact one of isosorbide's two hydroxyl groups with an introduced group.For example, under the purview of the present invention, the endohydroxyl group may be selectively reacted with active phenols orcarboxylic acids under slightly modified Mitsunobu reaction conditionswithout touching, or reacting, the exo hydroxyl group. Theregioselective synthesis of this kind of mono substitution etherderivatives in one step has yet to be reported in the literature.

Although there is a different chemical reactivity for two hydroxylgroups with endo and exo orientations, there has been limited success inmaking selective mono substituted isosorbide derivatives withoutprotection, with the exception of acetylation in the presence of metalsalts such as lead oxide (Synthesis, 1987, 174-176). The alkylation,benzylation (Carbohydrate Research, 1994, 261, 255-266), esterification(Synthesis, 1989, 610-612), tosylation (Can. J. Chem., 1960, 38,136-140), silylation or etherification under Mitsunobu reactionconditions (Synlett, 2003, 11, 1683-1687, Tetrahedron, 1999, 55,10713-10734) of isosorbide produced a mixture of endo or exomono-substituted derivatives with some extent bis-derivative (endo,exo). Whereas, the chemical reactivity of both hydroxyl groups ofisomannide or isoidide are difficult to differentiate for selectivechemical reactions.

The present application provides for an invention and variousembodiments that describes the selective etherification oresterification of the endo hydroxyl group of isosorbide without touchingthe exo hydroxy group under slightly modified Mitsunobu reactionconditions (Synthesis, 1981, 1) that provide the derivatives of(3S,3aR,6S,6aR)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diol(isoidide core). The present application also describes this chemicalreaction for the synthesis of MIF (macrophage migration inhibitoryfactor) inhibitors, EGFR (epidermal growth factor receptor) inhibitors,kinase targeting compounds, and prodrugs of alpha4 beta1 and alpha4beta7 integrin antagonists.

SUMMARY OF THE EMBODIMENTS

One aspect of this invention is the provision of compounds,compositions, and kits for the improved solubility of target compounds,including but not limited to, macrophage migration inhibitory factor(MIF) inhibitors, epidermal growth factor receptor (EGFR) inhibitors,kinase inhibitors, and prodrugs of alpha4 beta1 and alpha4 beta7integrin antagonists. Such applications are contained under the purviewof a compound of Formula I:

-   -   wherein:    -   R₁ is -aryl, -heteroaryl, or C(O)R₃, wherein        -   i) each of said aryl or heteroaryl may additionally be fused            with an independently selected aryl or heteroaryl; and        -   ii) each of said aryl, heteroaryl, and alkyl is either            unsubstituted or substituted with 1, 2, 3, 4 or 5            substituents which can be the same or different and are            independently selected from the group consisting of halo,            hydroxyl, cyano, oxo, amino, aminoalkyl-, (amino)alkoxy-,            -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy,            aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl,            -aryl(halo), -heteroaryl, C(O)OC_(n), —NR^(a)R^(b);            deuterium, hydroxyl-alkyl-, hydroxyl-aryl-, amino,            aminoalkyl, (amino)alkoxy-, —CONH₂, —C(O)NH(alkyl),            —C(O)N(alkyl)₂, —C(O)NH(aryl), —C(O)N(aryl)₂, —CH_(z)F₃-z,            —OCH_(z)F_(3-z), (alkoxyalkyl)amino-, —O(alkyl), —O(aryl),            O(heteroaryl), —NH(SO₂)alkyl, —NH(SO₂)aryl,            —NH(SO₂)heteroaryl, -(aryl)alkyl-, —S(O)₂-alkyl,            —S(O)₂-aryl, —C(O)alkyl, —NHC(O)-alkyl, NH—, —NH—C(O)—            R^(c)—(O)alkyl, —NH—C(O)-aryl, —NH—C(O)—NH-alkyl, NH—C(O)—            NH—C(O)—NH-aryl, —NH—C(O)—O-alkyl, —NH(R^(c))—C(O)-alkyl,            —NH(R^(c))—C(O)-aryl, —S(O₂)NH₂, —S(O₂)NH(alkyl),            —S(O₂)N(alkyl)₂, —C(O)N(H)(alkyl), —CH_(z)F_(3-z),            —OCH_(z)F_(3-z);    -   R₂ is hydrogen, hydroxyl, or a group selected from -oxy(alkyl),        -oxy(alkene), alkyl, -alkenyl, -oxy(alkyl)-aryl, -oxyalkynyl,        OC(O)(alkyl), OC(O)(haloalkyl), and OC(O)(aryl) which is either        substituted or non-substituted and straight or branched, where        the substituents can be the same or different and are from the        group consisting of oxo or halo;    -   R₃ is an alkyl, alkoxy(alkyl), substituted or unsubstituted        monocyclic or bicyclic aryl or heteroaryl, or alkyl(aryl), the        substituted or unsubstituted monocyclic or bicyclic heteroaryl        having 0, 1, 2 or 3 heteroatoms independently selected from N,        O, or S; R^(a) is an alkyl, alkoxy(alkyl), substituted or        unsubstituted monocyclic or bicyclic aryl or heteroaryl, or        alkyl(aryl), the substituted or unsubstituted monocyclic or        bicyclic heteroaryl having 0, 1, 2 or 3 heteroatoms        independently selected from N, O, or S; R^(b) is hydrogen or        halo;    -   R^(c) is hydrogen, halo, or alkyl;    -   ------ is an optional bond that is present only when R₂ is        hydrogen;    -   n is 0, 1, 2, or 3; and    -   z is 0, 1, or 2.

Another aspect of this invention is the provision of compounds,compositions, and kits for the improved solubility of target compounds,including but not limited to, macrophage migration inhibitory factor(MIF) inhibitors, epidermal growth factor receptor (EGFR) inhibitors,kinase inhibitors, and prodrugs of alpha4 beta1 and alpha4 beta7integrin antagonists of Formula II:

-   -   wherein:    -   R₂ is hydrogen, hydroxyl, or a group substituted or        non-substituted and straight or branched selected from        -oxy(alkyl), -oxy(alkene), alkyl, -alkenyl, -alkynyl,        —OC(O)(alkyl), —OC(O)(haloalkyl), and —OC(O)(aryl);    -   R₄ is cyano, amino, aminoalkyl-, alkyl, -alkyl(aryl),        substituted or non-substituted aryl, if substituted then        substituted with 1, 2, 3, 4 or 5 substituents which can be the        same or different and are independently selected from the group        consisting of halo, hydroxyl, cyano, oxo, amino, aminoalkyl-,        alkyl(arylhalide), (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl,        alkoxy-, hydroxy, -alkylhydroxy, -alkyl(aryl), aryloxy-,        -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo),        -heteroaryl, C(O)OC_(n), —NR^(a)R^(b); deuterium,        hydroxyl-alkyl-, hydroxyl-aryl-, amino, aminoalkyl;    -   R₅ is C(O)R^(c) or cyano;    -   R^(c) is hydrogen, or a group, substituted or unsubstituted,        selected from straight or branched C₁ to C₃ alkyl, CF₃, alkoxy,        aryl, and monocyclic or bicyclic heteroaryl having one to three        heteroatoms independently selected from O, S, and N and if        substituted then substituted with 1, 2, 3, 4 or 5 substituents        which can be the same or different and are independently        selected from the group consisting of halo, hydroxyl, cyano,        oxo, amino, aminoalkyl-, ethoxy, (amino)alkoxy-, -alkyl,        -alkenyl, -alkynyl, alkoxy-, hydroxy,        -alkylhydroxy,-alkyl(aryl), aryloxy-, -alkyl(aryl),        (alkoxyalkyl)amino-, -aryl, -aryl(halo),-heteroaryl, C(O)OC_(n),        —NR^(a)R^(b); deuterium, hydroxyl-alkyl-, hydroxyl-aryl-, amino,        aminoalkyl; and    -   Y is S or O.

Still another aspect of this invention is the provision of compounds,compositions, and kits for the improved solubility of target compounds,including but not limited to, macrophage migration inhibitory factor(MIF) inhibitors, epidermal growth factor receptor (EGFR) inhibitors,kinase inhibitors, and prodrugs of alpha4 beta1 and alpha4 beta7integrin antagonists of Formula III:

wherein;R₆ is hydrogen, halo, CN, alkyl, alkoxy, aryloxy, aryl, and SO₂(alkyl);R₇ is hydrogen, C(O)R^(c), alkyl, haloalkyl, alkenyl, alkynyl, and—CH₂(aryl);Ar is a substituted or non-substituted monocyclic or bicyclicheteroaryl, with one to four heteroatoms independently selected from O,S, and N, wherein the substituents are selected from the groupconsisting of halo, hydroxyl, oxy, cyano, amino, aminoalkyl-,(amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy,NR^(a)R^(b), OC_(n), —CH_(z)F_(3-z), —OCH_(z)F_(3-z), aryloxy-,(alkoxyalkyl)amino-, —O(alkyl), —O(aryl), —O(heteroaryl),—C(O)NH(alkyl), —C(O)N(aryl)₂, —NH(SO₂)alkyl, —NH(SO₂)aryl,—NH(SO₂)heteroaryl, (aryl)alkyl-, -heteroaryl, (heteroaryl)alkyl-,—S(O)₂-alkyl, —S(O)₂-aryl, —C(O)N(alkyl)₂, —C(O)alkyl, —NHC(O)-alkyl,—NH—C(O)— R^(c)—(O)alkyl, —NH—C(O)-aryl, —NH—C(O)—NH-alkyl,NH—C(O)—NH-aryl, —NH—C(O)—O-alkyl, —NH(R^(c))—C(O)-alkyl,—NH(R^(c))—C(O)-aryl, —S(O₂)NH₂, —S(O₂)NH(alkyl), —S(O₂)N(alkyl)₂,—C(O)N(H)(alkyl), —CH_(z)F_(3-z), —OCH_(z)F_(3-z), or -alkyl(aryl); and

-   -   R^(c) is hydrogen, or a group, substituted or unsubstituted,        selected from straight or branched C₁ to C₃ alkyl, alkenyl,        alkynyl, CF₃, alkoxy, aryl, and monocyclic or bicyclic        heteroaryl having one to three heteroatoms independently        selected from O, S, and N and if substituted then substituted        with 1, 2, 3, 4 or 5 substituents which can be the same or        different and are independently selected from the group        consisting of halo, hydroxyl, cyano, oxo, amino, aminoalkyl-,        ethoxy, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-,        hydroxy, -alkylhydroxy,-alkyl(aryl), aryloxy-, -alkyl(aryl),        (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl,        C(O)OC_(n), —NR^(a)R^(b); deuterium, hydroxyl-alkyl-,        hydroxyl-aryl-, amino, aminoalkyl.

Still another aspect of this invention is the provision of compounds,compositions, and kits for the improved solubility of target compounds,including but not limited to, macrophage migration inhibitory factor(MIF) inhibitors, epidermal growth factor receptor (EGFR) inhibitors,kinase inhibitors, and prodrugs of alpha4 beta1 and alpha4 beta7integrin antagonists of Formula IV:

-   -   wherein;    -   R₆ is hydrogen, halo, CN, alkyl, alkoxy, aryloxy, aryl, and        SO₂(alkyl);    -   R₇ is hydrogen, C(O)R^(c), alkyl, alkenyl, alkynyl, and        —CH₂(aryl);    -   R₈ is substituted or non-substituted aryl or cycloalkyl or        heterocycloalkyl, wherein the substituents are selected from the        group consisting of straight or branched alkyl, halo, hydroxyl,        oxy, cyano, amino, dimethylpropanone, aminoalkyl-,        (amino)alkoxy-, -alkyl(arylhalide), -alkyl, -alkenyl, -alkynyl,        alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl),        —SO₂(aryl), —SO₂(alkyl), (alkoxyalkyl)amino-, -aryl,        -heteroaryl, C(O)C_(n), C(O)OC_(n), —NR^(a)R^(b), and deuterium;    -   R^(c) is substituted or unsubstituted aryl, substituted or        unsubstituted alkyl, alkenyl, and alkynyl;    -   X is independently C, N, S, or O; and    -   n is 0, 1, or 2.

Another aspect of this invention is the provision of pharmaceuticalcompositions comprising therapeutically effective amounts of at leastone compound of Formula I, II, III, or IV.

Another preferred embodiment is a pharmaceutical formulation comprisinga pharmaceutically acceptable compound of the present invention, whichprovides, upon administration to a human, a decrease in tumor burdenand/or metastases. The pharmaceutical formulation can be administered byoral means or other suitable means.

Another preferred embodiment is a pharmaceutical formulation comprisinga pharmaceutically acceptable compound of the present invention fortreatment of a variety of cancers including but not limited to cervix,colon, breast, lung, non-small cell lung cancer, glioma and stomachcancers.

Another preferred embodiment is a pharmaceutical formulation comprisinga pharmaceutically acceptable compound of the present invention fortreatment hematologic cancer, such as but not limited to leukemia,lymphoma and multiple myeloma.

Another preferred embodiment is a pharmaceutical formulation comprisinga pharmaceutically acceptable compound of the present invention fortreatment of midline carcinomas, mesenchymal, hepatic, renal andneurological tumors.

Another preferred embodiment is a pharmaceutical formulation comprisinga pharmaceutically acceptable compound of the present invention fortreatment of melanoma, squamous cell carcinoma and cutaneous T-celllymphoma.

Another preferred embodiment is a pharmaceutical formulation comprisinga pharmaceutically acceptable compound of the present invention fortreatment of a variety of diseases or conditions related to systemic ortissue inflammation, inflammatory responses to infection or hypoxia,cellular activation and proliferation, lipid metabolism, fibrosis and inthe prevention and treatment of viral infections.

Another preferred embodiment is a pharmaceutical formulation comprisinga pharmaceutically acceptable compound of the present invention fortreatment of a variety of chronic and inflammatory conditions, includingbut not limited to rheumatoid arthritis, osteoarthritis, acute gout,psoriasis, systemic lupus erythematosus, multiple sclerosis, Crohn'sdisease, ulcerative colitis, asthma, chronic obstructive airwaysdisease, pneumonitis, myocarditis, pericarditis, myositis, eczema,dermatitis, alopecia, vitiligo, bullous skin disease, nephrititis,vasculitis, atherosclerosis, Alzheimer's disease, depression, Sjogren'ssyndrome, siloadenitis, central retinal vein occlusion, branched retinalvein occlusion, Irvine-Gass syndrome, parafoveal telangiectasis,retinitis pigmentosa, pars planitis, birdshot retinochoroidopathy,epiretinal membrane, cystic macular edema, maculopathies, vitreomaculartraction syndromes, retinal detachment, neuroretinitis, idiopathicmacular edema, retinitis, dry eye, vernal keratoconjuctivitis, atopickeratoconjuctivitis, anterior uveitis, pan uveitis, posterior uveitis,uveitis-associated macular edema, scleritis, diabetic retinopathy,diabetic macular edema, age-related macular dystrophy, hepatitis,pancreatitis, primary biliary cirrhosis, sclerosing cholangitis,Addison's disease, hypophysitis, thyroiditis, type I diabetes and acuterejection of transplanted organisms.

Another preferred embodiment is a pharmaceutical formulation comprisinga pharmaceutically acceptable compound of the present invention fortreatment of a variety of acute inflammatory conditions such as acutegout, giant cell arteritis, nephritis including lupus nephritis,vasculitis with organ involvement such as glomerulonephritis, vasculitisincluding giant cell arteritis, Wegner's granulomatosis, Polyarteritisnodosa, Becet's disease, Kawasaki disease, Takayasu's arteritis,pyoderma gangrenosum, vasculitis with organ involvement and acuterejection of transplanted organs.

Another preferred embodiment is a pharmaceutical formulation comprisinga pharmaceutically acceptable compound of the present invention fortreatment of a variety of diseases or conditions which involveinflammatory responses to infections with bacteria, viruses, fungi,parasites or their toxins, such as but not limited to sepsis, sepsissyndrome, septic shock, endotoxaemia, systemic inflammatory responsesyndrome, multi organ dysfunction syndrome, toxic shock syndrome, acutelung injury, acute respiratory distress syndrome, acute renal failure,fulmiant hepatitis, burns, acute pancreatitis, post-surgical syndromes,sarcoidosis, Herxheimer reactions, encephalitis, myelitis, meningitis,malaria, systemic inflammatory responses associated with viralinfections, such as but not limited to influenza, herpes zoster, herpessimplex and coronavirus.

Another preferred embodiment is a pharmaceutical formulation comprisingpharmaceutically acceptable compound of the present invention fortreatment of a variety of conditions associated with ischaemiareperfusion injury such as myocardial infarction, cerebrovascularischaemia, acute coronary syndromes, renal reperfusion injury, organtransplantation, coronary artery bypass procedures, cardio-, pulmonaryand bypass procedures, pulmonary, renal, hepatitic, gastrointestinal orperipheral limb embolism.

Another preferred embodiment is a pharmaceutical formulation comprisinga pharmaceutically acceptable compound of the present invention fortreatment of a variety of disorders of lipid metabolisms such ashypercholesterolemia, atherosclerosis and Alzheimer disease.

Another preferred embodiment is a pharmaceutical formulation comprisinga pharmaceutically acceptable compound of the present invention fortreatment of a variety of fibrotic conditions such as, but not limitedto idiopathic pulmonary fibrosis, renal fibrosis, post-operativestructure, keloid scar formation, scleroma and cardial fibrosis.

Another preferred embodiment is a pharmaceutical formulation comprisinga pharmaceutically acceptable compound of the present invention fortreatment of a variety of viral infections such as, but not limited toherpes virus, human papilloma virus, adenovirus, poxvirus, andDNA-viruses in general.

Another preferred embodiment is a pharmaceutical formulation comprisinga pharmaceutically acceptable compound of the present invention fortreatment of a variety of conditions such as non-malignant melanoma,actinic keratosis, basal cell melanoma, in situ melanoma, squamous cellcarcinoma and cutaneous T-cell lymphoma.

Another preferred embodiment is a pharmaceutical formulation comprisinga pharmaceutically acceptable compound of the present invention fortreatment of obesity.

Another preferred embodiment is a pharmaceutical formulation comprisinga pharmaceutically acceptable compound of the present invention for malecontraceptive.

Yet another embodiment is a method of treating a disease associated withsystemic inflammatory response syndrome, such as but not limited tosepsis, burns, pancreatitis, major trauma, hemorrhage and ischaemia.

Another preferred embodiment is a method to reduce incidence of SIRS,onset of shock, multi-organ dysfunction syndrome, acute lung injury,acute renal hepatic, cardiac and gastrointestinal injury at the point ofdiagnosis by administering compounds of this disclosure.

Another preferred embodiment is a method to reduce incidence of sepsis,hemorrhage, tissue damage, and multiple organ dysfunction before surgeryor any procedure with high risk of sepsis.

Pharmaceutical compositions of this invention may be administered by anyappropriate way: orally, including buccal or sublingual, rectal,inhaled, intranasal, topical, ocular, vaginal or parenteral, includingsubcutaneous, intramuscular, intravenous and intradermal route.

Yet another embodiment is a method of preparing a pharmaceuticalformulation of the present invention by mixing at least onepharmaceutically acceptable compound of the present invention, and,optionally, one or more pharmaceutically acceptable additives orexcipients.

According to one embodiment of this invention is a method of preparing apharmaceutical formulation of the present invention by mixing at leastone pharmaceutically acceptable compound of the present invention andone or more additional therapeutic agents.

According to one embodiment of the invention the additional therapeuticagents may be selected from the group consisting of cytotoxic agent,cisplatin, doxorubicin, taxotere, taxol, etoposide, irinotecan,camptostar, topotecan, paclitaxel, docetaxel, the epothilones,tamoxifen, 5-fluorouracil, methotrexate, temozolomide, cyclophosphamide,SCH 66336, tipifarnib (Zarnestra®), R115777, L778,123, BMS 214662,Iressa®, Tarceva®, C₂₂₅, GLEEVEC®, Intron®, Peg-Intron®, aromatasecombinations, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard,Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman,Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine,Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine,6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, leucovirin,oxaliplatin (ELOXATIN®), Pentostatine, Vinblastine, Vincristine,Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin,Idarubicin, Mithramycin™, Deoxycoformycin, Mitomycin-C, L-Asparaginase,Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone,Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone,Megestrol acetate, Methylprednisolone, Methyltestosterone, Prednisolone,Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide,Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide,Toremifene, goserelin, Carboplatin, Hydroxyurea, Amsacrine,Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene,Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine,Hexamethylmelamine, Avastin, herceptin, Bexxar, Velcade, Zevalin,Trisenox, Xeloda, Vinorelbine, Porfimer, Erbitux, Liposomal, Thiotepa,Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane,Rituximab, C225, Campath, leucovorin, dexamethasone, bicalutamide,carboplatin, letrozole, megestrol, and valrubicin.

For preparing pharmaceutical compositions from the compounds describedin this disclosure inert, pharmaceutically acceptable carriers can beeither solid or liquid. Solid form preparations include powders,tablets, dispersible granules, capsules, cachets and suppositories. Thepowders and tablets may be comprised of from about 5 percent to about 95percent active ingredient. Suitable solid carriers are known in the art,e.g., magnesium carbonate, magnesium stearate, talc, sugar or lactose.Tablets, powders, cachets and capsules can be used as solid dosage formssuitable for oral administration. Examples of pharmaceuticallyacceptable carriers and methods of manufacture for various compositionsmay be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences,18th Edition, (1990), Mack Publishing Co., Easton, Pa.

Liquid form preparations include solutions, suspensions and emulsions.For example, water or water-propylene glycol solutions for parenteralinjection or addition of sweeteners and opacifiers for oral solutions,suspensions and emulsions. Liquid form preparations may also includesolutions for intranasal administration.

Aerosol preparations suitable for inhalation may include solutions andsolids in powder form, which may be in combination with apharmaceutically acceptable carrier, such as an inert compressed gas,e.g. nitrogen.

Also included are solid form preparations that are intended to beconverted, shortly before use, to liquid form preparations for eitheroral or parenteral administration. Such liquid forms include solutions,suspensions and emulsions.

The compounds of the invention may also be deliverable transdermally.The transdermal compositions can take the form of creams, lotions,aerosols and/or emulsions and can be included in a transdermal patch ofthe matrix or reservoir type as are conventional in the art for thispurpose.

If formulated as a fixed dose, such combination products employ thecompounds of this invention within the dosage range described herein, oras known to those skilled in the art.

Since the compounds of this invention are intended for use inpharmaceutical compositions a skilled artisan will understand that theyare each preferably provided in substantially pure forms for example, atleast 60% pure, more suitably at least 75% pure, preferably at least 85%pure and most preferably at least 98% pure (w/w).

Preferably, the pharmaceutical preparation is in a unit dosage form. Insuch form, the preparation is subdivided into suitably sized unit dosescontaining appropriate quantities of the active component, e.g., aneffective amount to achieve the desired purpose.

The quantity of active compound in a unit dose of preparation may bevaried or adjusted from about 1 mg to about 1000 mg, preferably fromabout 1 mg to about 500 mg, more preferably from about 1 mg to about 250mg, still more preferably from about 1 mg to about 25 mg, according tothe particular application.

The actual dosage employed may be varied depending upon the requirementsof the patient and the severity of the condition being treated.Determination of the proper dosage regimen for a particular situation iswithin the skill of the art. For convenience, the total daily dosage maybe divided and administered in portions during the day as required.

The amount and frequency of administration of the compounds of theinvention and/or the pharmaceutically acceptable salts thereof will beregulated according to the judgment of the attending clinicianconsidering such factors as age, condition and size of the patient aswell as severity of the symptoms being treated. A typical recommendeddaily dosage regimen for oral administration can range from about 1mg/day to about 500 mg/day, preferably 1 mg/day to 200 mg/day, in two tofour divided doses.

Definitions

As used above, and throughout this disclosure, the following terms,unless otherwise indicated, shall be understood to have the followingmeanings. If a definition is missing, convention definition as known toone skilled in the art controls.

As used herein, the terms “including,” “containing,” and “comprising”are used in their open, non-limiting sense.

As used herein, the singular forms “a,” “an,” and “the” include pluralreferents unless the context clearly dictates otherwise.

To provide a more concise description, some of the quantitativeexpressions given herein are not qualified with the term “about”. It isunderstood that, whether the term “about” is used explicitly or not,every quantity given herein is meant to refer to the actual given value,and it is also meant to refer to the approximation to such given valuethat would reasonably be inferred based on the ordinary skill in theart, including equivalents and approximations due to the experimentaland/or measurement conditions for such given value. Whenever a yield isgiven as a percentage, such yield refers to a mass of the entity forwhich the yield is given with respect to the maximum amount of the sameentity that could be obtained under the particular stoichiometricconditions. Concentrations that are given as percentages refer to massratios, unless indicated differently

The terms “effective amount” or “therapeutically effective amount” referto a sufficient amount of the agent to provide the desired biologicalresult. That result can be reduction and/or alleviation of the signs,symptoms, or causes of a disease, or any other desired alteration of abiological system. For example, an “effective amount” for therapeuticuse is the amount of the composition comprising a compound as disclosedherein required to provide a clinically significant decrease in adisease. An appropriate “effective amount” in any individual case may bedetermined by one of ordinary skill in the art using routineexperimentation. Thus, the expression “effective amount” generallyrefers to the quantity for which the active substance has therapeuticeffects.

As used herein, the terms “treat” or “treatment” are synonymous with theterm “prevent” and are meant to indicate a postponement of developmentof diseases, preventing the development of diseases, and/or reducingseverity of such symptoms that will or are expected to develop. Thus,these terms include ameliorating existing disease symptoms, preventingadditional symptoms, ameliorating or preventing the underlying metaboliccauses of symptoms, inhibiting the disorder or disease, e.g., arrestingthe development of the disorder or disease, relieving the disorder ordisease, causing regression of the disorder or disease, relieving acondition caused by the disease or disorder, or stopping or alleviatingthe symptoms of the disease or disorder.

By using the terms “pharmaceutically acceptable” or “pharmacologicallyacceptable” it is intended to mean a material which is not biologicallyor otherwise undesirable—the material may be administered to anindividual without causing any substantially undesirable biologicaleffects or interacting in a deleterious manner with any of thecomponents of the composition in which it is contained.

“Carrier materials” or what are also referred to as “excipients” includeany commonly used excipients in pharmaceutics and should be selected onthe basis of compatibility and the release profile properties of thedesired dosage form. Exemplary carrier materials include, e.g., binders,suspending agents, disintegration agents, filling agents, surfactants,solubilizers, stabilizers, lubricants, wetting agents, diluents, and thelike.

“Pharmaceutically compatible carrier materials” may comprise, e.g.,acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate,calcium lactate, maltodextrin, glycerine, magnesium silicate, sodiumcaseinate, soy lecithin, sodium chloride, tricalcium phosphate,dipotassium phosphate, sodium stearoyl lactylate carrageenan,monoglyceride, diglyceride, pregelatinized starch, and the like. See,e.g., Hoover, John E., Remington's Pharmaceutical Sciences, MackPublishing Co., Easton, Pa. 1975.

The present invention also includes “prodrugs” of compounds of theinvention. The term “prodrug” includes any covalently bonded carriersthat release an active parent drug of the present invention in vivo whensuch prodrug is administered to an animal. Release of the activeingredient occurs in vivo. Prodrugs can be prepared by techniques knownto one skilled in the art. These techniques generally modify appropriatefunctional groups in a given compound. These modified functional groups,however, regenerate original functional groups by routine manipulationor in vivo. Prodrugs of compounds of the present invention includecompounds wherein a hydroxy, amino, carboxylic, or a similar group ismodified. Examples of prodrugs include, but are not limited to esters(e.g., acetate, formate, and benzoate derivatives), carbamates (e.g.,N,N-dimethylaminocarbonyl) of hydroxy or amino functional groups incompounds of the invention, amides (e.g., trifluoroacetylamino,acetylamino, and the like), and the like. Since prodrugs are known toenhance numerous desirable qualities of pharmaceuticals (e.g.,solubility, bioavailability, manufacturing, transport, pharmacodynamics,etc.), the compounds of the present invention may be delivered inprodrug form. Prodrugs, for instance, may be bioavailable by oraladministration even when the parent drug is not. Thus, the presentinvention is intended to cover prodrugs of the presently claimedcompounds, methods of delivering the same, and compositions containingthe same. Generally speaking, prodrugs are derivatives of per se drugsthat after administration undergo conversion or metabolism to thephysiologically active species. The conversion may be spontaneous, suchas hydrolysis in the physiological environment, or may beenzyme-catalyzed. Prodrugs include compounds that can be oxidized,reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed,esterified, alkylated, dealkylated, acylated, deacylated,phosphorylated, and/or dephosphorylated to produce the active compound.

The terms “administered”, “administration”, or “administering” acompound will be understood to mean providing any compound of theinvention to an individual, including an animal, in need of treatment bybringing such individual in contact with, or otherwise exposing suchindividual to, such compound.

As used herein, “alkyl” means a straight chain or branched saturatedchain having from 1 to 10 carbon atoms. Representative saturated alkylgroups include, but are not limited to, methyl, ethyl, n-propyl,isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl,3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl,2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl,2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl,2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl,isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl and the like,and longer alkyl groups, such as heptyl, and octyl and the like. Analkyl group can be unsubstituted or substituted. Alkyl groups containingthree or more carbon atoms may be straight, branched or cyclized. Asused herein, “lower alkyl” means an alkyl having from 1 to 6 carbonatoms.

As used herein, an “alkenyl” includes an unbranched or branchedhydrocarbon chain having one or more double bonds therein. The doublebond of an alkenyl group can be unconjugated or conjugated to anotherunsaturated group. Illustrative alkenyl groups include, but are notlimited to, (C₂-C₈) alkenyl groups, such as ethylenyl, vinyl, allyl,butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl,2-ethylhexenyl, 2-propyl-2-butenyl, 4-(2-methyl-3-butene)-pentenyl andthe like. An alkenyl group can be unsubstituted or substituted.

As used herein, “alkynyl” includes an unbranched or branched hydrocarbonchain having one or more triple bonds therein. The triple bond of analkynyl group can be unconjugated or conjugated to another unsaturatedgroup. Suitable alkynyl groups include, but are not limited to, (C₂-C₆)alkynyl groups, such as ethynyl, propynyl, butynyl, pentynyl, hexynyl,methylpropynyl, 4-methyl-1-butynyl, 4-propyl-2-pentynyl,4-butyl-2-hexynyl and the like. An alkynyl group can be unsubstituted orsubstituted.

The terms “trifluoromethyl”, “sulfonyl”, and “carboxyl” include CF₃,SO₂, and CO₂H, respectively.

The term “hydroxyl” means an OH group;

The term “alkyl hydroxyl” or “hydroxyalkyl” means an alkyl group asdefined above, where the alkyl group has an OH group disposed thereon.

The term “alkoxy” as used herein includes —O-(alkyl), wherein alkyl isdefined above.

The term “aminoalkyl” as used herein means a group having one or morenitrogen atoms and one or more alkyl groups as defined above on thenitrogen.

“Aralkyl” or “arylalkyl” means an aryl-alkyl-group in which the aryl(discussed later) and alkyl are as previously described. Preferredaralkyls comprise a lower alkyl group. Non-limiting examples of suitablearalkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. Thebond to the parent moiety is through the alkyl.

It should also be noted that any carbon as well as heteroatom withunsatisfied valences in the text, schemes, examples and Tables herein isassumed to have the sufficient number of hydrogen atom(s) to satisfy thevalences.

When any variable (e.g., aryl, heterocycle, R², etc.) occurs more thanone time in any constituent or in the Formulas, its definition on eachoccurrence is independent of its definition at every other occurrence.

As used herein, the term “composition” is intended to encompass aproduct comprising the specified ingredients in the specified amounts,as well as any product which results, directly or indirectly, from thecombination of the specified ingredients in the specified amounts.

The term “halo” as used herein means a substituent having at least onehalogen selected from fluorine, chlorine, bromine, and iodine.

The term “cyano” as used herein means a substituent having a carbon atomjoined to a nitrogen atom by a triple bond.

The term “amino” as used herein means a substituent containing at leastone nitrogen atom. Specifically, amide-, carbamide-, urea, and sulfamidesubstituents are included in the term “amino”.

The term “(amino)alkoxy” as used herein means a substituent having atleast one amino group and at least one alkoxy group.

The term “aryloxy” as used herein means a substituent of the form Ar—O—where Ar is an aryl group as defined herein.

As used herein, the term “aryl” refers to a monocyclic, or fusedpolycyclic, aromatic carbocycle (ring structure having ring atoms thatare all carbon) having from 3 to 24 ring atoms per ring.

As used herein, the term “heteroaryl” refers to a monocyclic, or fusedpolycyclic, aromatic heterocycle (ring structure having ring atomsselected from carbon atoms as well as nitrogen, oxygen, and sulfurheteroatoms) having from 3 to 24 ring atoms per ring.

As used herein, the term “substituted” means that the specified group ormoiety bears one or more suitable substituents wherein the substituentsmay connect to the specified group or moiety at one or more positions.For example, an aryl substituted with a cycloalkyl may indicate that thecycloalkyl connects to one atom of the aryl with a bond or by fusingwith the aryl and sharing two or more common atoms.

As used herein, the term “unsubstituted” means that the specified groupbears no substituents.

As used herein, the term “optionally substituted” means that thespecified group is unsubstituted or substituted by one or moresubstituents.

When used as a therapeutic agent, the MIF, EGRF, and kinase inhibitorsdescribed herein may be administered with one or more physiologicallyacceptable excipients. A physiologically acceptable carrier or excipientis a formulation to which the compound can be added to dissolve it orotherwise facilitate its administration.

The dosage forms of the present invention, may contain a mixture of oneor more compounds of this invention, and may include additionalmaterials known to those skilled in the art as pharmaceuticalexcipients. Stabilizing additives may be incorporated into the deliveryagent solution. With some drugs, the presence of such additives promotesthe stability and dispersibility of the agent in solution. Thestabilizing additives may be employed at a concentration ranging fromabout 0.1 and 5% (W/V), preferably about 0.5% (W/V). Suitable, butnon-limiting, examples of stabilizing additives include gum acacia,gelatin, methyl cellulose, polyethylene glycol, carboxylic acids andsalts thereof, and polylysine. The preferred stabilizing additives aregum acacia, gelatin and methyl cellulose.

Acidifying agents (acetic acid, glacial acetic acid, citric acid,fumaric acid, hydrochloric acid, diluted hydrochloric acid, malic acid,nitric acid, phosphoric acid, diluted phosphoric acid, sulfuric acid,tartaric acid); Aerosol propellants (butane, dichlorodifluoro-methane,dichlorotetrafluoroethane, isobutane, propane,trichloromonofluoromethane); Air displacements (carbon dioxide,nitrogen); Alcohol denaturants (denatonium benzoate, methyl isobutylketone, sucrose octaacetate); Alkalizing agents (strong ammoniasolution, ammonium carbonate, diethanolamine, diisopropanolamine,potassium hydroxide, sodium bicarbonate, sodium borate, sodiumcarbonate, sodium hydroxide, trolamine); Anticaking agents (seeglidant); Antifoaming agents (dimethicone, simethicone); Antimicrobialpreservatives (benzalkonium chloride, benzalkonium chloride solution,benzelthonium chloride, benzoic acid, benzyl alcohol, butylparaben,cetylpyridinium chloride, chlorobutanol, chlorocresol, cresol,dehydroacetic acid, ethylparaben, methylparaben, methylparaben sodium,phenol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuricnitrate, potassium benzoate, potassium sorbate, propylparaben,propylparaben sodium, sodium benzoate, sodium dehydroacetate, sodiumpropionate, sorbic acid, thimerosal, thymol); Antioxidants (ascorbicacid, ascorbyl palmitate, butylated hydroxyanisole, butylatedhydroxytoluene, hypophosphorous acid, monothioglycerol, propyl gallatesodium formaldehyde sulfoxylate sodium metabisulfite, sodiumthiosulfate, sulfur dioxide, tocopherol, tocopherols excipient);Buffering agents (acetic acid, ammonium carbonate, ammonium phosphate,boric acid, citric acid, lactic acid, phosphoric acid, potassiumcitrate, potassium metaphosphate, potassium phosphate monobasic, sodiumacetate, sodium citrate, sodium lactate solution, dibasic sodiumphosphate, monobasic sodium phosphate); Capsule lubricants (see tabletand capsule lubricant); Chelating agents (edetate disodium,ethylenediaminetetraacetic acid and salts, edetic acid); Coating agents(sodium carboxymethylcellulose, cellulose acetate, cellulose acetatephthalate ethylcellulose, gelatin, pharmaceutical glaze, hydroxypropylcellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulosephthalate methacrylic acid copolymer, methylcellulose, polyethyleneglycol, polyvinyl acetate phthalate shellac, sucrose, titanium dioxide,carnauba wax, microcrystalline wax, zein); Colorants (caramel, red,yellow, black or blends, ferric oxide); Complexing agents(ethylenediaminetetraacetic acid and salts (EDTA), edetic acid, gentisicacid ethanolamide, oxyquinoline sulfate); Desiccants (calcium chloride,calcium sulfate, silicon dioxide); Emulsifying and/or solubilizingagents (acacia, cholesterol, diethanolamine (adjunct), glycerylmonostearate, lanolin alcohols, lecithin, mono- and di-glycerides,monoethanolamine (adjunct), oleic acid (adjunct), oleyl alcohol(stabilizer), poloxamer, polyoxyethylene 50 stearate, polyoxyl 35 casteroil, polyoxyl 40 hydrogenated castor oil, polyoxyl 10 oleyl ether,polyoxyl 20 cetostearyl ether, polyoxyl 40 stearate, polysorbate 20,polysorbate 40, polysorbate 60, polysorbate 80, propylene glycoldiacetate, propylene glycol monostearate, sodium lauryl sulfate, sodiumstearate, sorbitan monolaurate, sorbitan monooleate, sorbitanmonopalmitate, sorbitan monostearate, stearic acid, trolamine,emulsifying wax); Filtering aids (powdered cellulose, purified siliceousearth); Flavors and perfumes (anethole, benzaldehyde, ethyl vanillin,menthol, methyl salicylate monosodium glutamate, orange flower oil,peppermint, peppermint oil, peppermint spirit, rose oil, stronger rosewater, thymol, tolu balsam tincture, vanilla, vanilla tincture,vanillin); Glidants and/or anticaking agents (calcium silicate,magnesium silicate, colloidal silicon dioxide, talc); Humectants(glycerin, hexylene glycol, propylene glycol, sorbitol); Plasticizers(castor oil, diacetylated monoglycerides, diethyl phthalate glycerin,mono- and di-acetylated monoglycerides, polyethylene glycol, propyleneglycol, triacetin, triethyl citrate); Polymers (e.g., cellulose acetate,alkyl celluloses, hydroxyalkylcelluloses, acrylic polymers andcopolymers); Solvents (acetone, alcohol, diluted alcohol, amylenehydrate, benzyl benzoate, butyl alcohol, carbon tetrachloride,chloroform, corn oil, cottonseed oil, ethyl acetate, glycerin, hexyleneglycol, isopropyl alcohol, methyl alcohol, methylene chloride, methylisobutyl ketone, mineral oil, peanut oil, polyethylene glycol, propylenecarbonate, propylene glycol, sesame oil, water for injection, sterilewater for injection, sterile water for irrigation, purified water);Sorbents (powdered cellulose, charcoal, purified siliceous earth);Carbon dioxide sorbents (barium hydroxide lime, soda lime); Stiffeningagents (hydrogenated castor oil, cetostearyl alcohol, cetyl alcohol,cetyl esters wax, hard fat, paraffin, polyethylene excipient, stearylalcohol, emulsifying wax, white wax, yellow wax); Suspending and/orviscosity-increasing agents (acacia, agar, alginic acid, aluminummonostearate, bentonite, purified bentonite, magma bentonite, carbomer934p, carboxymethylcellulose calcium, carboxymethylcellulose sodium,carboxymethylcellulose sodium 12, carrageenan, microcrystalline andcarboxymethylcellulose sodium cellulose, dextrin, gelatin, guar gum,hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethylcellulose, magnesium aluminum silicate, methylcellulose, pectin,polyethylene oxide, polyvinyl alcohol, povidone, propylene glycolalginate, silicon dioxide, colloidal silicon dioxide, sodium alginate,tragacanth, xanthan gum); Sweetening agents (aspartame, dextrates,dextrose, excipient dextrose, fructose, mannitol, saccharin, calciumsaccharin, sodium saccharin, sorbitol, solution sorbitol, sucrose,compressible sugar, confectioner's sugar, syrup); Tablet binders(acacia, alginic acid, sodium carboxymethylcellulose, microcrystallinecellulose, dextrin, ethylcellulose, gelatin, liquid glucose, guar gum,hydroxypropyl methylcellulose, methylcellulose, polyethylene oxide,povidone, pregelatinized starch, syrup); Tablet and/or capsule diluents(calcium carbonate, dibasic calcium phosphate, tribasic calciumphosphate, calcium sulfate, microcrystalline cellulose, powderedcellulose, dextrates, dextrin, dextrose excipient, fructose, kaolin,lactose, mannitol, sorbitol, starch, pregelatinized starch, sucrose,compressible sugar, confectioner's sugar); Tablet disintegrants (alginicacid, microcrystalline cellulose, croscarmellose sodium, crospovidone,polacrilin potassium, sodium starch glycolate starch, pregelatinizedstarch); Tablet and/or capsule lubricants (calcium stearate, glycerylbehenate, magnesium stearate, light mineral oil, polyethylene glycol,sodium stearyl fumarate, stearic acid, purified stearic acid, talc,hydrogenated vegetable oil, zinc stearate); Tonicity agent (dextrose,glycerin, mannitol, potassium chloride, sodium chloride); Vehicle:flavored and/or sweetened (aromatic elixir, compound benzaldehydeelixir, iso-alcoholic elixir, peppermint water, sorbitol solution,syrup, tolu balsam syrup); Vehicle: oleaginous (almond oil, corn oil,cottonseed oil, ethyl oleate, isopropyl myristate, isopropyl palmitate,mineral oil, light mineral oil, myristyl alcohol, octyldodecanol, oliveoil, peanut oil, persic oil, sesame oil, soybean oil, squalane);Vehicle: solid carrier (sugar spheres); Vehicle: sterile (bacteriostaticwater for injection, bacteriostatic sodium chloride injection);Viscosity-increasing (see suspending agent); Water repelling agent(cyclomethicone, dimethicone, simethicone); and Wetting and/orsolubilizing agent (benzalkonium chloride, benzethonium chloride,cetylpyridinium chloride, docusate sodium, nonoxynol 9, nonoxynol 10,octoxynol 9, poloxamer, polyoxyl 35 castor oil, polyoxyl 40,hydrogenated castor oil, polyoxyl 50 stearate, polyoxyl 10 oleyl ether,polyoxyl 20, cetostearyl ether, polyoxyl 40 stearate, polysorbate 20,polysorbate 40, polysorbate 60, polysorbate 80, sodium lauryl sulfate,sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate,sorbitan monostearate, tyloxapol) may be used as excipients. This listis not meant to be exclusive, but instead merely representative of theclasses of excipients and the particular excipients which may be used indosage forms of the present invention.

The compounds of Formulas I to IV can also form salts which are alsowithin the scope of this invention. Reference to a compound of theFormula herein is understood to include reference to salts thereof,unless otherwise indicated.

The term “salt(s)”, as employed herein, denotes acidic salts formed withinorganic and/or organic acids, as well as basic salts formed withinorganic and/or organic bases. In addition, when a compound of theFormula contains both a basic moiety, such as, but not limited to apyridine or imidazole, and an acidic moiety, such as, but not limited toa carboxylic acid, zwitterions (“inner salts”) may be formed and areincluded within the term “salt(s)” as used herein. Pharmaceuticallyacceptable (i.e., non-toxic, physiologically acceptable) salts arepreferred, although other salts are also useful. Salts of the compoundsof the Formula may be formed, for example, by reacting a compound ofFormula with an amount of acid or base, such as an equivalent amount, ina medium such as one in which the salt precipitates or in an aqueousmedium followed by lyophilization.

Exemplary acid addition salts include acetates, ascorbates, benzoates,benzenesulfonates, bisulfates, borates, butyrates, citrates,camphorates, camphorsulfonates, fumarates, hydrochlorides,hydrobromides, hydroiodides, lactates, maleates, methanesulfonates,naphthalenesulfonates, nitrates, oxalates, phosphates, propionates,salicylates, succinates, sulfates, tartarates, thiocyanates,toluenesulfonates (also known as tosylates) and the like. Additionally,acids which are generally considered suitable for the formation ofpharmaceutically useful salts from basic pharmaceutical compounds arediscussed, for example, by P. Stahl et al, Camille G. (eds.) Handbook ofPharmaceutical Salts. Properties, Selection and Use. (2002) Zurich:Wiley-VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977)66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33201-217; Anderson et al, The Practice of Medicinal Chemistry (1996),Academic Press, New York; and in The Orange Book (Food & DrugAdministration, Washington, D.C. on their website). These disclosuresare incorporated herein by reference thereto.

Exemplary basic salts include ammonium salts, alkali metal salts such assodium, lithium, and potassium salts, alkaline earth metal salts such ascalcium and magnesium salts, salts with organic bases (for example,organic amines) such as dicyclohexylamines, t-butyl amines, and saltswith amino acids such as arginine, lysine and the like. Basicnitrogen-containing groups may be quarternized with agents such as loweralkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides andiodides), dialkyl sulfates (e.g. dimethyl, diethyl, and dibutylsulfates), long chain halides (e.g. decyl, lauryl, and stearylchlorides, bromides and iodides), aralkyl halides (e.g. benzyl andphenethyl bromides), and others.

All such acid salts and base salts are intended to be pharmaceuticallyacceptable salts within the scope of the invention and all acid and basesalts are considered equivalent to the free forms of the correspondingcompounds for purposes of the invention.

Compounds of the various Formulas, and salts, solvates, esters andprodrugs thereof, may exist in their tautomeric form (for example, as anamide or imino ether). All such tautomeric forms are contemplated hereinas part of the present invention.

The compounds of the various Formulas may contain asymmetric or chiralcenters, and, therefore, exist in different stereoisomeric forms. It isintended that all stereoisomeric forms of the compounds of the variousFormulas as well as mixtures thereof, including racemic mixtures, formpart of the present invention. In addition, the present inventionembraces all geometric and positional isomers. For example, if acompound of the various Formulas incorporates a double bond or a fusedring, both the cis- and trans-forms, as well as mixtures, are embracedwithin the scope of the invention. Each compound herein disclosedincludes all the enantiomers that conform to the general structure ofthe compound. The compounds may be in a racemic or enantiomerically pureform, or any other form in terms of stereochemistry. The assay resultsmay reflect the data collected for the racemic form, theenantiomerically pure form, or any other form in terms ofstereochemistry.

Diastereomeric mixtures can be separated into their individualdiastereomers on the basis of their physical chemical differences bymethods well known to those skilled in the art, such as, for example, bychromatography and/or fractional crystallization. Enantiomers can beseparated by converting the enantiomeric mixture into a diastereomericmixture by reaction with an appropriate optically active compound (e.g.,chiral auxiliary such as a chiral alcohol or Mosher's acid chloride),separating the diastereomers and converting (e.g., hydrolyzing) theindividual diastereomers to the corresponding pure enantiomers. Also,some of the compounds of the various Formulas may be atropisomers (e.g.,substituted biaryls) and are considered as part of this invention.Enantiomers can also be separated by use of a chiral HPLC column.

It is also possible that the compounds of the various Formulas may existin different tautomeric forms, and all such forms are embraced withinthe scope of the invention. Also, for example, all keto-enol andimine-enamine forms of the compounds are included in the invention.

All stereoisomers (for example, geometric isomers, optical isomers andthe like) of the present compounds (including those of the salts,solvates, esters and prodrugs of the compounds as well as the salts,solvates and esters of the prodrugs), such as those which may exist dueto asymmetric carbons on various substituents, including enantiomericforms (which may exist even in the absence of asymmetric carbons),rotameric forms, atropisomers, and diastereomeric forms, arecontemplated within the scope of this invention, as are positionalisomers (such as, for example, 4-pyridyl and 3-pyridyl). (For example,if a compound of the various Formulas incorporates a double bond or afused ring, both the cis- and trans-forms, as well as mixtures, areembraced within the scope of the invention. Also, for example, allketo-enol and imine-enamine forms of the compounds are included in theinvention.) Individual stereoisomers of the compounds of the inventionmay, for example, be substantially free of other isomers, or may beadmixed, for example, as racemates or with all other, or other selected,stereoisomers. The chiral centers of the present invention can have theS or R configuration as defined by the IUPAC 1974 Recommendations. Theuse of the terms “salt”, “solvate”, “ester,” “prodrug” and the like, isintended to equally apply to the salt, solvate, ester and prodrug ofenantiomers, stereoisomers, rotamers, tautomers, positional isomers,racemates or prodrugs of the inventive compounds.

The foregoing merely summarizes the various aspects and preferredembodiments thereof, of the invention and is not intended to be limitingin nature. These aspects and embodiments are described more fully below.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Reference will now be made in detail to each embodiment of the presentinvention. Such embodiments are provided by way of explanation of thepresent invention, which is not intended to be limited thereto. In fact,those of ordinary skill in the art may appreciate upon reading thepresent specification and viewing the present drawings that variousmodifications and variations can be made thereto.

Compounds of the Invention

The present invention relates to particular molecules andpharmaceutically acceptable salts or isomers thereof. The inventionfurther relates to molecules which are useful in macrophage migrationinhibitory factor (MIF) inhibitors, epidermal growth factor receptor(EGRF) inhibitors, kinase inhibitors, and prodrugs of alpha4 beta1 andalpha4 beta7 integrin antagonists and pharmaceutically acceptable saltsor isomers thereof.

The invention is directed to compounds as described herein andpharmaceutically acceptable salts or isomers thereof, and pharmaceuticalcompositions comprising one or more compounds as described herein andpharmaceutically acceptable salts or isomers thereof. One aspect of thisinvention is the provision of compounds, compositions, and kits formacrophage migration inhibitory factor (MIF) inhibitors, epidermalgrowth factor receptor (EGFR) inhibitors, kinase inhibitors, andprodrugs of alpha4 beta1 and alpha4 beta7 integrin antagonistscomprising a compound of Formula I:

-   -   wherein:    -   R₁ is -aryl, -heteroaryl, or C(O)R₃, wherein        -   i) each of said aryl or heteroaryl may additionally be fused            with an independently selected aryl or heteroaryl; and        -   ii) each of said aryl, heteroaryl, and alkyl is either            unsubstituted or substituted with 1, 2, 3, 4 or 5            substituents which can be the same or different and are            independently selected from the group consisting of halo,            hydroxyl, cyano, oxo, amino, aminoalkyl-, (amino)alkoxy-,            -alkyl, -alkenyl,-alkynyl, alkoxy-, hydroxy, -alkylhydroxy,            aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl,            -aryl(halo), -heteroaryl, C(O)OC_(n), —NR^(a)R^(b);            deuterium, hydroxyl-alkyl-, hydroxyl-aryl-, amino,            aminoalkyl, —CONH₂, —C(O)NH(alkyl), —C(O)N(alkyl)₂,            —C(O)NH(aryl), —C(O)N(aryl)₂, —CH_(z)F_(3-z),            —OCH_(z)F_(3-z), (alkoxyalkyl)amino-, —O(alkyl), —O(aryl),            O(heteroaryl), NH(SO₂)alkyl, —NH(SO₂)aryl,            —NH(SO₂)heteroaryl, (aryl)alkyl-, —S(O)₂-alkyl, —S(O)₂-aryl,            —C(O)alkyl, —NHC(O)-alkyl, NH—, —NH—C(O)— R^(c)—(O)alkyl,            —NH—C(O)-aryl, —NH—C(O)—NH-alkyl, NH—C(O)— NH—C(O)—NH-aryl,            —NH—C(O)—O-alkyl, —NH(R^(c))—C(O)-alkyl,            —NH(R^(c))—C(O)-aryl, —S(O₂)NH₂, —S(O₂)NH(alkyl),            —S(O₂)N(alkyl)₂, —C(O)N(H)(alkyl), —CH_(z)F₃-z,            —OCH_(z)F_(3-z);    -   R₂ is hydrogen, hydroxyl, OC(O)CH₃, -oxy(aryl), or a group        selected from -oxy(alkyl), -oxy(alkene), alkyl, -alkenyl,        -oxy(alkyl)-aryl, -oxyalkynyl, —OC(O)(alkyl), —OC(O)(haloalkyl),        and —OC(O)(aryl) which is either substituted or non-substituted        and straight or branched, where the substituents can be the same        or different and are from the group consisting of oxo or halo;    -   R₃ is an alkyl, alkyl(benzyl), alkoxy(alkyl) all of which may be        substituted or unsubstituted, substituted or unsubstituted        monocyclic or bicyclic aryl or heteroaryl, or alkyl(aryl), the        substituted or unsubstituted monocyclic or bicyclic heteroaryl        having 0, 1, 2 or 3 heteroatoms independently selected from N,        O, or S;    -   R^(a) is an alkyl, alkyl(benzyl), alkoxy(alkyl) all of which may        be substituted or unsubstituted, substituted or unsubstituted        monocyclic or bicyclic aryl or heteroaryl, or alkyl(aryl), the        substituted or unsubstituted monocyclic or bicyclic heteroaryl        having 0, 1, 2 or 3 heteroatoms independently selected from N,        O, or S;    -   R^(b) is hydrogen or halo;    -   R^(c) is hydrogen, halo, or alkyl;    -   ------ is an optional bond that is present only when R₂ is        hydrogen;    -   n is 0, 1, 2, or 3; and    -   z is 0, 1, or 2.

In another embodiment R₂ of Formula I is hydrogen.

In another embodiment R₁ of Formula I is a substituted bicyclic ringhaving 0, 1, 2, or 3 heteroatoms independently selected from N, O, or S;and R₂ is hydroxyl or OC(O)C_(n)R^(b).

In another embodiment, the compound of Formula I is represented by thecompound of Formula II:

-   -   wherein:    -   R₂ is hydroxyl, or a group substituted or non-substituted and        straight or branched selected from -oxy(alkyl), -oxy(alkene),        alkyl, -alkenyl, -oxyalkynyl, —OC(O)(alkyl), —OC(O)(haloalkyl),        and OC(O)(aryl);    -   R₄ is cyano, amino, aminoalkyl-, alkyl, -alkyl(aryl),        substituted or non-substituted aryl, if substituted then        substituted with 1, 2, 3, 4 or 5 substituents which can be the        same or different and are independently selected from the group        consisting of halo, hydroxyl, cyano, oxo, amino, aminoalkyl-,        alkyl(arylhalide), (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl,        alkoxy-, hydroxy, -alkylhydroxy, -alkyl(aryl), aryloxy-,        -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo),        -heteroaryl, C(O)OC_(n), —NR^(a)R^(b); deuterium,        hydroxyl-alkyl-, hydroxyl-aryl-, amino, aminoalkyl;    -   R₅ is C(O)R^(c) or cyano;    -   R^(c) is hydrogen, or a group, substituted or unsubstituted,        selected from straight or branched C₁ to C₃ alkyl, CF₃, alkoxy,        aryl, and monocyclic or bicyclic heteroaryl having one to three        heteroatoms independently selected from O, S, and N and if        substituted then substituted with 1, 2, 3, 4 or 5 substituents        which can be the same or different and are independently        selected from the group consisting of halo, hydroxyl, cyano,        oxo, amino, aminoalkyl-, ethoxy, (amino)alkoxy-, -alkyl,        -alkenyl, -alkynyl, alkoxy-, hydroxy,        -alkylhydroxy,-alkyl(aryl), aryloxy-, (alkoxyalkyl)amino-,        -aryl, -aryl(halo), -heteroaryl, C(O)OC_(n), —NR^(a)R^(b);        deuterium, hydroxyl-alkyl-, hydroxyl-aryl-, amino, aminoalkyl;        and    -   Y is S or O.

In another embodiment of Formula II, R₄ is selected from the groupconsisting of:

In another embodiment of Formula II, R₄ is alkyl(aryl), Y is oxy, R₅ isC(O)OC_(n), and where n is 0, 1, 2, or 3.

In another embodiment, the compound of Formula I is represented by thecompound of Formula III:

-   -   wherein;    -   R₆ is hydrogen, halo, CN, alkyl, alkoxy, aryloxy, aryl, and        SO₂(alkyl);    -   R₇ is hydrogen, C(O)R^(c), alkyl, haloalkyl, alkenyl, alkynyl,        and —CH₂(aryl);    -   Ar is a substituted or non-substituted monocyclic or bicyclic        heteroaryl, with one to four heteroatoms independently selected        from O, S, and N, wherein the substituents are selected from the        group consisting of halo, hydroxyl, oxy, cyano, amino,        aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl,        alkoxy-, hydroxy, NR^(a)R^(b), OC_(n), —CH_(z)F₃-z,        —OCH_(z)F_(3-z), aryloxy-, (alkoxyalkyl)amino-, —O(alkyl),        —O(aryl), —O(heteroaryl), —C(O)NH(alkyl), —C(O)N(aryl)₂,        —NH(SO₂)alkyl, —NH(SO₂)aryl, —NH(SO₂)heteroaryl, (aryl)alkyl-,        -heteroaryl, (heteroaryl)alkyl-, —S(O)₂-alkyl, —S(O)₂-aryl,        —C(O)N(alkyl)₂, —C(O)alkyl, —NHC(O)-alkyl, —NH—C(O)—        R^(c)—(O)alkyl, —NH—C(O)-aryl, —NH—C(O)—NH-alkyl,        NH—C(O)—NH-aryl, —NH—C(O)—O-alkyl, —NH(R^(c))—C(O)-alkyl,        —NH(R^(c))—C(O)-aryl, —S(O₂)NH₂, —S(O₂)NH(alkyl),        —S(O₂)N(alkyl)₂, —C(O)N(H)(alkyl), —CH_(z)F_(3-z),        —OCH_(z)F_(3-z), or -alkyl(aryl); and R^(c) is a group,        substituted or unsubstituted, selected from straight or branched        C₁ to C₃ alkyl, alkenyl, alkynyl, CF₃, alkoxy, aryl, and        monocyclic or bicyclic heteroaryl having one to three        heteroatoms independently selected from O, S, and N and if        substituted then substituted with 1, 2, 3, 4 or 5 substituents        which can be the same or different and are independently        selected from the group consisting of halo, hydroxyl, cyano,        oxo, amino, aminoalkyl-, ethoxy, (amino)alkoxy-, -alkyl,        -alkenyl, -alkynyl, alkoxy-, hydroxy,        -alkylhydroxy,-alkyl(aryl), aryloxy-, -alkyl(aryl),        (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl,        C(O)OC_(n), —NR^(a)R^(b); deuterium, hydroxyl-alkyl-,        hydroxyl-aryl-, amino, aminoalkyl.

In another embodiment Ar of Formula III is selected from the groupconsisting of:

In another embodiment, the compound of Formula I is represented by thecompound of Formula IV:

-   -   wherein;    -   R₆ is hydrogen, halo, alkyl, alkoxy, aryloxy, aryl, and        —SO₂(alkyl);    -   R₇ is hydrogen, C(O)R^(c), alkyl, alkenyl, alkynyl, and        —CH₂(aryl);    -   R₈ is substituted or non-substituted aryl or cycloalkyl or        heterocycloalkyl, wherein the substituents are selected from the        group consisting of straight or branched alkyl, halo, hydroxyl,        oxy, cyano, amino, dimethylpropanone, aminoalkyl-,        (amino)alkoxy-, -alkyl(arylhalide),-alkyl, -alkenyl, -alkynyl,        alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl),        —SO₂(aryl), —SO₂(alkyl), (alkoxyalkyl)amino-, -aryl,        -heteroaryl, C(O)C_(n), C(O)OC_(n), —NR^(a)R^(b), and deuterium;    -   R^(c) is hydrogen, halo, aryl, or alkyl;    -   X is independently C, N, S, or O; and    -   n is 0, 1, or 2.

In another embodiment R₇ of Formula IV is C(O)OC.

EXAMPLES

The following are illustrative, but non-limiting, examples of certainembodiments of the present invention. The synthetic schemes arepresented for the synthesis of certain compounds herein disclosed. Theprocess and results for the assays testing the effects on the targetcompound solubility are also described.

Definitions used in the following Schemes and elsewhere herein are:

4-F-PH 4-fluorophenyl

calcd calculated

DIAD diisopropyl azodicarboxylate

DIPEA N,N-diisopropylethylamine

DMF N,N-dimethylformamide

EA ethyl acetate

EtI iodo ethane

EtOH ethanol

HCl hydrochloric acid

HPLC high pressure liquid chromatography

h hours

iso-PrOH isopropanol

LC/MS liquid chromatography/mass spectrometry

MeOH methanol

mcpba m-chloroperbenzoic acid

MS mass spectrometry

NEt₃ neat triethylamine

NMP n-methyl-2-pyrrolidone

obsd observed

Ph phenyl

Ph₃P triphenylphosphine

rt room temperature

TEA triethylamine

TFA trifluoroacetic acid

THF tetrahydrofuran

TLC thin layer chromotography

Materials

Unless otherwise noted, the starting materials and reagents used inpreparing these compounds were obtained from commercial suppliers, suchas Aldrich Chemical Co., Oakwood Chemical Inc., Alfa Aesar, A JohnsonMatthey Company, and Matrix Scientific. In some instances, the compoundsprepared by methods known to those skilled in the art of followingprocedures set forth in references such as Fieser and Fieser's Reagentsfor Organic Synthesis: Wiley & Sons: New York, 1991, Volumes 1-15; andOrganic Reactions, Wiley & Sons: New York, 1991, Volumes 1-40.

The following synthetic reaction schemes are merely illustrative of somemethods by which the compounds of the present invention can besynthesized, and various modifications to these synthetic reactionschemes can be made and will be suggested to one skilled in the art ofhaving referred to the disclosure contained in this application. Theinvention described in this application can be applied to many targetcompounds. Here, we describe a few of those applications.

The starting materials and intermediates of the synthetic reactionschemes can be isolated and purified if desired using conventionaltechniques, including but not limited to, filtration, distillation,crystallization, chromatography, and the like. Such materials can becharacterized using conventional means, including physical constants andspectral data.

Intermediates and final compounds were purified by either flashchromatography and/or by reverse-phase preparative HPLC. Unlessotherwise noted, flash chromatography was performed using the ISCOCombiFlash chromatography instrument (from Teledyne Isco, Inc). Unlessotherwise noted, the silica gel brand and pore size utilized werepre-packed 230-400 mesh columns provided by Teledyne, Inc.

Mass spectrometry was performed using a Watres ZQ 4000 (from WatresCorporation), a Waters Quattro micro API. Mass spectra data generallyonly indicate the parent ions unless otherwise stated. MA data isprovided for a particular intermediate or compound where indicated.

Nuclear magnetic resonance spectroscopy (NMR) was performed using aVarian Mercury 300 MHz NMR spectrometer or a Bruker 500 MHz NMRspectrometer. ¹H NMR data is provided for a particular intermediate orcompound where indicated.

Unless specified to the contrary, the reactions described hereinpreferably are conducted under an inert atmosphere at atmosphericpressure at a reaction temperature range of from about −10° C. to about180° C., more preferably from about 0° C. to 110° C., and mostpreferably and conveniently at about room (or ambient) temperature,e.g., about 20° C. Reagents were used as received from commercialsuppliers unless otherwise noted. THF was distilled over sodium andbenzophenone before use.

The compounds in the invention of formula I, II, III (above) can beprepared according to Scheme 1. Isosorbide was reacted with a phenolderivative of type VI in the presence of 1.5-3.0 equivalents oftriphenylphosphine and diisopropyl azodicarboxylate (DIAD) in thepresence of a base such as N,N-diisopropylethylamine (DIPEA) ortriethylamine (TEA) in an inert solvent such as tetrahydrofuran (THF) inan inert atmosphere. The reactions can be performed at temperaturesbetween 0° C. and room temperature or 0° C. to 65° ° C. for severalhours. As reported (Synthesis, 1981, 1), under these conditions theinversion of stereochemistry occurred at endo hydroxyl position toprovide the(3S,3aR,6S,6aR)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diolderivatives (isoidide type, exo, exo) of the compound of general formulaI which are rarely available.

The stereochemistry of the product was confirmed by preparation ofendo-mono-benzyl ether and exo-mono-benzyl ether isosorbide derivativesfollowing the literature procedure (Carbohydrate Research, 1994, 261,255-266), it was then found that the exo-mono-benzyl ether isosorbidereacted under these conditions. On the other hand, the endo-mono-benzylether isosorbide did not react under these conditions even afterextended hours of reaction time.

The esterification reaction of compound I to provide compound II may becarried out in the presence of an alkyl or aryl acid chloride such asVII in the presence of a base such as DIPEA or TEA in an inert solventsuch as methylene chloride in an inert atmosphere. The reactions can beperformed at temperatures between 0° C. and room temperature for severalhours.

Compounds of the invention of general formula III may be prepared fromisosorbide and phenol derivative of type VI under similar conditionsusing 3-6 equivalents of triphenylphosphine, DIAD and DIPEA in an inertsolvent such as THF at room temperature for an extended period ofreaction time, 6-7 days. This observation is in contrary to theliterature report (Synlett, 2003, 11, 1683-1687) where the endo-TBSprotected isosorbide reacted with 3-cyanophenol in the presence of DEAD,triphenylphosphine in THF to provide the ether derivative. The currentconditions may be different than regular Mitsunobu conditions. Thedouble bond in the compound of the invention of formula III can be avery useful intermediate for further transformations that should beexplored in the future.

Compounds of the invention of general formula IV and V (above) can beprepared according to Scheme 2. In some instances the isoidide portioncan act as a prodrug and the active acid can be released in the in vivostudies. In some cases the isoidide portion behaves as a part of themolecule. Isosorbide was treated with an alkyl, substituted alkyl,aromatic, substituted aromatic, heteroaromatic or substitutedheteroaromatic carboxylic acid derivative of type VIII in the presenceof 1.5 equivalents of triphenylphosphine and diisopropylazodicarboxylate in the presence of a base such as DIPEA or TEA in aconvenient solvent such as THF in an inert atmosphere. The reactions maybe performed at temperatures between 0° C. and room temperature forseveral hours. Again, under these conditions, the inversion ofstereochemistry occurred at the endo hydroxyl position to provide the3-mono substituted ester derivatives of type(3S,3aR,6S,6aR)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diol(isoidide type, 3-exo and 6-exo) of compound IV.

The esterification reaction of compound IV to provide compound V may becarried out in the presence of an alkyl, substituted alkyl, aromatic orsubstituted aromatic acid chloride in the presence of a base such asDIPEA or TEA in an inert solvent such as methylene chloride in an inertatmosphere. The reactions may be performed at temperatures between 0° C.and room temperature for several hours.

Compounds of the invention of general formula X can be preparedaccording to Scheme 3 and these targets can act as MIF inhibitors.Isosorbide was reacted with a reactive1-substituted-4-hydroxy-2-oxo-1,2-dihydroquinoline derivative of type IX(where R₂ is methyl, phenyl, or 4-fluorophenyl and R₃ is CO₂Et or CN) toprovide compound X in the presence of 1.5 equivalents oftriphenylphosphine and DIAD in the presence of a base such as DIPEA orTEA in an inert solvent such as THF and an inert atmosphere. Thereactions may be performed at temperatures between 0° C. and roomtemperature or 0° C. and 65° C. in the case of R₃ is CN for severalhours.

The reactive 4-hydroxy-2-oxo-1,2-dihydroquinoline derivative of type IX(where R₂ is methyl, phenyl, or 4-fluorophenyl and R₃ is CO₂Et or CN)may be prepared following the literature procedures as described in apatent (WO 2007/109251 A2) and literature (Organic Process Research &Development 2004, 8, 802-807).

The esterification reaction of compound X to provide compounds of theinvention of formula XI can be carried out in the presence of an acidchloride such as VII (where R is CH₃, CH₂Cl, C(CH₃)₃, or phenyl) in thepresence of a base such as DIPEA or TEA in a convenient solvent such asmethylene chloride in an inert atmosphere. The reactions may beperformed between 0° C. and room temperature for several hours.

Compounds of the invention of formula XIII can be prepared fromisosorbide and 4-nitrophenol or 2-substituted-4-nitrophenol of type XII(where Y is hydrogen, chlorine or fluorine) under the above mentionedMitsunobu reaction conditions according to Scheme 4. The reduction ofthe nitro group of compound XIII to provide compound XIV can be carriedout in the presence of excess zinc dust and ammonium chloride in amixture of solvents such as methanol and water. The reaction may beperformed at room temperature and 60° C. for several hours.

The esterification reaction of compound XIII to provide compound XV canbe carried out in the presence of an acid chloride such as VII (R can beas described above) in the presence of a base such as DIPEA or TEA in aconvenient solvent such as methylene chloride in an inert atmosphere.The reactions may be performed at temperatures between 0° C. and roomtemperature for several hours. The reduction of the nitro group ofcompound XV to give the amine intermediate XVI can be accomplished inthe presence of an excess zinc dust and ammonium chloride. The reactionmay be carried out in a mixture of solvents such as methanol and waterat room temperature to 60° C. for several hours. Most importantly, thesereduction reaction conditions are tolerable in the presence of achloride substituent on the aromatic ring.

Compounds of the invention of formula XIV are versatile intermediateswhile a few applications of the amine intermediate are shown in Scheme 5to prepare compounds of the interest of invention such as XVIII, XX,XXII and XXIV for the treatment of cancer and inflammatory diseases.

Compounds of the invention of formula XVIII are novel EGFR inhibitorsthat can be prepared from aniline intermediate such as compound XIV and4-chloro-6,7-dialkoxyquinazoline such as XVII. The reactions may becarried out in a convenient solvent such as iso-propanol. The reactionsmay be performed at elevated temperatures between 85° C. and 110° C. forseveral hours.

Similarly, compounds of invention of the formula XX can be prepared fromaniline intermediates such as compound XIV and4-chlorothieno[3,2-d]pyrimidines such as XIX. The reactions can becarried out in a convenient solvent such as iso-propanol. The reactionsmay be carried out at elevated temperatures between 85° C. and 110° C.for several hours. These derivatives may be novel kinase inhibitors.

Also, compounds of invention of the formula XXII can be prepared fromaniline intermediates such as compound XIV and4-iodo-2-methylsulfanylpyrimidines such as XXI. The reactions can becarried out in a convenient solvent such as iso-propanol and thereactions can be conducted at elevated temperatures between 85° C. and110° C. for several hours. These derivatives may be novel kinaseinhibitors.

Compounds of invention of the formula XXIV can be prepared from anilineintermediates such as compound XIV and reactive1-substituted-4-chloro-2-oxo-3-cyano-1,2-dihydroquinoline intermediatesuch as XXIII. The reactions can be carried out in a convenient solventsuch as iso-propanol and acetonitrile in the presence of a base such asTEA. The reactions can be carried out at elevated temperatures between85° C. and 110° C. for several hours.

These derivatives can be novel MIF inhibitors.

Compounds of the invention of formula XVI are also versatileintermediates while a few applications of one amine intermediate areshown in Scheme 6 above to prepare compounds of the invention ofinterest such as XXV, XXVI and XXVII for the treatment of cancer.Compounds of the invention of formula XXV are novel EGFR inhibitors andthey can be prepared from aniline intermediate such as compound XVI and4-chloro-6,7-dialkoxyquinazolines such as XVII. The reactions can becarried out in a convenient solvent such as iso-propanol. The reactionsmay be performed at elevated temperatures between 85° C. and 110° C. forseveral hours.

Similarly, compounds of invention of the formula XXVI can be preparedfrom aniline intermediates such as compound XVI and4-chlorothieno[3,2-d]pyrimidines such as XIX. The reactions may beconducted in a convenient solvent such as iso-propanol and the reactionsmay be carried out at temperatures between 85° C. and 110° C. forseveral hours. These derivatives may be novel kinase inhibitors.

Also, compounds of invention of the formula XXVII can be prepared fromaniline intermediates such as compound XVI and4-iodo-2-methylsulfanylpyrimidines such as XXI. The reactions can beperformed in a convenient solvent such as iso-propanol and the reactionsmay be conducted at elevated temperatures between 85° C. and 110° C. forseveral hours. These derivatives may be novel kinase inhibitors.

Compounds of the invention of formula XXIX can be prepared fromisosorbide and 2-methylsulfanylpyrimidine-4-ol of type XXVIII underabove described Mitsunobu reaction conditions according to Scheme 7. Theesterification reaction of compound XXIX to provide compound XXX can becarried out in the presence of an acid chloride such as VII (R can be asdescribed above) in the presence of a base such as DIPEA or TEA in aninert solvent such as methylene chloride in an inert atmosphere. Thereactions may be performed at temperatures between 0° C. and roomtemperature for several hours.

The oxidation of methylsulfide of intermediate XXX to provide themethylsulfoxide of an intermediate can be performed in the presence ofmcpba (m-chloroperbenzoic acid). The reaction may be conducted in aninert solvent such as methylene chloride at 0° C. and room temperaturefor several hours.

The nucleophilic substitution of methylsulfoxide in intermediate XXX toprovide compound XXXII can be performed with 4-amino-1-Boc-piperidinesuch as XXXI in the presence of a base such as DIPEA or TEA. Thereaction can be carried out in a convenient solvent such as DMF or NMP.The reactions may be conducted at elevated temperatures between 120° C.and 140° C. for several hours.

Removal of the tert-butylcarbamate protective group in the compounds offormula XXXII to give a secondary piperidine intermediate can be carriedout by treating the compound of formula XXXII with trifluoroacetic acidin an inert solvent such as methylene chloride. The reactions can beconducted at temperatures 0° C. and room temperature for several hours.Sulfonamides of the invention of formula XXXIII are convenientlyprepared by treating the secondary piperidine intermediate with alkyl orarylsulfonyl chlorides such as R₅SO₂Cl in the presence of a base such asDIPEA or TEA in an inert solvent such as tetrahydrofuran or methylenechloride. The reactions may be conducted at 0° C. and room temperaturefor several hours.

Compounds of the invention of formula XXXVI (where R₆ is lower alkyl,substituted lower alkyl, phenyl, or substituted phenyl) can be preparedaccording to Scheme 8 above. In this process, the reaction of secondarypiperidine of compound XXXIV with acid chloride of type XXXV to providethe amide derivatives of type XXXVI in the presence of a base such asDIPEA or TEA in an inert solvent such as methylene chloride. Thereactions may be conducted at 0° C. and room temperature for severalhours.

Compounds of the invention of formula XXXIX (where Z is halogen,preferably chlorine or fluorine, lower alkoxy, or lower alkylsulfonyl)can be prepared according to Scheme 9 above. In this process, themethylsulfoxide intermediate of compound XXXVII is reacted with thebenzyl amine of type XXXVIII to produce the compounds of the formulaXXXIX in the presence of a base such as DIPEA or TEA in a convenientsolvent such as NMP or DMF. The reactions may be conducted at 120° C.and 140° C. for several hours.

Compounds of the invention of formula XIV are also versatileintermediates and another such application is shown in Scheme 10 aboveto prepare novel compounds of the invention of interest such as XLI andXLIV for the treatment of cancer and inflammation.

Compounds of invention of the formula XLI can be prepared by thereaction of 2-3 equivalents of aniline intermediates such as compoundXIV and 2,4-dichloropyrimidines such as XL. The reactions can beperformed in a convenient solvent system such as methanol and water in1:1 ratio. The reactions may be conducted at elevated temperaturesbetween 120° C. and 140° C. for several hours.

Compounds of the intermediates of formula XLII can also be prepared bythe reaction of 1.1 equivalents of aniline intermediates such ascompound XIV and 1.0 equivalent of 2,4-dichloropyrimidines such as XL.The reactions can be conducted in a convenient solvent system such asmethanol and water in 1:1 or 1:2 ratios. The reactions can be carriedout at room temperature and 60° C. for several hours.

The compounds of the invention of formula XLIV can be obtained by thereaction of intermediates of formula XLII with the substituted anilinesor substituted heteroaromatic amines such as formula XLIII. Thereactions may be carried out in appropriate solvents such as NMP or DMFor methanol and water. The reactions may be performed at elevatedtemperatures between 120° C. and 140° C. for several hours. The abovementioned derivatives may be novel kinase inhibitors.

Compounds of the invention of formula XLVI can be prepared fromisosorbide and 5-bromo-2-(methylthio)-pyrimidine-4-carboxylic acid XLVunder the above mentioned Mitsunobu reaction conditions according toScheme 11 above.

The oxidation of the methylsulfide of intermediate XLVI to provide themethylsulfoxide of intermediate XLVII can be performed in the presenceof mcpba. The reaction may be carried out in an inert solvent such asmethylene chloride at 0° C. and room temperature for several hours.

The compounds of the invention of formula XLVIII can be prepared by thereaction of the methylsulfoxide intermediate XLVII with the benzyl amineof type XXXVIII (where Z is chlorine, fluorine, methylsulfonyl) in thepresence of a base such as DIPEA or TEA in a convenient solvent such asNMP or DMF. The reactions may be performed at 120° C. and 140° C.temperature for several hours.

Compounds of the invention of formula XLX or XLXII can be prepared fromisosorbide or isosorbide 2-acetate or isosorbide 2-benzyl ether and(2S)-2-[(2-chloro-5-methyl-benzoyl)amino]-3-[4-[(2,6-dichlorobenzoyl)amino]phenyl]propanoicacid XLIX (for preparation, see WO1999/10312) or(2S)-2-[(2-chloro-6-methyl-benzoyl)amino]-3-[4-(1,3,4-trimethyl-2,6-dioxo-pyrimidin-5-yl)phenyl]propanoicacid XLXI (For preparation, see U.S. Ser. No. 00/638,0387B 1) under theabove mentioned Mitsunobu reaction conditions according to Scheme 12above.

In this invention of formula XLX and XLXII, the isoidide derivative canact as a prodrug moiety and the active compound can be released in thebody by esterases and the active compounds XLIX and XLXI are potentalpha4 beta1 and alpha4 beta7 integrin antagonists (see the patents(WO1999/10312 and U.S. Ser. No. 00/638,0387B 1).

General Methods for Compound Synthesis Example A Synthesis of ethyl4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-ethyl-2-oxo-1,2-dihydroquinoline-3-carboxylate

Step 1: Preparation of 1-ethyl-isatoic anhydride

A 250 mL 2-neck round bottom flask was charged with isatoic anhydride(16.3 g, 100 mmol) and then DMF (100 mL) was added followed by portionwise (2 times) addition of sodium hydride (4.4 g, 183 mmol, 60%dispersion in oil) for 5 minutes under an argon atmosphere. Duringaddition of NaH, the reaction was exothermic and lot of gas evolved withfoam.

The resulting brown suspension was stirred for 1 h and then neatiodoethane (15.6 g, 8.04 mL, 110 mmol) was added drop-wise over 5minutes. The resulting light brown thick slurry was stirred at roomtemperature for 15 h at which time a lot of solids precipitated (paste).Then, water was added drop-wise for 10 minutes after which another 100mL of water was added and the resulting slurry was stirred for 1 h.Then, it was poured into 500 mL of water and stirred for 30 minutes. Theresulting solids were collected by filtration and washed with water andhexanes.

After air drying, 15 g (79%) of 1-ethyl isatoic anhydride was isolatedas an off-white solid.

Step 2: Preparation of ethyl1-ethyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate

A 250 mL 2-neck round bottom flask was charged with 1-ethyl isatoicanhydride (7.64 g, 40 mmol) and DMF (80 mL) was added followed bydiethylmalonate (7.05 g, 6.7 mL, 44 mmol). Then, the solid sodiumhydride (3.87 g, 161.33 mmol, 60% dispersion in oil) was added in twoportions during 15 minute intervals at room temperature under an argonatmosphere. The resulting light yellowish foam suspension was stirredfor 5 h. During this period, foam like solids formed that floated on thetop. After 5 h at room temperature, TLC analysis of the reaction mixtureindicated the absence of starting material.

Then, water (5 mL) was added very slowly which produced a lot of foam.After 10 minutes of stirring, the light yellow suspension was pouredinto 1.0 N HCl (20 mL) and diluted with water (100 mL).

Then, the organic compound was extracted into EA (2×100 mL). Thecombined extracts were washed with water (2×100 mL), brine solution (100mL), and dried over anhydrous MgSO₄. Filtration of the drying agent andconcentration produced crude brown oil which was dissolved in EA (˜5 mL)and then diluted with hexanes. The resulting brown solution was storedin the refrigerator overnight. The resulting solids were collected bydecanting the mother liquor and the desired ethyl1-ethyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate (3.0 g) wasisolated as off-white solids. The mother liquor was purified using anISCO (330 g) column chromatography to obtain another 4 g with a total of7.0 g (70%) of ethyl1-ethyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate. LC/MS calcd.for C₁₄H₁₅NO₄ [(M+H)⁺] 262, obsd. 262.

Step 3: Preparation of ethyl4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-ethyl-2-oxo-1,2-dihydroquinoline-3-carboxylate

To a solution of triphenylphosphine (393 mg, 1.5 mmol) in THF (10 mL) ina 25 mL 2-neck RB flask was added di-isopropylazodicarboxylate (303 mg,295 uL, 1.5 mmol) at 0-5° C. (ice+water) for 2-3 minutes under an argonatmosphere. The resulting light yellow suspension was stirred for 10minutes at this temperature. Then, a solution of ethyl1-ethyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate (260 mg, 1.0mmol) in THF (6 mL) was added drop-wise for 5 minutes. After 2 minutes,the cooling bath was removed to allow the reaction mixture to warm toroom temperature where it was stirred for 10 minutes.

Then, a solution of isosorbide (176 mg, 1.2 mmol) in THF (5 mL) wasslowly added followed by the neat DIPEA (194 mg, 261 uL, 1.5 mmol) atroom temperature. The resulting light yellow suspension was stirred for48 h and TLC (1:1, Hex:EA) analysis of the reaction mixture indicatedthe appearance of a new spot. Then, the solvent was removed under vacuumand the crude residue was purified using an ISCO (120 g) columnchromatography to obtain 350 mg (90%) ethyl4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-ethyl-2-oxo-1,2-dihydroquinoline-3-carboxylateas a colorless paste. ¹H-NMR (CDCl₃): δ 8.04 (d, J=7.3 Hz, 1H), 7.56 (t,J=7.3 Hz, 1H), 7.25 (d, J=7.8 Hz, 1H), 7.15 (t, J=7.4 Hz, 1H), 5.02 (d,J=2.8 Hz, 1H), 4.93 (d, J=3.4 Hz, 1H), 4.64 (d, J=3.4 Hz, 1H), 4.5-4.25(m, 5H), 4.15 (d, J=10.1 Hz, 1H), 3.92-3.75 (m, 3H), 1.45-1.25 (m, 6H).LC/MS calcd. for C₂₀H₂₃NO₇ [(M+H)⁺] 390, obsd. 390.

Example B Preparation of ethyl4-[[(3S,3aR,6S,6aR)-6-acetoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]oxy]-1-ethyl-2-oxo-1,2-dihydroquinoline-3-carboxylate

To a colorless solution of ethyl4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-ethyl-2-oxo-1,2-dihydroquinoline-3-carboxylate(155 mg, 0.4 mmol) in dichloromethane (10 mL) in a 25 mL 2-neck RB flaskwere added first acetyl chloride (79 mg, 72 uL, 1.0 mmol) then followedby the neat DIPEA (258 mg, 348 uL, 2.0 mmol) at 0-5° C. under an argonatmosphere. After addition of DIPEA, the reaction mixture turned into alight brown solution. The resulting light brown solution was allowed towarm to room temperature without removing the cooling bath and stirredfor 15 h.

Then, it was diluted with water and the organic compound was extractedinto dichloromethane. The combined extracts were washed with brinesolution and dried over anhydrous magnesium sulfate. Filtration andconcentration resulted in a crude dark brown oil that was purified usingan ISCO (80 g) column chromatography to yield 138 mg (80%) of ethyl4-[[(3S,3aR,6S,6aR)-6-acetoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]oxy]-1-ethyl-2-oxo-1,2-dihydroquinoline-3-carboxylateas a white solid. ¹H-NMR (CDCl₃): δ 8.04 (d, J=7.3 Hz, 1H), 7.56 (t,J=7.3 Hz, 1H), 7.25 (d, J=7.8 Hz, 1H), 7.15 (t, J=7.3 Hz, 1H), 5.15 (d,J=2.8 Hz, 1H), 5.01 (d, J=3.4 Hz, 1H), 4.81 (d, J=3.4 Hz, 1H), 4.68 (d,J=3.9 Hz, 1H), 4.4 (q, J=6.2 Hz, 2H), 4.22 (q, J=6.3 Hz, 2H), 4.12 (d,J=10.1 Hz, 1H), 3.95-3.85 (m, 2H), 3.81 (dd, J=8.4, 3.4 Hz, 1H), 2.04(s, 3H), 1.32 (t, J=7.5 Hz, 3H), 1.25 (t, J=7.5 Hz, 3H). LC/MS calcd.for C₂₂H₂₅NO₈ [(M+H)⁺] 432, obsd. 432.

Example C Preparation of ethyl4-[[(3S,3aR,6S,6aR)-6-(2-chloroacetyl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]oxy]-1-ethyl-2-oxo-1,2-dihydroquinoline-3-carboxylate

To a colorless solution of ethyl4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-ethyl-2-oxo-1,2-dihydroquinoline-3-carboxylate(195 mg, 0.5 mmol) in dichloromethane (10 mL) in a 25 mL 2-neck RB flaskwere added first 2-chloroacetyl chloride (113 mg, 80 uL, 1.0 mmol) thenfollowed by the neat DIPEA (258 mg, 348 uL, 2.0 mmol) at 0-5° C. underan argon atmosphere. After addition of DIPEA, the reaction mixtureturned into a dark brown solution. The resulting dark brown solution wasallowed to warm to room temperature without removing the cooling bathand stirred for 15 h.

Then, it was diluted with water and the organic compound was extractedinto dichloromethane. The combined extracts were washed with brinesolution and dried over anhydrous magnesium sulfate. Filtration andconcentration gave the crude dark brown oil which was purified using anISCO (80 g) column chromatography to afford 198 mg (85%) of ethyl4-[[(3S,3aR,6S,6aR)-6-(2-chloroacetyl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]oxy]-1-ethyl-2-oxo-1,2-dihydroquinoline-3-carboxylateas a light brown viscous oil. ¹H-NMR (CDCl₃): δ 7.98 (d, J=7.3 Hz, 1H),7.71 (t, J=7.3 Hz, 1H), 7.42 (d, J=7.8 Hz, 1H), 7.24 (t, J=8.4 Hz, 1H),5.28 (d, J=2.8 Hz, 1H), 5.05 (d, J=3.4 Hz, 1H), 4.76 (d, J=3.4 Hz, 1H),4.65 (d, J=3.4 Hz, 1H), 4.42 (q, J=6.4 Hz, 2H), 4.31 (q, J=6.4 Hz, 2H),4.18 (d, J=10.1 Hz, 1H), 4.01 (s, 2H), 3.95-3.85 (m, 2H), 3.81 (dd,J=8.4, 3.4 Hz, 1H), 1.5-1.15 (m, 6H). LC/MS calcd. for C₂₂H₂₄ClNO₈[(M+H)⁺] 466, obsd. 466.

Example D Preparation of ethyl4-[[(3S,3aS,6aR)-2,3,3a,6a-tetrahydrofuro[3,2-b]furan-3-yl]oxy]-1-ethyl-2-oxo-1,2-dihydroquinoline-3-carboxylate

To a solution of triphenylphosphine (787 mg, 3.0 mmol) in THF (5 mL) ina 25 mL 2-neck RB flask was added di-isopropylazodicarboxylate (606 mg,591 uL, 3.0 mmol) at 0-5° C. (ice+water) for 2-3 minutes under an argonatmosphere. The resulting light yellow suspension was stirred for 10minutes at this temperature. Then, a solution of ethyl1-ethyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate (261 mg, 1.0mmol) in THF (6 mL) was added drop-wise for 5 minutes. After 2 minutes,the cooling bath was removed to allow the reaction mixture to warm toroom temperature where it was stirred for 10 minutes.

Then, a solution of isosorbide (88 mg, 0.6 mmol) in THF (2 mL) wasslowly added followed by the neat DIPEA (388 mg, 522 uL, 1.5 mmol) atroom temperature. The resulting thick yellow suspension was stirred for15 h after which it was still a yellow suspension, but less viscouscompared to the initial appearance. After another 24 h of stirring itbecame a light orange colored solution and after being stirred foranother 48 h by which time it turned to a light yellow solution. Aftertotal 72 h, TLC (1:1, Hex:EA) analysis of the reaction mixture indicatedthe appearance of a new and less polar spot. The solvent was removedunder vacuum and the crude residue was purified using an ISCO (80 g)column chromatography to provide 220 mg (99%, based on the amount ofisosorbide used) of ethyl4-[[(3S,3aS,6aR)-2,3,3a,6a-tetrahydrofuro[3,2-b]furan-3-yl]oxy]-1-ethyl-2-oxo-1,2-dihydroquinoline-3-carboxylateas a light yellow amorphous solid. ¹H-NMR (CDCl₃): δ 8.0 (d, J=7.3 Hz,1H), 7.56 (t, J=7.8 Hz, 1H), 7.32 (d, J=7.3 Hz, 1H), 7.24 (t, J=8.4 Hz,1H), 6.5 (d, J=3.3 Hz, 1H), 5.55 (dd, J=4.9, 2.8 Hz, 1H), 5.1-5.01 (m,3H), 4.49 (q, J=6.4 Hz, 2H), 4.28 (q, J=6.4 Hz, 2H), 4.18 (d, J=10.1 Hz,1H), 3.49 (dd, J=9.8, 3.4 Hz, 1H), 1.5-1.2 (m, 6H). LC/MS calcd. forC₂₀H₂₁NO₆ [(M+H)⁺] 372, obsd. 372.

Example E Synthesis of ethyl4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylate

Step 1: Preparation of 1-benzyl isatoic anhydride

A 250 mL 2-neck round bottom flask was charged with isatoic anhydride(14.69 g, 90 mmol) and then DMF (100 mL) was added followed by theaddition of sodium hydride (3.99 g, 166 mmol, 60% dispersion in oil) in2-portions at 15 minute intervals under an argon atmosphere. Duringaddition of NaH, the reaction was exothermic and lot of gas evolved withfoam. The resulting brown suspension was stirred for 1 h and then theneat benzyl bromide (16.93 g, 11.77 mL, 99 mmol) was added for 5-10minutes. The resulting light brown thick slurry was stirred at roomtemperature for 36 h.

Then, the brown reaction mixture was quenched by drop-wise addition ofwater (10 mL) for 2 minutes and the reaction mixture was stirred for 10minutes. Then, more water (˜50 mL) was added and the resulting brown oilwas poured into 500 mL of water while stirring with spatula. Theprecipitated brown solids were collected by filtration and washed withwater and hexanes. After air drying, 21.48 g (94%) of 1-benzyl isatoicanhydride was isolated as an off-white solid.

Step 2: Preparation of ethyl1-benzyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate

A 250 mL 2-neck round bottom flask was charged with 1-benzyl isatoicanhydride (10.13 g, 40 mmol) and then DMF (80 mL) was added followed bydiethylmalonate (7.05 g, 6.7 mL, 44 mmol) at room temperature under anargon atmosphere. Then, the solid sodium hydride (3.87 g, 161.33 mmol,60% dispersion in oil) was added in 2-portions at 20 minute intervals atroom temperature. The resulting light yellowish foam suspension wasstirred for 15 h and then the reaction mixture was quenched slowly with˜10 mL of water (lot of foam formed). After 15 minutes stirring, another10 mL of water was added. After 15 minutes stirring, the foam suspensionwas poured into 500 mL of water while stirring with spatula. The neutralorganic impurities were extracted into EA (2×250 mL) and the basicaqueous layer was neutralized with 1.0 N HCl and the resulting whitesuspension was extracted into EA (2×150 mL).

The combined extracts were washed with brine solution (100 mL) and driedover anhydrous MgSO₄. Filtration of the drying agent and concentrationyielded crude viscous oil which was dissolved in EA (20-30 mL) in hotconditions and then diluted with hexanes (50-60 mL) until a lightprecipitate appeared. The resulting yellow solution was stored in thefreezer for 2 days. The resulting light brown solids were collected byfiltration and washed with hexanes. After air drying, 6.0 g (46%) ofethyl 1-benzyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate wasisolated as off-white solids. LC/MS calcd. for C₁₉H₁₇NO₄ [(M+H)⁺] 324,obsd. 324.

Step 3: Preparation of ethyl4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylate

To a solution of triphenylphosphine (3.93 g, 15 mmol) in THF (100 mL) ina 500 mL 3-neck RB flask was added di-isopropylazodicarboxylate (3.03 g,2.95 mL 15 mmol) at 0-5° C. (ice+water) for 5-7 minutes under an argonatmosphere. The resulting light yellow suspension was stirred for 10-15minutes at this temperature. Then, a solution of ethyl1-benzyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate (3.23 g, 10mmol) in THF (100 mL) was added drop-wise for 10 minutes. After 2minutes, the cooling bath was removed to allow the reaction mixture towarm to room temperature where it was stirred for 10-15 minutes.

Then, a solution of isosorbide (1.75 g, 12 mmol) in THF (70 mL) wasslowly added followed by the neat DIPEA (1.94 g, 2.61 mL, 15 mmol) atroom temperature. The resulting light yellow solution was stirred for 36h at which time TLC (1:1, Hex:EA) analysis of the reaction mixtureindicated the appearance of a new spot. Then, the solvent was removedunder vacuum and the crude residue was purified using an ISCO (330 g)column chromatography to obtain 3.43 g (76%) of ethyl4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylateas a white solid. ¹H-NMR (CDCl₃): δ 7.98 (d, J=7.3 Hz, 1H), 7.51 (t,J=7.3 Hz, 1H), 7.3-7.15 (m, 7H), 5.51 (s, 2H), 5.21 (d, J=2.8 Hz, 1H),4.98 (d, J=3.4 Hz, 1H), 4.62 (d, J=3.4 Hz, 1H), 4.42 (q, J=6.5 Hz, 2H),4.3 (d, J=3.3 Hz, 1H), 4.25 (d, J=10.1 Hz, 1H), 3.99-3.9 (m, 3H), 1.48(t, J=7.5 Hz, 3H). LC/MS calcd. for C₂₅H₂₅NO₇ [(M+H)⁺] 452, obsd. 452.

Example F Preparation of ethyl4-[[(3S,3aR,6S,6aR)-6-acetoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylate

To a colorless solution of ethyl4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylate(113 mg, 0.25 mmol) in dichloromethane (5 mL) in a 25 mL 2-neck RB flaskwere added first 2-acetyl chloride (39 mg, 35 uL, 0.5 mmol) followed bythe neat DIPEA (129 mg, 174 uL, 1.0 mmol) at room temperature under anargon atmosphere. After the addition of DIPEA, the reaction mixturebecame a light brown solution. The resulting light brown solution wasstirred for 48 h at which time TLC (1:1, Hex:EA) analysis of thereaction mixture indicated the appearance of a new less polar spot.

Then, it was diluted with water and the organic compound was extractedinto dichloromethane (2×50 mL). The combined organic extracts werewashed with brine solution and dried over anhydrous MgSO₄. Filtrationand concentration gave the crude residue which was purified using anISCO (80 g) column chromatography to afford 99 mg (80%) of ethyl4-[[(3S,3aR,6S,6aR)-6-acetoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylateas an amorphous off-white solid. ¹H-NMR (CDCl₃): δ 7.98 (d, J=7.3 Hz,1H), 7.51 (t, J=7.3 Hz, 1H), 7.34-7.2 (m, 7H), 5.52 (s, 2H), 5.25 (d,J=2.8 Hz, 1H), 5.15 (d, J=3.4 Hz, 1H), 5.0 (d, J=3.4 Hz, 1H), 4.83 (d,J=3.4 Hz, 1H), 4.52 (q, J=6.2 Hz, 2H), 4.32 (d, J=10.1 Hz, 1H), 4.2-4.1(m, 2H), 4.01 (dd, J=8.4, 3.4 Hz, 1H), 2.15 (s, 3H), 1.51 (t, J=7.5 Hz,3H). LC/MS calcd. for C₂₇H₂₇NO₈ [(M+H)⁺] 494, obsd. 494.

Example G Preparation of ethyl4-[[(3S,3aR,6S,6aR)-6-(2-chloroacetyl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylate

To a colorless solution of ethyl4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylate(3.24 g, 7.2 mmol) in dichloromethane (100 mL) in a 250 mL 2-neck RBflask were added first 2-chloroacetyl chloride (972 mg, 685 uL, 8.6mmol) followed by the neat triethylamine (1.81 g, 2.49 mL, 18 mmol) at0-5° C. under an argon atmosphere. The resulting light brown solutionwas allowed to warm to room temperature without removing the coolingbath and stirred for 36 h.

Then, it was diluted with water and the organic compound was extractedinto dichloromethane (2×100 mL). The combined organic extracts werewashed with brine solution and dried over anhydrous MgSO₄. Filtrationand concentration provided a crude residue that was purified using anISCO (330 g) column chromatography to afford 1.89 g (50%) of ethyl4-[[(3S,3aR,6S,6aR)-6-(2-chloroacetyl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylateas an amorphous white solid. ¹H-NMR (CDCl₃): δ 7.95 (d, J=8.4 Hz, 1H),7.63 (t, J=8.4 Hz, 1H), 7.45 (d, J=8.9 Hz, 1H), 7.33-7.3 (m, 3H), 7.24(t, J=6.7 Hz, 1H), 7.21 (d, J=7.3 Hz, 2H), 5.5 (s, 2H), 5.2 (d, J=3.4Hz, 1H), 4.96 (d, J=2.3 Hz, 1H), 4.84 (d, J=3.9 Hz, 1H), 4.81 (d, J=3.4Hz, 1H), 4.42 (s, 2H), 4.3 (q, J=6.2 Hz, 2H), 4.12 (d, J=10.6 Hz, 1H),3.97 (dd, J=10.6, 3.4 Hz, 1H), 3.92 (d, J=10.1 Hz, 1H), 3.89 (dd,J=10.6, 3.4 Hz, 1H), 1.45 (t, J=7.5 Hz, 3H). LC/MS calcd. forC₂₇H₂₆ClNO₈ [(M−H)⁻] 526, obsd. 526.

Example H Preparation of ethyl4-[[(3S,3aS,6aR)-2,3,3a,6a-tetrahydrofuro[3,2-b]furan-3-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylate

To a solution of triphenylphosphine (787 mg, 3.0 mmol) in THF (10 mL) ina 50 mL 2-neck RB flask was added di-isopropylazodicarboxylate (606 mg,591 uL, 3.0 mmol) at 0-5° C. (ice+water) for 2-3 minutes under an argonatmosphere. The resulting light yellow suspension was stirred for 10minutes at this temperature. Then, a solution of ethyl1-benzyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate (323 mg, 1.0mmol) in THF (6 mL) was added drop-wise for 5 minutes. After 2 minutes,the cooling bath was removed to allow the reaction mixture to warm toroom temperature and it was stirred for 10 minutes.

Then, a solution of isosorbide (146 mg, 1.0 mmol) in THF (5 mL) wasslowly added followed by the neat DIPEA (388 mg, 522 uL, 3.0 mmol) atroom temperature. The resulting thick yellow suspension was stirred for15 h when it became an orange color suspension after it was stirred for7 days. Then, the solvent was removed under vacuum and the crude mixturewas purified using an ISCO (80 g) column chromatography to afford 364 mg(84%) of ethyl4-[[(3S,3aS,6aR)-2,3,3a,6a-tetrahydrofuro[3,2-b]furan-3-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylateas a light yellow amorphous solid. ¹H-NMR (CDCl₃): δ 8.0 (d, J=8.3 Hz,1H), 7.5 (t, J=8.5 Hz, 1H), 7.34-7.2 (m, 7H), 6.56 (s, 1H), 5.56 (d,J=3.5 Hz, 1H), 5.5 (s, 2H), 5.2-5.02 (m, 2H), 4.5 (q, J=6.4 Hz, 2H), 4.2(d, J=10.1 Hz, 1H), 4.15-4.05 (m, 1H), 3.51 (dd, J=10.1, 3.4 Hz, 1H),1.4 (t, J=7.5 Hz, 3H). LC/MS calcd. for C₂₅H₂₃NO₆ [(M+H)⁺] 434, obsd.434.

Example I Synthesis of ethyl4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-[(4-fluorophenyl)methyl]-2-oxo-1,2-dihydroquinoline-3-carboxylate

Step 1: Preparation of 1-(4-fluorobenzyl)-isatoic anhydride

A 250 mL 2-neck round bottom flask was charged with isatoic anhydride(14.69 g, 90 mmol) and then DMF (100 mL) was added followed by theaddition of sodium hydride (3.99 g, 166 mmol, 60% dispersion in oil) in2-portions at 15 minute intervals under an argon atmosphere. Duringaddition of NaH, the reaction was exothermic and lot of gas evolved withfoam. The resulting brown suspension was stirred for 1 h and then theneat 4-fluorobenzyl bromide (18.71 g, 12.33 mL, 99 mmol) was added for10 minutes. The light brown foam suspension was stirred at roomtemperature for 48 h.

Then, the brown reaction mixture was quenched by drop-wise addition ofwater (˜5 mL) for 2 minutes and the reaction mixture was stirred for 10minutes. Then, the brown solution was poured into 600 mL of water whilestirring with spatula. The resulting solids were crushed and collectedby filtration. The mother liquor was extracted one time with EA. Thefiltered solids were dissolved in EA (˜200 mL) in hot conditions afterwhich it was combined with the extracted EA. It contained some waterthat separated. The EA layer was dried over MgSO₄, filtered andconcentrated to obtain the crude product which was dissolved again in˜100 mL of EA in hot conditions then diluted with hexanes.

The solution was cooled to room temperature. The resulting solids werecollected by filtration and washed with hexanes. After air drying, 16.7g (68%) of 1-(4-fluorobenzyl)-isatoic anhydride was isolated asoff-white solid.

Step 2: Preparation of ethyl1-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate

A 100 mL 2-neck round bottom flask was charged with1-[(4-fluorophenyl)methyl]-isatoic anhydride (5.42 g, 20 mmol) and thenDMF (40 mL) was added followed by diethylmalonate (3.52 g, 3.34 mL, 22mmol) at room temperature under an argon atmosphere. Then, the solidsodium hydride (1.94 g, 80.6 mmol, 60% dispersion in oil) was added intwo portions during 20 minute intervals at room temperature. Theresulting light yellowish foam suspension was stirred for 15 h and thenthe reaction mixture was quenched slowly with ˜10 mL of water (lot offoam was formed). After 15 minutes of stirring, the foam suspension waspoured into 200 mL of water while stirring with a spatula.

The neutral organic impurities were extracted into EA (2×100 mL) and thebasic aqueous layer was neutralized with 1.0 N HCl while the resultingwhite suspension was extracted into EA (2×150 mL). The combined extractswere washed with brine solution (100 mL) and dried over anhydrous MgSO₄.Filtration of the drying agent and concentration yielded a crude viscousoil that was dissolved in EA (10 mL) at hot condition and then dilutedwith hexanes (25 mL). A precipitate started to form at room temperature,and it was stored in the freezer for 1 h. The resulting light brownsolids were collected by filtration and washed with hexanes. After airdrying, 4.33 g (63%) of ethyl1[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylatewas isolated as white solids. LC/MS calcd. for C₁₉H₁₆FNO₄ [(M−H)⁻] 340,obsd. 340.

Step 3: Preparation of ethyl4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-[(4-fluorophenyl)methyl]-2-oxo-1,2-dihydroquinoline-3-carboxylate

To a solution of triphenylphosphine (787 mg, 3 mmol) in THF (20 mL) in a100 mL 2-neck RB flask was added di-isopropylazodicarboxylate (607 mg,591 uL, 3 mmol) at 0-5° C. (ice+water) for 5-7 minutes under an argonatmosphere. The resulting light yellow suspension was stirred for 10-15minutes at this temperature. Then, a solution of ethyl1-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate(683 mg, 2 mmol) in THF (15 mL) was added drop-wise for 5 minutes. After2 minutes, the cooling bath was removed to allow the reaction mixture towarm to room temperature where it was stirred for 10-15 minutes.

Then, a solution of isosorbide (452 mg, 2.4 mmol) in THF (10 mL) wasslowly added followed by the neat DIPEA (388 mg, 522 uL, 3 mmol) at roomtemperature. The resulting light yellow suspension was stirred for 36 hat which time TLC (1:1, Hex:EA) analysis of the reaction mixtureindicated the appearance of a new spot. Then, the solvent was removedunder vacuum and the crude residue was purified using an ISCO (220 g)column chromatography to obtain 713 mg (76%) of ethyl4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-[(4-fluorophenyl)methyl]-2-oxo-1,2-dihydroquinoline-3-carboxylateas a white solid. ¹H-NMR (DMSO-d6): δ 7.93 (d, J=7.3 Hz, 1H), 7.65-7.54(m, 2H), 7.47 (d, J=7.8 Hz, 1H), 7.32 (t, J=7.3 Hz, 1H), 7.28-7.25 (m,2H), 7.16 (t, J=8.4 Hz, 1H), 5.47 (s, 2H), 5.29 (d, J=3.4 Hz, 1H), 4.89(d, J=2.8 Hz, 1H), 4.76 (d, J=3.4 Hz, 1H), 4.56 (d, J=3.4 Hz, 1H), 4.34(q, J=6.2 Hz, 2H), 4.13 (s, 1H), 4.05-4.02 (m, 1H), 3.8 (dd, J=10.1, 2.8Hz, 1H), 3.73 (dd, J=8.4, 3.4 Hz, 1H), 3.72 (d, J=8.4 Hz, 1H), 1.3 (t,J=7.5 Hz, 3H). LC/MS calcd. for C₂₅H₂₄FNO₇ [(M+H)⁺] 470, obsd. 470.

Example J Preparation of ethyl4-[[(3S,3aR,6S,6aR)-6-(2-chloroacetyl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]oxy]-1-[(4-fluorophenol)methyl]-2-oxo-1,2-dihydroquinoline-3-carboxylate

To a colorless solution of ethyl4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-[(4-fluorophenyl)methyl]-2-oxo-1,2-dihydroquinoline-3-carboxylate(519 mg, 1.1 mmol) in dichloromethane (30 mL) in a 100 mL 2-neck RBflask were added first 2-chloroacetyl chloride (155 mg, 110 uL, 1.38mmol) followed by the neat triethylamine (279 mg, 385 uL, 2.76 mmol) at0-5° C. under an argon atmosphere. The resulting light brown solutionwas allowed to warm to room temperature without removing the coolingbath and stirred for 15 h.

Then, it was diluted with water and the organic compound was extractedinto dichloromethane (2×50 mL). The combined organic extracts werewashed with brine solution and dried over anhydrous MgSO₄. Filtrationand concentration gave the crude residue which was purified using anISCO (220 g) column chromatography to afford 240 mg (40%) of ethyl4-[[(3S,3aR,6S,6aR)-6-(2-chloroacetyl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]oxy]-1-[(4-fluorophenyl)methyl]-2-oxo-1,2-dihydroquinoline-3-carboxylateas an amorphous white solid. ¹H-NMR (DMSO-d6): δ 7.94 (d, J=7.8 Hz, 1H),7.65-7.62 (m, 2H), 7.47 (d, J=8.4 Hz, 1H), 7.32 (t, J=7.3 Hz, 1H),7.27-7.26 (m, 2H), 7.15 (t, J=8.9 Hz, 1H), 5.47 (s, 2H), 5.19 (d, J=2.8Hz, 1H), 4.95 (d, J=2.3 Hz, 1H), 4.84-4.74 (m, 2H), 4.41 (s, 2H), 4.34(q, J=7.3 Hz, 2H), 4.12 (d, J=10.6 Hz, 1H), 3.96 (dd, J=10.1, 3.4 Hz,1H), 3.91 (d, J=10.6 Hz, 1H), 3.88 (dd, J=10.6, 3.4 Hz, 1H), 1.28 (t,J=7.5 Hz, 3H). LC/MS calcd. for C₂₇H₂₅ClFNO₈ [(M+H)⁺] 546, obsd. 546.

Example K Synthesis of4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile

Step 1: Preparation of1-benzyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonitrile

A 250 mL 2-neck round bottom flask was charged with 1-benzyl isatoicanhydride (5.06 g, 20 mmol) and then DMF (45 mL) was added followed byethyl cyanoacetate (2.375 g, 2.23 mL, 21 mmol) at room temperature underan argon atmosphere. Then, the solid sodium hydride (1.95 g, 80.66 mmol,60% dispersion in oil) was added in two portions at 20 minute periods atroom temperature. The resulting pale yellow foam suspension was stirredfor 36 h at room temperature under an argon atmosphere by which time itturned into a very thick black viscous suspension.

Then, it was slowly quenched by adding a few drops of water though itwas not exothermic. The suspension was poured into 500 mL of water whilestirring with spatula. The neutral organic impurities were extractedinto EA (2×250 mL) and the basic aqueous layer was neutralized with 1.0N HCl while the resulting white suspension was extracted into EA (2×150mL). A lot of solid precipitated in the combined extracts which werecooled with ice. The resulting off-white solids were collected byfiltration and washed with hexanes. After air drying, 3.75 g (68%) of1-benzyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonitrile wasisolated as an off-white solid. LC/MS calcd. for C₁₇H₁₂N₂O₂ [(M−H)⁻]275, obsd. 275.

Step 2: Preparation of4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile

To a solution of triphenylphosphine (1.97 g, 7.5 mmol) in THF (50 mL) ina 250 mL 3-neck RB flask was added di-isopropylazodicarboxylate (1.52 g,1.48 mL, 7.5 mmol) at 0-5° C. (ice+water) for 3-5 minutes under an argonatmosphere. The resulting light yellow suspension was stirred for 10-15minutes at this temperature. Then, a solution of1-benzyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonitrile (1.38 g,5.0 mmol) in THF (50 mL, heated to dissolve) was added drop-wise for 5minutes. After 2 minutes, the cooling bath was removed to allow thereaction mixture to warm to room temperature and it was stirred for10-15 minutes.

Then, a solution of isosorbide (877 mg, 6.0 mmol) in THF (30 mL) wasslowly added followed by the neat DIPEA (970 mg, 1.31 mL, 7.5 mmol) atroom temperature. After 3 h stirring, it gave a light yellow solutionwhich was stirred for 15 h at which time TLC analysis of the reactionmixture indicated the absence of any new spot.

Then, it was heated to 65° C. and stirred for 15 h while TLC analysisindicated the presence of lot of starting material, but a new spotappeared and it was continued for another 36 h. Then, the reactionmixture was cooled to room temperature and the solvent was removed undervacuum. The crude residue was purified using an ISCO (330 g) columnchromatography to afford 1.61 g (80%) of4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carbonitrileas a white solid. ¹H-NMR (DMSO-d6): δ 8.01 (d, J=7.3 Hz, 1H), 7.69 (t,J=7.3 Hz, 1H), 7.43 (d, J=8.4 Hz, 1H), 7.35-7.3 (m, 3H), 7.26-7.24 (m,3H), 5.74 (d, J=2.3 Hz, 1H), 5.51 (s, 2H), 5.35 (d, J=3.9 Hz, 1H), 4.92(d, J=3.9 Hz, 1H), 4.65 (d, J=3.4 Hz, 1H), 4.26 (d, J=10.6 Hz, 1H), 4.18(br, s, 1H), 3.93 (dd, J=10.6, 2.8 Hz, 1H), 3.81 (dd, J=9.0, 3.4 Hz,1H), 3.76 (d, J=9.0 Hz, 1H). LC/MS calcd. for C₂₃H₂₀N₂O₅ [(M+H)⁺] 405,obsd. 405.

Example L Preparation of[(3S,3aR,6S,6aR)-3-[(1-benzyl-3-cyano-2-oxo-4-quinolyl)oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

To a colorless solution of4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile(101 mg, 0.25 mmol) in dichloromethane (5 mL) in a 25 mL 2-neck RB flaskwere added first 2-acetyl chloride (39 mg, 35 uL, 0.5 mmol) followed bythe neat DIPEA (129 mg, 174 uL, 1.0 mmol) at 0-5° C. under an argonatmosphere. After addition of DIPEA, the reaction mixture turned into alight brown solution that warmed to room temperature without removingthe cooling bath and was stirred for 48 h by which time TLC (1:1,Hex:EA) analysis of the reaction mixture indicated the appearance of anew less polar spot.

Then, it was diluted with water and the organic compound was extractedinto dichloromethane (2×50 mL). The combined organic extracts werewashed with brine solution and dried over anhydrous MgSO₄. Filtrationand concentration resulted in crude residue that was purified using anISCO (120 g) column chromatography to isolate 106 mg (95%) of[(3S,3aR,6S,6aR)-3-[(1-benzyl-3-cyano-2-oxo-4-quinolyl)oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate as an amorphous white solid. ¹H-NMR (CDCl₃): δ 8.01 (d, J=7.3Hz, 1H), 7.68 (t, J=7.3 Hz, 1H), 7.38-7.2 (m, 7H), 5.98 (d, J=2.3 Hz,1H), 5.5 (s, 2H), 5.22 (d, J=3.9 Hz, 1H), 4.95 (d, J=3.9 Hz, 1H), 4.86(d, J=3.4 Hz, 1H), 4.41 (d, J=10.6 Hz, 1H), 4.18 (dd, J=10.6, 2.8 Hz,1H), 4.0-3.97 (m, 2H), 2.05 (s, 3H). LC/MS calcd. for C₂₅H₂₂N₂O₆[(M+H)⁺] 447, obsd. 447.

Example M Preparation of[(3S,3aR,6S,6aR)-3-[(1-benzyl-3-cyano-2-oxo-4-quinolyl)oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]2-chloroacetate

To a colorless solution of4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile(101 mg, 0.25 mmol) in dichloromethane (5 mL) in a 25 mL 2-neck RB flaskwere added first 2-chloroacetyl chloride (112 mg, 80 uL, 1.0 mmol) thenfollowed by the neat DIPEA (388 mg, 522 uL, 3.0 mmol) at roomtemperature under an argon atmosphere. After addition of DIPEA, thereaction mixture turned into a dark brown solution. The resultingsolution was stirred for 48 h by which time TLC (1:1, Hex:EA) analysisof the reaction mixture indicated the appearance of a new less polarspot.

Then, it was diluted with water and the organic compound was extractedinto dichloromethane (2×50 mL). The combined organic extracts werewashed with brine solution and dried over anhydrous MgSO₄. Filtrationand concentration gave the crude residue which was purified by using anISCO (120 g) column chromatography to isolate 105 mg (87%) of[(3S,3aR,6S,6aR)-3-[(1-benzyl-3-cyano-2-oxo-4-quinolyl)oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]2-chloroacetate as an amorphous off-white solid. ¹H-NMR (CDCl₃): δ 8.05(d, J=7.4 Hz, 1H), 7.52 (t, J=7.4 Hz, 1H), 7.38-7.1 (m, 7H), 5.91 (d,J=2.3 Hz, 1H), 5.5 (s, 2H), 5.35 (d, J=3.9 Hz, 1H), 5.0 (d, J=3.9 Hz,1H), 4.94 (d, J=3.4 Hz, 1H), 4.42 (d, J=10.6 Hz, 1H), 4.21-4.0 (m, 5H).LC/MS calcd. for C₂₅H₂₁ClN₂O₆ [(M+H)⁺] 481, obsd. 481.

Example N Synthesis of4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-[(4-fluorophenyl)methyl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile

Step 1: Preparation of1-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonitrile

A 250 mL 3-neck round bottom flask was charged with1-[(4-fluorophenyl)methyl]-isatoic anhydride (11.77 g, 40 mmol) and DMF(90 mL) was added followed by ethyl cyanoacetate (4.75 g, 4.47 mL, 42mmol) under an argon atmosphere. Then, the solid sodium hydride (3.87 g,161.32 mmol, 60% dispersion in oil) was added in two portions at 20minute intervals at room temperature. During the addition, a lot of gasevolved resulting in a light yellowish foam suspension. It was stirredfor 48 h at room temperature under an argon atmosphere by which time itbecame a black suspension.

Then, it was slowly quenched by the addition of a few drops of water andit was slightly exothermic. The suspension was poured into 500 mL ofwater while stirred with the spatula. The neutral organic compounds wereextracted into EA (250 mL) and the basic aqueous layer was neutralizedwith 1.0N HCl though the resulting white precipitate was not afilterable solid. Then, it was diluted with -30% EA in hexane solutionand as a result some nice solids were formed after being stirred with aspatula. The solids were collected by filtration and washed with waterand hexanes. After air drying, 11.7 g (99%) of1-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonitrilewas isolated as a light brown solids. LC/MS calcd. forC₁₇H₁₁FN₂O₂[(M−H)⁻] 293, obsd. 293.

Step 2: Preparation of4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-[(4-fluorophenyl)methyl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile

To a solution of triphenylphosphine (3.93 g, 15 mmol) in THF (100 mL) ina 500 mL 3-neck RB flask was added di-isopropylazodicarboxylate (3.03 g,2.95 mL, 15 mmol) at 0-5° C. (ice+water) for 10 minutes under an argonatmosphere. Within 2 minutes, a light yellow suspension was formed whichwas stirred for 10 minutes at this temperature. Then, a solution of1-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonitrile(2.94 g, 10 mmol) in THF (100 mL, dissolved at r.t.) was added drop-wisefor 15 minutes. After 2 minutes, the cooling bath was removed to allowthe reaction mixture to warm to room temperature and stirred for 10-15minutes.

Then, a solution of isosorbide (1.75 g, 12 mmol) in THF (60 mL) wasslowly added followed by the neat triethylamine (1.52 g, 2.09 mL, 15mmol) at room temperature. The resulting light brown solution wasstirred for 3 h at room temperature. Then, it was heated to 65° C. andstirred for 36 h by which time TLC analysis indicated the presence of anew polar spot. The reaction mixture was cooled to room temperature andthe solvent was removed under vacuum. Then, the crude residue waspurified using an ISCO (220 g) column chromatography to afford 4.1 g ofa white solid. However, TLC analysis of this solid indicated thepresence of some triphenylphosphine oxide impurity. A 1.5 g of thismaterial was crystallized from hot acetonitrile to obtain 906 mg. Theremaining material was crystallized from hot EA and hexanes to obtain2.1 g with a total of 3.06 g (72%) of pure4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-[(4-fluorophenyl)methyl]-2-oxo-1,2-dihydroquinoline-3-carbonitrileas a white solid. ¹H-NMR (DMSO-d6): δ 8.01 (d, J=7.3 Hz, 1H), 7.70 (t,J=7.8 Hz, 1H), 7.46 (d, J=8.4 Hz, 1H), 7.35-7.3 (m, 3H), 7.14 (t, J=8.4Hz, 2H), 5.74 (d, J=2.3 Hz, 1H), 5.49 (s, 2H), 5.35 (d, J=3.4 Hz, 1H),4.92 (d, J=3.9 Hz, 1H), 4.65 (d, J=3.4 Hz, 1H), 4.26 (d, J=11.2 Hz, 1H),4.19 (br, s, 1H), 3.93 (dd, J=10.6, 3.4 Hz, 1H), 3.81 (dd, J=9.0, 3.4Hz, 1H), 3.76 (d, J=9.0 Hz, 1H). LC/MS calcd. for C₂₃H₁₉FN₂O₅ [(M+H)⁺]423, obsd. 423.

Example O Preparation of[(3S,3aR,6S,6aR)-3-[[3-cyano-1-[(4-fluorophenyl)methyl]-2-oxo-4-quinolyl]oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

To a light brown solution of4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-[(4-fluorophenyl)methyl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile(1.05 g, 2.48 mmol) in dichloromethane (50 mL) in a 100 mL 2-neck RBflask were added first acetyl chloride (243 mg, 220 uL, 3.1 mmol)followed by the neat NEt₃ (627 mg, 864 uL, 6.2 mmol) at 0-5° C. under anargon atmosphere. There was no color change so the light brown solutionwas allowed to warm to room temperature without removing the coolingbath and stirred for 15 h by which time TLC (1:1, Hex:EA) analysis ofthe reaction mixture indicated the appearance of a new less polar spot.

Then, it was diluted with water and the organic compound was extractedinto dichloromethane. The combined organic extracts were washed withbrine solution and dried over anhydrous MgSO₄. Filtration andconcentration gave the crude residue which was purified by using an ISCO(220 g) column chromatography to isolate 657 mg (57%) of[(3S,3aR,6S,6aR)-3-[[3-cyano-1-[(4-fluorophenyl)methyl]-2-oxo-4-quinolyl]oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate as an amorphous white solid. ¹H-NMR (DMSO-d6): δ 8.05 (d, J=7.8Hz, 1H), 7.70 (t, J=8.4 Hz, 1H), 7.46 (d, J=8.4 Hz, 1H), 7.34-7.3 (m,3H), 7.14 (t, J=9.0 Hz, 2H), 5.80 (d, J=2.3 Hz, 1H), 5.49 (s, 2H), 5.13(d, J=3.4 Hz, 1H), 4.99 (d, J=3.9 Hz, 1H), 4.86 (d, J=3.9 Hz, 1H), 4.32(d, J=10.6 Hz, 1H), 4.03-3.98 (m, 2H), 3.92 (d, J=10.1 Hz, 1H), 2.05 (s,3H). LC/MS calcd. for C₂₅H₂₁FN₂O₆ [(M+H)⁺] 465, obsd. 465.

Example P Preparation of[(3S,3aR,6S,6aR)-3-[[3-cyano-1-[(4-fluorophenyl)methyl]-2-oxo-4-quinolyl]oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate

To a colorless solution of4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-[(4-fluorophenyl)methyl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile(435 mg, 1.03 mmol) in dichloromethane (15 mL) in a 50 mL 2-neck RBflask were added first benzoyl chloride (174 mg, 144 uL, 1.24 mmol)followed by the neat triethylamine (253 mg, 348 uL, 2.5 mmol) at 0-5° C.under an argon atmosphere. The resulting light yellow solution wasallowed to warm to room temperature without removing the cooling bathand stirred for 15 h by which time TLC (1:1, Hex:EA) analysis of thereaction mixture indicated the appearance of a new less polar spot.

Then, it was diluted with water and the organic compound was extractedinto dichloromethane (2×50 mL). The combined organic extracts werewashed with brine solution and dried over anhydrous MgSO₄. Filtrationand concentration yielded a crude residue that was purified using anISCO (80 g) column chromatography to obtain 360 mg (66%) of[(3S,3aR,6S,6aR)-3-[[3-cyano-1-[(4-fluorophenyl)methyl]-2-oxo-4-quinolyl]oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate as an amorphous white solid. ¹H-NMR (DMSO-d6): δ 8.0-7.93 (m,3H), 7.68 (t, J=7.6 Hz, 1H), 7.62 (t, J=8.4 Hz, 1H), 7.55-7.4 (m, 3H),7.42 (d, J=7.5 Hz, 1H), 7.33-7.20 (m, 4H), 5.76 (d, J=2.3 Hz, 1H), 5.49(s, 2H), 5.12 (d, J=3.9 Hz, 1H), 4.96 (d, J=3.9 Hz, 1H), 4.85 (d, J=3.4Hz, 1H), 4.32 (d, J=10.6 Hz, 1H), 4.03-3.98 (m, 2H), 3.92 (d, J=10.1 Hz,1H). LC/MS calcd. for C₃₀H₂₃FN₂O₆ [(M+H)⁺] 527, obsd. 527.

Example Q Preparation of[(3S,3aR,6S,6aR)-3-[[3-cyano-1-[(4-fluorophenyl)methyl]-2-oxo-4-quinolyl]oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]2-chloroacetate

To a light brown solution of4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-[(4-fluorophenyl)methyl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile(1.05 g, 2.48 mmol) in dichloromethane (50 mL) in a 100 mL 2-neck RBflask were added first 2-chloroacetyl chloride (351 mg, 248 uL, 3.1mmol) followed by the neat NEt₃ (627 mg, 864 uL, 6.2 mmol) at 0-5° C.under an argon atmosphere. There was no color change and the light brownsolution was allowed to warm to room temperature itself and stirred for15 h at room temperature by which time TLC (1:1, Hex:EA) analysis of thereaction mixture indicated the appearance of a new less polar spot.

Then, it was diluted with water and the organic compound was extractedinto dichloromethane (2×50 mL). The combined organic extracts werewashed with brine solution and dried over anhydrous MgSO₄. Filtrationand concentration produced a crude residue that was purified using anISCO (220 g) column chromatography to afford 390 mg (32%) of[(3S,3aR,6S,6aR)-3-[[3-cyano-1-[(4-fluorophenyl)methyl]-2-oxo-4-quinolyl]oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]2-chloroacetate as an amorphous white solid. ¹H-NMR (DMSO-d6): δ 8.03(d, J=6.7 Hz, 1H), 7.72 (t, J=7.3 Hz, 1H), 7.46 (d, J=7.8 Hz, 1H),7.35-7.31 (m, 3H), 7.15 (t, J=7.8 Hz, 2H), 5.81 (d, J=2.3 Hz, 1H), 5.49(s, 2H), 5.23 (d, J=3.9 Hz, 1H), 4.98 (d, J=3.9 Hz, 1H), 4.90 (d, J=3.4Hz, 1H), 4.44 (s, 2H), 4.33 (d, J=10.6 Hz, 1H), 4.03-34.01 (m, 2H), 3.97(d, J=10.6, 1H). LC/MS calcd. for C₂₅H₂₀ClFN₂O₆ [(M+H)⁺] 499, obsd. 499.

Example R Preparation of4-[4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-3-chloro-anilino]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile

Step 1: Preparation of(3S,3aR,6S,6aR)-6-(2-chloro-4-nitro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol

To a solution of triphenylphosphine (7.87 g, 30 mmol) in THF (200 mL) ina 500 mL 3-neck RB flask was added di-isopropylazodicarboxylate (6.06 g,5.9 mL, 30 mmol) at 0-5° C. (ice+water) for 10 minutes under an argonatmosphere. The resulting light yellow suspension was stirred for 10-15minutes at this temperature. Then, a clear solution of2-chloro-4-nitrophenol (3.47 g, 20 mmol) in THF (100 mL) was addeddrop-wise over 10-15 minutes. After 2 minutes, the cooling bath wasremoved to allow the reaction mixture to warm to room temperature whereit was stirred for 10-15 minutes.

Then, a solution of isosorbide (3.51 g, 24 mmol) in THF (60 mL) wasslowly added followed by the neat DIPEA (3.87 g, 5.22 mL, 30 mmol) atroom temperature. It produced a light yellow color solution after theaddition of isosorbide solution. Then, the resulting light yellowsolution was stirred for 36 h and the cloudy reaction mixture was heatedto 65° C. and stirred for 4 h by which time TLC (1:1, Hex:EA) analysisof the reaction mixture indicated the appearance of a new spot.

Then, the reaction mixture was cooled to room temperature and thesolvent was removed under vacuum. The crude residue was dissolved in aminimum amount of EA at hot condition and then diluted with hexanes. Theresulting solution was stored in the freezer over the weekend. Theresulting off-white solids were collected by filtration and washed withhexanes. After air drying, 20.05 g of solid was isolated as a mixture ofthe desired product and triphenylphosphine oxide based on the TLC. Thissolid was dissolved in acetonitrile (˜30 mL) in hot conditions and thenstored in the freezer. The resulting triphenylphosphine oxide solidswere collected by filtration and the filtration was removed under vacuumwhich mostly contained the desired product.

Then, the residue was again dissolved in minimum EA at hot condition anddiluted with hexanes and the clear solution was stored in the freezer.The remaining triphenylphosphine oxide precipitated which was removed byfiltration under vacuum to obtain 5.56 g (92%) of(3S,3aR,6S,6aR)-6-(2-chloro-4-nitro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-olas a light brown paste. ¹H-NMR (DMSO-d6): δ 8.34 (d, J=2.3 Hz, 1H), 8.23(dd, J=8.4, 2.8 Hz, 1H), 7.46 (d, J=8.4 Hz, 1H), 5.30 (d, J=3.9 Hz, 1H),5.16 (d, 2.8 Hz, 1H), 4.64 (d, J=3.9 Hz, 1H), 4.48 (d, J=3.9 Hz, 1H),4.15 (br, s, 1H), 4.02 (dd, J=10.1, 3.9 Hz, 1H), 3.93 (d, J=10.1 Hz,1H), 3.81 (dd, J=8.4, 3.4 Hz, 1H), 3.74 (d, J=9.0 Hz, 1H). LC/MS calcd.for C₁₂H₁₂ClNO₆ [(M−H)⁻]300, obsd. 300.

Step 2: Preparation of(3S,3aR,6S,6aR)-6-(4-amino-2-chloro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol

To a solution of(3S,3aR,6S,6aR)-6-(2-chloro-4-nitro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol(3.01 g, 10 mmol) in methanol (100 mL) in a 250 mL single neck RB flaskwere added an excess zinc dust (6.54 g, 100 mmol) and ammonium chloride(8.02 g, 150 mmol) followed by water (50 mL) at room temperature underan argon atmosphere. It was exothermic reaction after the addition ofwater. Then, the reaction mixture was heated twice with a heat gun.

Then, it was stirred for another 3 h at room temperature by which timeTLC analysis of the mixture indicated the absence of starting material.During this period the initial yellow color solution changed into acolorless solution. The excess zinc dust was filtered off using thecotton plug and the solid cake was washed with methanol and water. Thefiltrate was removed under vacuum and the aqueous layer was saturatedwith the solid NaCl. Then, the organic compound was extracted with EA(3×100 mL) and the combined extracts were washed with brine solution.The organic layer was dried over anhydrous MgSO₄, filtration andconcentration gave the crude 2.7 g (100%) of(3S,3aR,6S,6aR)-6-(4-amino-2-chloro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-olas a light brown solid which was used directly in the next step withoutpurification. LC/MS calcd. for C₁₂H₁₄ClNO₄ [(M−H)⁻] 270, obsd. 270.

Step 3: Preparation of1-benzyl-4-chloro-2-oxo-1,2-dihydroquinoline-3-carbonitrile

To a light brown solution of1-benzyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonitrile (2.53 g,9.15 mmol) in DMF (30 mL) in a 100 mL 2-neck round bottom flask wereadded first lithium chloride (1.94 g, 45.75 mmol, previously dried underhigh vacuum at 150° C. for 3 h) followed by methanesulfonyl chloride(2.09 g, 1.42 mL, 18.3 mmol) under an argon atmosphere at roomtemperature. The resulting brown solution was stirred for 48 h at roomtemperature.

Then, it was slowly quenched with 4 mL of water and stirred for 10minutes. The resulting solid mixture was poured into 300 mL of waterwhile being stirred with a spatula. The light yellow solids werecollected by filtration and washed with water and hexanes. After airdrying, 1.59 g (59%) of1-benzyl-4-chloro-2-oxo-1,2-dihydroquinoline-3-carbonitrile was isolatedas light brown solids. LC/MS calcd. for C₁₇H₁₁ClN₂O [(M−H)⁻] 293, obsd.293.

Step 4: Preparation of4-[4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-3-chloro-anilino]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile

To a mixture of1-benzyl-4-chloro-2-oxo-1,2-dihydroquinoline-3-carbonitrile (1.47 g, 5.0mmol) and(3S,3aR,6S,6aR)-6-(4-amino-2-chloro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol(1.66 g, 6.1 mmol) in a 50 mL single neck RB flask was addediso-propanol (35 mL) at room temperature under an argon atmosphere.Then, an excess of triethylamine (1.01 g, 1.39 mL, 10.0 mmol) was addedand the resulting light brown suspension was heated to reflux (110° C.,bath temperature) for 5 h.

Then, 35 mL of acetonitrile was added to dissolve all solids and theresulting brown solution was refluxed for another 4 days by which timeTLC (EA) analysis indicated the presence of a new polar spot. Thereaction mixture was cooled to room temperature and the solvent wasremoved under vacuum. The crude residue was diluted with water andsaturated ammonium chloride solution. Then, the organic compound wasextracted into ethyl acetate (3×70 mL). The combined extracts werewashed with brine solution and the organic layer was dried, filtered andthe solvent was removed under vacuum. The crude residue was dissolved inacetonitrile at hot condition and then it was diluted with ethylacetate. As a result, lot of yellow solids were precipitated which wasdiluted with hexanes. The suspension was stored in the freezer for 15 hand the solids were collected by filtration and dried to afford 1.31 g(50%) of4-[4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-3-chloro-anilino]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carbonitrileas a light yellow solid. ¹H-NMR (DMSO-d6): δ 9.78 (s, 1H), 8.32 (d,J=7.3 Hz, 1H), 7.63 (t, J=7.8 Hz, 1H), 7.52 (d, J=2.3 Hz, 1H), 7.38-7.22(m, 9H), 5.47 (s, 2H), 5.27 (d, J=3.4 Hz, 1H), 4.98 (d, J=2.8 Hz, 1H),4.60 (d, J=3.4 Hz, 1H), 4.49 (d, J=3.4 Hz, 1H), 4.14 (br, s, 1H), 3.96(dd, J=10.1, 3.4 Hz, 1H), 3.91 (d, J=10.1 Hz, 1H), 3.80 (dd, J=9.0, 3.4Hz, 1H), 3.72 (d, J=9.0 Hz, 1H). LC/MS calcd. for C₂₉H₂₄ClN₃O₅ [(M+H)⁺]530, obsd. 530.

Example S Synthesis of ethyl4-[4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-3-chloro-anilino]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylate

Step 1: Preparation of ethyl1-benzyl-4-chloro-2-oxo-quinoline-3-carboxylate

To a light brown solution of ethyl1-benzyl-4-hydroxy-2-oxo-quinoline-3-carboxylate (2.8 g, 8.6 mmol) inDMF (30 mL) in a 100 mL 2-neck round bottom flask were added firstlithium chloride (1.91 g, 45.0 mmol, previously dried under high vacuumat 150° C. for 3 h) followed by methanesulfonyl chloride (2.06 g, 1.39mL, 18.0 mmol) under an argon atmosphere at room temperature. Within 5minutes, it gave a clear light brown solution which was stirred for 48 hat room temperature.

Then, it was slowly quenched with 10 mL of water and stirred for 10minutes. The resulting brown solution was poured into 300 mL of waterwhile being stirred with a spatula. The resulting off-white solids werecollected by filtration and washed with water and hexanes. After airdrying, 1.91 g (65%) of ethyl1-benzyl-4-chloro-2-oxo-quinoline-3-carboxylate was isolated as lightbrown solids. LC/MS calcd. for C₁₉H₁₆ClNO₃ [(M−H)⁻] 340, obsd. 340.

Step 2: Preparation of ethyl4-[4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-3-chloro-anilino]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylate

To a mixture of ethyl 1-benzyl-4-chloro-2-oxo-quinoline-3-carboxylate(390 mg, 1.1 mmol) and(3S,3aR,6S,6aR)-6-(4-amino-2-chloro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol(269 mg, 0.9 mmol) in a 50 mL 2-neck RB flask was added iso-propanol (5mL) at room temperature under an argon atmosphere. Then, an excess oftriethylamine (304 mg, 418 uL, 3.0 mmol) was added and the resultinglight brown suspension was heated to reflux (110° C., bath temperature)for 6 h. Then, 5 mL of acetonitrile was added and the resulting solutionwas refluxed for another 48 h by which time TLC (EA) analysis of themixture indicated the presence of a new polar spot.

The reaction mixture was cooled to room temperature and water was added.The resulting white precipitate was extracted into EA (2×50 mL) and thecombined organic extracts were washed with brine solution and dried overanhydrous magnesium sulfate. Filtration and concentration gave the crudepaste which was purified using an ISCO (120 g) column chromatography toafford 116 mg (20%) of ethyl4-[4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-3-chloro-anilino]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylateas a light yellow solid. ¹H-NMR (DMSO-d6): δ 8.85 (s, 1H), 8.29 (d,J=6.7 Hz, 1H), 7.64-7.53 (m, 4H), 7.37 (d, 9.0 Hz, 1H), 7.32-7.2 (m,5H), 7.07 (dd, J=9.0, 2.8 Hz, 1H), 5.47 (s, 2H), 5.26 (d, J=3.4 Hz, 1H),4.9 (d, J=3.4 Hz, 1H), 4.56 (d, J=3.4 Hz, 1H), 4.48 (d, J=3.4 Hz, 1H),4.13 (s, 1H), 3.97 (dd, J=10.8, 4.2 Hz, 1H), 3.89 (d, J=9.6 Hz, 1H),3.79 (dd, J=9.6, 3.0 Hz, 1H), 3.77 (d, J=9.6 Hz, 1H), 3.56 (q, J=6.6 Hz,2H), 1.08 (t, J=7.8, 3H). LC/MS calcd. for C₃₁H₂₉ClN₂O₇ [(M+H)⁺] 577,obsd. 577.

Example T Preparation of(3S,3aR,6S,6aR)-6-[2-chloro-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol

To a mixture of 4-chloro-6,7-dimethoxyquinazoline (449 mg, 2.0 mmol) and(3S,3aR,6S,6aR)-6-(4-amino-2-chloro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol(680 mg, 2.5 mmol) in a 100 mL single neck RB flask was addediso-propanol (40 mL) at room temperature under an argon atmosphere. Theresulting suspension was heated to reflux (110° C., bath temperature)which produced a clear solution when the temperature reached to 100° C.After 10 minutes reflux, a light yellow precipitate started to formwhich became a thick suspension during 4 h reflux.

Then, the reaction mixture was diluted with EA at reflux and it wascooled to room temperature. The resulting light yellow solids werecollected by filtration and washed with EA. After air drying, 498 mg(54%) of(3S,3aR,6S,6aR)-6-[2-chloro-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-olwas isolated as a light yellow solid. TLC analysis (EA) of the solidsindicated the presence of some impurity. Then, the solids were dissolvedin acetonitrile with a small amount of methanol in hot conditions andthen stored in the freezer for 1 h. The resulting solids were collectedby filtration and washed with acetonitrile. After air drying, 190 mg ofpure(3S,3aR,6S,6aR)-6-[2-chloro-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol was isolated as a light yellowsolid. ¹H-NMR (DMSO-d6): δ 11.55 (s, 1H), 8.84 (s, 1H), 8.32 (s, 1H),8.0 (d, J=2.2 Hz, 1H), 7.88 (dd, J=8.4, 2.2 Hz, 1H), 7.44-7.43 (m, 2H),4.98 (d, J=3.4 Hz, 1H), 4.61 (d, J=3.9 Hz, 1H), 4.49 (d, 3.4 Hz, 1H),4.15 (d, J=2.8 Hz, 1H), 4.02 (s, 3H), 4.01 (br, s, 1H), 3.99 (s, 3H),3.98 (d, J=5.6 Hz, 1H), 3.91 (d, J=9.5 Hz, 1H), 3.80 (dd, J=8.9, 3.9 Hz,1H), 3.72 (d, J=8.9 Hz, 1H). LC/MS calcd. for C₂₂H₂₂ClN₃O₆ [(M+H)⁺] 460,obsd. 460.

Example U Preparation of(3S,3aR,6S,6aR)-6-[2-chloro-4-(thieno[3,2-d]pyrimidin-4-ylamino)phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol

To a mixture of 4-chlorothieno[3,2-d]pyrimidine (171 mg, 1.0 mmol) and(3S,3aR,6S,6aR)-6-(4-amino-2-chloro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol(543 mg, 2.0 mmol) in a 50 mL single neck RB flask was addediso-propanol (20 mL) at room temperature under an argon atmosphere. Theresulting suspension was heated to reflux (110° C., bath temperature)yielding a clear solution. After 3 h reflux, some light yellowprecipitate formed and this mixture was stirred for another 3 h at thistemperature. After cooling to 80° C., some EA was added and the reactionsuspension was allowed to cool to room temperature.

Then, the solids were collected by filtration and washed with EA. Afterair drying, 317 mg (78%) of(3S,3aR,6S,6aR)-6-[2-chloro-4-(thieno[3,2-d]pyrimidin-4-ylamino)phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-olwas isolated as a light yellow solid. ¹H-NMR (DMSO-d6): δ 11.27 (s, 1H),8.85 (s, 1H), 8.46 (d, J=5.6 Hz, 1H), 7.89 (d, J=2.8 Hz, 1H), 7.63 (d,J=6.2 Hz, 1H), 7.62 (d, J=5.0 Hz, 1H), 7.35 (d, J=8.4 Hz, 1H), 5.3 (d,J=3.4 Hz, 1H), 5.09 (s, 1H), 4.68-4.65 (m, 2H), 4.12-4.0 (m, 5H). LC/MScalcd. for C₁₈H₁₆ClN₃O₄S [(M+H)⁺] 406, obsd. 406.

Example V Preparation of(3S,3aR,6S,6aR)-6-[2-chloro-4-[(2-methylsulfanylpyrimidin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol

To a mixture of 4-iodo-2-methylthiopyrimidine (504 mg, 2.0 mmol) and(3S,3aR,6S,6aR)-6-(4-amino-2-chloro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol(679 mg, 2.5 mmol) in a 50 mL single neck RB flask was addediso-propanol (30 mL) at room temperature under an argon atmosphere. Theresulting suspension was heated to reflux (110° C., bath temperature)which produced a clear solution. After 20 minutes reflux, some lightyellow precipitate started to form and it was stirred for another 5 h atthis temperature.

Then, it was lowered the temperature to 85° C. and stirred for 15 h. Atthis time, some EA was added and the reaction suspension was cooled toroom temperature. Then, the solids were collected by filtration andwashed with EA. After air drying, 522 mg (62%) of(3S,3aR,6S,6aR)-6-[2-chloro-4-[(2-methylsulfanylpyrimidin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-olwas isolated as a light yellow solid. ¹H-NMR (DMSO-d6): δ 10.55 (s, 1H),8.16 (d, J=6.2 Hz, 1H), 7.94 (s, 1H), 7.48 (dd, J=8.4, 2.3 Hz, 1H), 7.29(d, J=8.4 Hz, 1H), 6.58 (d, J=6.2 Hz, 1H), 4.91 (d, J=3.2 Hz, 1H), 4.58(d, J=3.9 Hz, 1H), 4.46 (d, 3.9 Hz, 1H), 4.13 (d, J=3.4 Hz, 1H), 3.95(dd, J=10.5, 3.9 Hz, 1H), 3.89 (d, J=9.8 Hz, 1H), 3.78 (dd, J=9.5, 3.4Hz, 1H), 3.77 (d, J=9.5 Hz, 1H), 2.56 (s, 3H). LC/MS calcd. forC₁₇H₁₈ClN₃O₄S [(M+H)⁺] 396, obsd. 396.

Example W Preparation of(3S,3aR,6S,6aR)-6-[4-[[2-[4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-3-chloro-anilino]pyrimidin-4-yl]amino]-2-chloro-phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol

To a solution of(3S,3aR,6S,6aR)-6-(4-amino-2-chloro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol(350 mg, 1.2 mmol) in MeOH (2.0 mL) in a 25 mL sealed tube were added2,4-dichloropyrimidine (75 mg, 0.5 mmol) and water (2 mL) at roomtemperature under an argon atmosphere. Then, the rubber septum wasreplaced with a screw cap and the resulting clear colorless solution washeated to 120° C. (bath temperature). After 3 h at this temperature, itbecame a cloudy solution which was stirred for another 2 h. Then, it wascooled to room temperature as a result some white paste formed.

Then, it was diluted with water and the resulting white solid wascollected by filtration and washed with water and hexanes. After airdrying, 230 mg of off-white solid was isolated. TLC analysis of thissolid that was dissolved in methanol was indicated the presence of someimpurity. Then, the solid was suspended in EA and acetonitrile in hotcondition and the suspension was stored in the freezer for overnight.The white solid was collected by filtration and washed with EA. Afterair drying, 171 mg (55%) of(3S,3aR,6S,6aR)-6-[4-[[2-[4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-3-chloro-anilino]pyrimidin-4-yl]amino]-2-chloro-phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-olwas isolated as a white solid. ¹H-NMR (DMSO-d6): δ 11.07 (s, 1H), 10.6(s, 1H), 7.96 (d, J=6.2 Hz, 1H), 7.78 (s, 1H), 7.64 (s, 1H), 7.49 (s,1H), 7.38 (d, J=7.8 Hz, 1H), 7.27 (d, J=8.6 Hz, 1H), 7.22 (d, J=9.0 Hz,1H), 6.49 (d, J=5.6 Hz, 1H), 4.9 (s, 1H), 4.89 (s, 1H), 4.58 (d, J=3.2Hz, 1H), 4.56 (d, J=3.2 Hz, 1H), 4.47-4.46 (m, 2H), 4.13 (s, 2H),3.96-3.94 (m, 2H), 3.88-3.85 (m, 2H), 3.79-3.77 (m, 2H), 3.71-3.70 (m,2H), 3.41 (br, s, 2H). LC/MS calcd. for C₂₈H₂₈Cl₂N₄O₈ [(M+H)⁺] 619,obsd. 619.

Example X Synthesis of[(3S,3aR,6S,6aR)-3-[4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

Step 1: Preparation of(3S,3aR,6S,6aR)-6-(4-nitrophenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol

To a solution of triphenylphosphine (1.57 g, 6 mmol) in THF (30 mL) in a100 mL 2-neck RB flask was added di-isopropylazodicarboxylate (1.21 g,1.18 mL, 6 mmol) at 0-5° C. (ice+water) for 5 minutes under an argonatmosphere. The resulting light yellow suspension was stirred for 10-15minutes at this temperature. Then, a clear solution of 4-nitrophenol(556 mg, 4 mmol) in THF (20 mL) was added drop-wise over 5 minutes.After 2 minutes, the cooling bath was removed to allow the reactionmixture to warm to room temperature where it was stirred for 10-15minutes.

Then, a solution of isosorbide (701 mg, 4.8 mmol) in THF (15 mL) wasslowly added followed by the neat DIPEA (775 mg, 1.05 mL, 6 mmol) atroom temperature. The resulting light yellow suspension was stirred for48 h by which time TLC (1:1, Hex:EA) analysis of the reaction mixtureindicated the appearance of a new spot. Then, the solvent was removedunder vacuum and the crude residue was purified using an ISCO (220 g)column chromatography to afford 1.02 g (96%) of(3S,3aR,6S,6aR)-6-(4-nitrophenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-olas a light brown viscous oil. LC/MS calcd. for C₁₂H₁₃NO₆ [(M−H)⁻] 266,obsd. 266.

Step 2: Preparation of[(3S,3aR,6S,6aR)-3-(4-nitrophenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

To a colorless solution of(3S,3aR,6S,6aR)-6-(4-nitro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol(1.0 g, 3.7 mmol) in dichloromethane (30 mL) in a 100 mL single neck RBflask were added first acetyl chloride (390 mg, 356 uL, 5 mmol) followedby an excess of triethylamine (1.01 g, 1.4 mL, 10 mmol) at 0-5° C. underan argon atmosphere. The resulting light brown solution was allowed towarm to room temperature without removing the cooling bath and then itwas stirred for 15 h at room temperature by which time TLC (1:1, Hex:EA)analysis of the reaction mixture indicated the appearance of a new spot.Then, it was diluted with water and the organic compound was extractedinto dichloromethane (2×50 mL). The combined organic extracts werewashed with brine solution and dried over anhydrous MgSO₄. Filtrationand concentration provided a crude light brown oil that was purifiedusing an ISCO (120 g) column chromatography to obtain 1.08 g (95%) of[(3S,3aR,6S,6aR)-3-(4-nitrophenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate as a viscous light yellow oil. LC/MS calcd. for C₁₄H₁₅NO₇[(M−H)⁻] 308, obsd. 308.

Step 3: Preparation of[(3S,3aR,6S,6aR)-3-(4-aminophenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

To a mixture of zinc dust (2.28 g, 35 mmol) and ammonium chloride (2.8g, 52.5 mmol) in a 100 mL 2-neck RB flask was added first a solution of[(3S,3aR,6S,6aR)-3-(4-nitrophenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate (1.08 g, 3.5 mmol) in methanol (40 mL) followed by water (20 mL)at room temperature under an argon atmosphere. It was exothermicreaction after the addition of methanol solution. Cement coloredclusters formed after the addition of water. It was stirred for 1.5 hand then the reaction mixture was heated with a heat gun.

After being stirred for another 1 h at room temperature, TLC analysis ofthe mixture indicated the absence of starting material. The excess zincdust was filtered off and the solid cake was washed with methanol andwater. The solvent was removed under vacuum and the organic compound wasextracted into EA (2×50 mL) while the combined extracts were washed withbrine solution. The organic layer was dried over anhydrous MgSO₄,filtration and concentration gave the crude oil which was purified usingan ISCO (80 g) column chromatography to obtain 685 mg (70%) of[(3S,3aR,6S,6aR)-3-(4-aminophenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate as a white solid. LC/MS calcd. for C₁₄H₁₇NO₅ [(M−H)⁻] 278, obsd.278.

Step 4: Preparation of[(3S,3aR,6S,6aR)-3-[4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

To a mixture of 4-chloro-6,7-dimethoxyquinazoline (112 mg, 0.5 mmol) and[(3S,3aR,6S,6aR)-3-(4-aminophenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate (251 mg, 0.9 mmol) in a 50 mL 2-neck RB flask was addediso-propanol (10 mL) at room temperature under an argon atmosphere. Theresulting suspension was heated to reflux (110° C., bath temperature)which produced a clear solution when the temperature reached ˜70° C.Within few minutes some yellow precipitate started to form which wasstirred for 8 h at this temperature and 12 h at 85° C.

Then, it was cooled to room temperature and later it was stored in therefrigerator for 5 h. The resulting light yellow solids were collectedby filtration and washed with iso-propanol. The solids were dried overweekend to obtain 234 mg (100%) of[(3S,3aR,6S,6aR)-3-[4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetateas a light yellow solid. ¹H-NMR (DMSO-d6): δ 11.35 (s, 1H), 8.75 (s,1H), 8.32 (s, 1H), 7.62-7.6 (m, 2H), 7.34 (s, 1H), 7.09 (d, J=7.8 Hz,2H), 5.09 (d, J=3.4 Hz, 1H), 4.95 (d, J=3.4 Hz, 1H), 4.66 (d, J=3.9 Hz,1H), 4.64 (d, J=3.4 Hz, 1H), 4.06 (dd, J=9.5, 3.4 Hz, 1H), 4.01 (s, 3H),3.99 (s, 3H), 3.97-3.96 (m, 1H), 3.94 (d, J=10.1 Hz, 1H), 3.88 (d,J=10.1 Hz, 1H), 2.03 (s, 3H). LC/MS calcd. for C₂₄H₂₅N₃O₇ [(M+H)⁺] 468,obsd. 468.

Example Y Preparation of[(3S,3aR,6S,6aR)-3-[4-(thieno[3,2-d]pyrimidin-4-ylamino)phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

To a mixture of 4-chlorothieno[3,2-d]pyrimidine (85 mg, 0.5 mmol) and[(3S,3aR,6S,6aR)-3-(4-aminophenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate (149 mg, 0.53 mmol) in a single neck 50 mL RB flask was addediso-propanol (5 mL) at room temperature under an argon atmosphere. Theresulting suspension was heated to reflux (110° C., bath temperature)which produced a clear solution at ˜60° C. After refluxing for 1 h, someyellow precipitate formed and that was stirred for 4 h. It was cooled toroom temperature and the suspension was stored in the refrigerator for15 h.

The resulting light yellow solids were collected by filtration andwashed with EA. The solids were dried over weekend to afford 202 mg(98%) of[(3S,3aR,6S,6aR)-3-[4-(thieno[3,2-d]pyrimidin-4-ylamino)phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate as a light yellow solid. ¹H-NMR (DMSO-d6): δ 11.28 (s, 1H), 8.86(s, 1H), 8.47 (d, J=5.0 Hz, 1H), 7.58-7.55 (m, 3H), 7.09 (d, J=8.4 Hz,2H), 5.09 (d, J=3.4 Hz, 1H), 4.96 (d, J=2.8 Hz, 1H), 4.66-4.64 (m, 2H),4.06 (dd, J=9.5, 3.9 Hz, 1H), 3.99 (dd, J=10.1, 3.9 Hz, 1H), 3.92 (d,J=10.2 Hz, 1H), 3.88 (d, J=10.1 Hz, 1H), 2.03 (s, 3H). LC/MS calcd. forC₂₀H₁₉N₃O₅S [(M+H)⁺] 414, obsd. 414.

Example Z Synthesis ofN-[4-[[(3S,3aR,6S,6aR)-3-benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]phenyl]-6,7-dimethoxy-quinazolin-4-amine

Step 1: Preparation of(3S,3aR,6S,6aR)-3-benzyloxy-6-(4-nitrophenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan

To a solution of triphenylphosphine (1.96 g, 7.5 mmol) in THF (50 mL) ina 250 mL 2-neck RB flask was added di-isopropylazodicarboxylate (1.52 g,1.48 mL, 7.5 mmol) at 0-5° C. (ice+water) for 5 minutes under an argonatmosphere. The resulting light yellow suspension was stirred for 10-15minutes at this temperature. Then, a clear solution of 4-nitrophenol(695 mg, 5 mmol) in THF (40 mL) was added drop-wise over 5 minutes.After 2 minutes, the cooling bath was removed to allow the reactionmixture to warm to room temperature where it was stirred for 10-15minutes.

Then, a solution of isosorbide 2-benzyl ether (1.42 g, 6 mmol) (preparedfollowing the literature procedure, Carbohydrate Research 1994, 261,255-266) in THF (36 mL) was slowly added followed by the neattriethylamine (759 mg, 1.05 mL, 7.5 mmol) at room temperature. Theresulting light yellow suspension was stirred for 48 h by which time TLC(1:1, Hex:EA) analysis of the reaction mixture indicated the appearanceof a new spot. Then, the solvent was removed under vacuum and the cruderesidue was purified using an ISCO (330 g) column chromatography toafford 1.7 g (98%) of(3S,3aR,6S,6aR)-3-benzyloxy-6-(4-nitrophenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furanas a light brown viscous oil. LC/MS calcd. for C₁₉H₁₉NO₆ [(M−H)⁻] 356,obsd. 356.

Step 2: Preparation of4-[[(3S,3aR,6S,6aR)-3-benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]aniline

To a mixture of zinc dust (3.3 g, 50 mmol) and ammonium chloride (4.1 g,75 mmol) in a 250 mL single neck RB flask was added first a solution of(3S,3aR,6S,6aR)-3-benzyloxy-6-(4-nitrophenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan(1.7 g, 4.75 mmol) in methanol (50 mL) followed by water (25 mL) at roomtemperature under an argon atmosphere. It was exothermic reaction afterthe addition of methanol solution. Cement colored clusters formed afterthe addition of water. It was stirred for 2 h and then the reactionmixture was heated with a heat gun.

After being stirred for another 1 h at room temperature, TLC analysis ofthe mixture indicated the absence of starting material. The excess zincdust was filtered off and the solid cake was washed with methanol andwater. The solvent was removed under vacuum and the organic compound wasextracted into EA (2×50 mL) while the combined extracts were washed withbrine solution. The organic layer was dried over anhydrous MgSO₄,filtration and concentration gave the crude oil which was purified usingan ISCO (120 g) column chromatography to obtain 1.3 g (79%) of4-[[(3S,3aR,6S,6aR)-3-benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]anilineas a light brown oil. LC/MS calcd. for C₁₉H₂₁NO₄ [(M−H)⁻] 326, obsd.326.

Step 3: Preparation ofN-[4-[[(3S,3aR,6S,6aR)-3-benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]phenyl]-6,7-dimethoxy-quinazolin-4-amine

To a suspension of 4-chloro-6,7-dimethoxyquinazoline (336 mg, 1.5 mmol)in a 100 mL single neck RB flask in iso-propanol (30 mL) was added asolution of4-[[(3S,3aR,6S,6aR)-3-benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]aniline(654 mg, 2 mmol) in iso-propanol (15 mL) at room temperature under anargon atmosphere. The resulting ash suspension was heated to reflux(110° C., bath temperature) which produced a clear light brown solutionwhen the temperature reached ˜90° C. Within few minutes some yellowprecipitate started to form which was stirred for 4 h.

Then, it was cooled to room temperature and later it was stored in therefrigerator for 1 h. The resulting light yellow solids were collectedby filtration and washed with iso-propanol. The solids were dried overweekend to obtain 660 mg (85%) ofN-[4-[[(3S,3aR,6S,6aR)-3-benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]phenyl]-6,7-dimethoxy-quinazolin-4-amine.TLC analysis (1:1, Hex:EA) indicated the presence of some impurity.Then, it was triturated with hot EA and the solids were collected byfiltration to obtain 400 mg (52%) of pureN-[4-[[(3S,3aR,6S,6aR)-3-benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]phenyl]-6,7-dimethoxy-quinazolin-4-amineas off-white solid. ¹H-NMR (DMSO-d6): δ 11.35 (s, 1H), 8.75 (s, 1H),8.32 (s, 1H), 7.58-755 (m, 2H), 7.4-7.37 (m, 6H), 7.09 (d, J=8.9 Hz,2H), 4.9 (d, J=2.4 Hz, 1H), 4.72 (d, J=4.2 Hz, 1H), 4.62 (d, J=3.9 Hz,1H), 4.59 (s, 2H), 4.56 (d, J=11.9 Hz, 1H), 4.09 (d, J=3.4 Hz, 1H), 4.02(dd, J=10.2, 4.2 Hz, 1H), 4.01 (s, 3H), 3.99 (s, 3H), 3.97-3.84 (m, 2H).LC/MS calcd. for C₂₉H₂₉N₃O₆ [(M+H)⁺] 516, obsd. 516.

Example AA Synthesis ofN-[4-[[(3S,3aR,6S,6aR)-3-benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-vi]oxy]-3-chloro-phenyl]-6,7-dimethoxy-quinazolin-4-amine

Step 1: Preparation of(3S,3aR,6S,6aR)-3-benzyloxy-6-(2-chloro-4-nitrophenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan

To a solution of triphenylphosphine (5.9 g, 22.5 mmol) in THF (150 mL)in a 500 mL 3-neck RB flask was added di-isopropylazodicarboxylate (4.55g, 4.43 mL, 22.5 mmol) at 0-5° C. (ice+water) for 5-10 minutes under anargon atmosphere. The resulting light yellow suspension was stirred for10-15 minutes at this temperature. Then, a clear solution of2-chloro-4-nitrophenol (2.6 g, 15 mmol) in THF (100 mL) was addeddrop-wise over 5-10 minutes. After 2 minutes, the cooling bath wasremoved to allow the reaction mixture to warm to room temperature whereit was stirred for 10-15 minutes.

Then, a solution of isosorbide 2-benzyl ether (4.25 g, 18 mmol)(prepared following the literature procedure, Carbohydrate Research1994, 261, 255-266) in THF (100 mL) was slowly added followed by theneat triethylamine (2.28 g, 3.2 mL, 22.5 mmol) at room temperature. Theresulting light yellow suspension was stirred for 48 h by which time TLC(1:1, Hex:EA) analysis of the reaction mixture indicated the appearanceof a new spot. Then, the solvent was removed under vacuum and the cruderesidue was purified using an ISCO (330 g) column chromatography toafford 5.29 g (90%) of(3S,3aR,6S,6aR)-3-benzyloxy-6-(2-chloro-4-nitrophenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furanas a light brown viscous oil. LC/MS calcd. for C₁₉H₁₈ClNO₆[(M−H)⁻] 390,obsd. 390.

Step 2: Preparation of4-[[(3S,3aR,6S,6aR)-3-benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-3-chloro-aniline

To a solution of(3S,3aR,6S,6aR)-3-benzyloxy-6-(2-chloro-4-nitrophenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan(5.29 g, 13.5 mmol) in methanol (150 mL) in a 500 mL single neck RBflask were added an excess of zinc dust (9.81 g, 150 mmol) and ammoniumchloride (12.03 g, 225 mmol). Then, water (25 mL) was added at roomtemperature under an argon atmosphere. It was exothermic reaction afterthe addition of water. Cement colored clusters formed after the additionof water. It was stirred for 2 h and then the reaction mixture washeated with a heat gun.

After being stirred for another 1 h at room temperature, TLC analysis ofthe mixture indicated the absence of starting material. The excess zincdust was filtered off and the solid cake was washed with methanol andwater. The solvent was removed under vacuum and the organic compound wasextracted into EA (2×100 mL) while the combined extracts were washedwith brine solution. The organic layer was dried over anhydrous MgSO₄,filtration and concentration gave 4.79 g (98%) of4-[[(3S,3aR,6S,6aR)-3-benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-3-chloro-anilineas a light brown oil. LC/MS calcd. for C₁₉H₂₀ClNO₄[(M−H)⁻]360, obsd.360.

Step 3: Preparation ofN-[4-[[(3S,3aR,6S,6aR)-3-benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-3-chloro-phenyl]-6,7-dimethoxy-quinazolin-4-amine

To a solution of4-[[(3S,3aR,6S,6aR)-3-benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-3-chloro-aniline(1.45 g, 4 mmol) in iso-propanol (90 mL, heated with heat gun todissolve) in a 250 mL single neck RB flask was added a solid4-chloro-6,7-dimethoxyquinazoline (673 mg, 3 mmol) at room temperatureunder an argon atmosphere. The resulting suspension was heated to reflux(110° C., bath temperature) which produced a clear light brown solutionwhen the temperature reached ˜90° C. Within few minutes some yellowprecipitate started to form which was stirred for 4 h.

Then, it was cooled to room temperature and the resulting light yellowsolids were collected by filtration and washed with iso-propanol. Thesolids were dried to obtain 880 mg ofN-[4-[[(3S,3aR,6S,6aR)-3-benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-3-chloro-phenyl]-6,7-dimethoxy-quinazolin-4-amine.TLC analysis (1:1, Hex:EA) indicated the presence of some impurity.Then, it was attempted to dissolve in hot methanol, but it was notdissolved completely. Then, the suspension was stored in the freezer for15 h and the solids were collected by filtration to obtain 780 mg (47%)of pureN-[4-[[(3S,3aR,6S,6aR)-3-benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-3-chloro-phenyl]-6,7-dimethoxy-quinazolin-4-aminea light yellow solid. ¹H-NMR (DMSO-d6): δ 11.35 (s, 1H), 8.81 (s, 1H),8.38 (s, 1H), 7.9 (s, 1H), 7.64 (d, J=8.9 Hz, 1H), 7.4-7.28 (m, 7H), 5.0(d, J=2.2 Hz, 1H), 4.74 (d, J=4.2 Hz, 1H), 4.64 (d, J=4.2 Hz, 1H), 4.59(s, 2H), 4.58 (d, J=12.0 Hz, 1H), 4.1 (d, J=3.0 Hz, 1H), 4.04 (d, J=4.2Hz, 1H), 4.02 (s, 3H), 3.99 (s, 3H), 3.94-3.92 (m, 1H) 3.87 (dd, J=10.2,4.2 Hz, 1H). LC/MS calcd. for C₂₉H₂₈ClN₃O₆ [(M+H)⁺] 551, obsd. 551.

Example BB Synthesis of[(3S,3aR,6S,6aR)-3-[2-chloro-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

Step 1: Preparation of[(3S,3aR,6S,6aR)-3-(2-chloro-4-nitrophenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

To a colorless solution of(3S,3aR,6S,6aR)-6-(2-chloro-4-nitro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol(1.05 g, 3.5 mmol) in dichloromethane (30 mL) in a 100 mL single neck RBflask were added first acetyl chloride (353 mg, 319 uL, 4.5 mmol)followed by the neat triethylamine (911 mg, 1.25 mL, 9 mmol) at 0-5° C.under an argon atmosphere. The resulting light brown solution wasallowed to warm to room temperature without removing the cooling bathand then it was stirred for 15 h at room temperature by which time TLC(1:1, Hex:EA) analysis of the reaction mixture indicated the appearanceof a new spot.

Then, it was diluted with water and the organic compound was extractedinto dichloromethane (2×50 mL). The combined organic extracts werewashed with brine solution and dried over anhydrous MgSO₄. Filtrationand concentration gave the crude light brown oil which was purifiedusing an ISCO (120 g) column chromatography to obtain 1.14 g (95%) of[(3S,3aR,6S,6aR)-3-(2-chloro-4-nitrophenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetateas a light yellow colored paste. LC/MS calcd. for C₁₄H₁₄ClNO₇ [(M−H)⁻]342, obsd. 342.

Step 2: Preparation of[(3S,3aR,6S,6aR)-3-(4-amino-2-chloro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

To a solution of[(3S,3aR,6S,6aR)-3-(2-chloro-4-nitro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate (1.14 g, 3.3 mmol) in methanol (40 mL) in a single neck 100 mLRB flask were added an excess zinc dust (2.15 g, 33 mmol) and ammoniumchloride (2.64 g, 49.5 mmol) followed by water (20 mL) was added at roomtemperature under an argon atmosphere. It was an exothermic reactionafter the addition of water. The reaction mixture was stirred for 30minutes and then heated with a heat gun. Then, it was stirred foranother 2.5 h at room temperature at which time TLC analysis of themixture indicated the absence of starting material.

The excess zinc dust was filtered off and the solid cake was washed withEA and water. The solvent was removed under vacuum and the organiccompound was extracted into EA (3×50 mL) while the combined extractswere washed with brine solution. The organic layer was dried overanhydrous MgSO₄, filtration and concentration gave the crude oil whichwas purified using an ISCO (220 g) column chromatography to obtain 880mg (84%) of[(3S,3aR,6S,6aR)-3-(4-amino-2-chloro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate as a viscous colorless oil. LC/MS calcd. for C₁₄H₁₆ClNO₅[(M−H)⁻] 312, obsd. 312.

Step 3: Preparation of[(3S,3aR,6S,6aR)-3-[2-chloro-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

To a suspension of 4-chloro-6,7-dimethoxyquinazoline (337 mg, 1.5 mmol)in iso-propanol (35 mL) in a single neck 100 mL RB flask was added asolution of[(3S,3aR,6S,6aR)-3-(4-amino-2-chloro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate (627 mg, 2.0 mmol) in iso-propanol (10 mL) at room temperatureunder an argon atmosphere. The resulting suspension was heated to reflux(110° C., bath temperature) which produced a clear solution at ˜80° C.Within a few minutes some yellow precipitate started to form which wasstirred for 4 h at reflux.

Then, it was cooled to room temperature and the resulting light yellowsolids were collected by filtration and washed with EA. After airdrying, 750 mg (100%) of[(3S,3aR,6S,6aR)-3-[2-chloro-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate was isolated as a light yellow solid. ¹H-NMR (DMSO-d6): δ 11.49(s, 1H), 8.82 (s, 1H), 8.37 (s, 1H), 7.89 (d, J=2.2 Hz, 1H), 7.68 (dd,J=8.4, 2.2 Hz, 1H), 7.35-7.33 (m, 2H), 5.10 (d, J=3.4 Hz, 1H), 5.04 (s,1H), 4.69-4.66 (m, 2H), 4.07-4.04 (m, 2H), 4.01 (s, 3H), 3.99 (s, 3H),3.97-3.95 (m, 1H), 3.89 (d, J=7.8 Hz, 1H), 2.04 (s, 3H). LC/MS calcd.for C₂₄H₂₄ClN₃O₇ [(M+H)⁺] 502, obsd. 502.

Example CC Preparation of[(3S,3aR,6S,6aR)-3-[2-chloro-4-(thieno[3,2-d]pyrimidin-4-ylamino)phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

To a mixture of 4-chlorothieno[3,2-d]pyrimidine (256 mg, 1.5 mmol) and[(3S,3aR,6S,6aR)-3-(4-amino-2-chloro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate(530 mg, 1.7 mmol) in a single neck 100 mL RB flask was addediso-propanol (25 mL) at room temperature under an argon atmosphere. Itgave mostly a clear solution at room temperature with a few solidparticles in the bottom which dissolved at reflux. After 1 h reflux(110° C., bath temperature), a light yellow precipitate formed and itwas stirred for 4 h.

The light yellow suspension was diluted with EA (˜10 mL) during refluxand then cooled to room temperature. The resulting light yellow solidswere collected by filtration and washed with EA. After air drying, 595mg (89%) of[(3S,3aR,6S,6aR)-3-[2-chloro-4-(thieno[3,2-d]pyrimidin-4-ylamino)phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate was isolated as a light yellow solid. ¹H-NMR (DMSO-d6): δ 11.23(s, 1H), 8.89 (s, 1H), 8.49 (d, J=5.6 Hz, 1H), 7.89 (d, J=2.8 Hz, 1H),7.63 (d, J=8.9 Hz, 1H), 7.58 (d, J=5.0 Hz, 1H), 7.35 (d, J=8.4 Hz, 1H),5.1 (d, J=3.4 Hz, 1H), 5.04 (s, 1H), 4.68-4.65 (m, 2H), 4.06 (dd,J=10.1, 3.9 Hz, 1H), 3.99-3.95 (m, 2H), 3.89 (d, J=9.5 Hz, 1H), 2.04 (s,3H). LC/MS calcd. for C₂₀H₁₈ClN₃O₅S [(M+H)⁺] 448, obsd. 448.

Example DD Synthesis of[(3S,3aR,6S,6aR)-3-[2-chloro-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate

Step 1: Preparation of[(3S,3aR,6S,6aR)-3-(2-chloro-4-nitro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate

To a colorless solution of(3S,3aR,6S,6aR)-6-(2-chloro-4-nitro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol(3.01 g, 10 mmol) in dichloromethane (60 mL) in a 100 mL single neck RBflask were added first benzoyl chloride (1.68 g, 1.4 mL, 12 mmol) thenfollowed by an excess of triethylamine (2.53 g, 3.48 mL, 25 mmol) at0-5° C. under argon atmosphere. The resulting light brown solution waswarmed to room temperature without removing the cooling bath and thenstirred for 36 h at which time TLC (1:1, Hex:EA) analysis of thereaction mixture indicated the appearance of a new less polar spot.

Then, it was diluted with water and the organic compound was extractedinto dichloromethane. The combined organic extracts were washed withbrine solution and dried over anhydrous MgSO₄. Filtration andconcentration gave the crude light brown oil which was purified using anISCO (220 g) column chromatography to afford 3.8 g (94%) of[(3S,3aR,6S,6aR)-3-(2-chloro-4-nitro-phenoxy)-2,33a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate as a viscous lightbrown oil. LC/MS calcd. for C₁₉H₁₆ClNO₇ [(M−H)⁻] 404, obsd. 404.

Step 2: Preparation of[(3S,3aR,6S,6aR)-3-(4-amino-2-chloro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate

To a solution of[(3S,3aR,6S,6aR)-3-(2-chloro-4-nitro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate (3.04 g, 7.5 mmol) in methanol (70 mL) in a 250 mL single neckRB flask were added an excess zinc dust (4.9 g, 75 mmol) and ammoniumchloride (6.02 g, 112.5 mmol) followed by water (35 mL) at roomtemperature under an argon atmosphere. It was an exothermic reactionafter the addition of water. The reaction mixture was heated with a heatgun twice at 30 minute intervals.

Then, it was stirred for a total 3-4 h at room temperature by which timeTLC analysis of the mixture indicated the presence of additionalstarting material. Then, the reaction mixture was heated to 60° C. andstirred for 1.5 h. The reaction mixture was cooled to room temperatureand the excess zinc dust was filtered off using cotton plug while thesolid cake was washed with methanol and water. The filtrate was removedunder vacuum and the aqueous layer was saturated with the solid NaCl.Then, the organic compound was extracted with EA (3×50 mL) and thecombined extracts were washed with brine solution. The organic layer wasdried over anhydrous MgSO₄, filtration and concentration yielded a crude2.4 g (85%) of[(3S,3aR,6S,6aR)-3-(4-amino-2-chloro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate as a light brown oil which was directly used for the next stepwithout purification. LC/MS calcd. for C₁₉H₁₈ClNO₅ [(M−H)⁻] 374, obsd.374.

Step 3: Preparation of[(3S,3aR,6S,6aR)-3-[2-chloro-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate

To a mixture of 4-chloro-6,7-dimethoxyquinazoline (562 mg, 2.5 mmol) and[(3S,3aR,6S,6aR)-3-(4-amino-2-chloro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate(1.4 g, 3.7 mmol) in a 100 mL single neck RB flask was addediso-propanol (40 mL) at room temperature under an argon atmosphere. Theresulting suspension was heated to reflux (110° C., bath temperature)which gave a clear solution when the temperature reached 95° C. After 30minutes reflux, a light yellow precipitate formed and it was stirred for6 h.

The reaction mixture (suspension) was diluted with EA at reflux andcooled to room temperature. The resulting light yellow solids werecollected by filtration and washed with EA. After air drying, 959 mg(70%) of[(3S,3aR,6S,6aR)-3-[2-chloro-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate was isolated as a light yellow solid. ¹H-NMR (DMSO-d6): δ 11.45(s, 1H), 8.84 (s, 1H), 8.32 (s, 1H), 8.0 (d, J=7.3 Hz, 2H), 7.87 (d,J=2.8 Hz, 1H), 7.69-7.66 (m, 2H), 7.55 (t, J=7.8 Hz, 2H), 7.39 (d, J=8.4Hz, 1H), 7.33 (s, 1H), 5.37 (d, J=2.8 Hz, 1H), 5.09 (d, J=2.2 Hz, 1H)4.85-4.83 (m, 2H), 4.13 (d, J=3.4 Hz, 1H), 4.11 (d, 3.4 Hz, 1H), 4.09(d, J=3.4 Hz, 1H), 4.06 (d, J=10.1 Hz, 1H), 4.01 (s, 3H), 3.99 (s, 3H).LC/MS calcd. for C₂₉H₂₆ClN₃O₇ [(M+H)⁺] 564, obsd. 564.

Example EE Preparation of[(3S,3aR,6S,6aR)-3-[2-chloro-4-(thieno[3,2-d]pyrimidin-4-ylamino)phenoxy]-2,3,3a,5,6,6a-hexahydrofuro3,2-b]furan-6-yl benzoate

To a mixture of 4-chlorothieno[3,2-d]pyrimidine (171 mg, 1.0 mmol) and[(3S,3aR,6S,6aR)-3-(4-amino-2-chloro-phenoxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate(420 mg, 1.1 mmol) in a 50 mL single neck RB flask was addediso-propanol (30 mL) at room temperature under an argon atmosphere. Theresulting suspension was heated to reflux (110° C., bath temperature)which gave a clear solution when the temperature reached 100° C. After 3h reflux, a white precipitate started to form which was stirred for 6 h.It was cooled to 80° C. and stirred for another 15 h at thistemperature.

Then, the reaction mixture (suspension) was diluted with EA (5 mL) andcooled to room temperature. The resulting light yellow solids werecollected by filtration and washed with EA. After air drying, 448 mg(88%) of[(3S,3aR,6S,6aR)-3-[2-chloro-4-(thieno[3,2-d]pyrimidin-4-ylamino)phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate was isolated as a light yellow solid. ¹H-NMR (DMSO-d6): δ 11.4(s, 1H), 8.9 (s, 1H), 8.5 (d, J=5.0 Hz, 1H), 8.0-7.98 (m, 2H), 7.9 (d,J=2.2 Hz, 1H), 7.69-7.64 (m, 2H), 7.6 (d, J=5.6 Hz, 1H), 7.55-7.52 (m,2H), 7.37 (d, J=8.4 Hz, 1H), 5.37 (d, J=3.4 Hz, 1H), 5.09 (d, J=2.8 Hz,1H) 4.85-4.83 (m, 2H), 4.12 (d, J=3.4 Hz, 1H), 4.11 (dd, J=9.5, 3.4 Hz,1H), 4.06 (d, J=10.1, 1H), 4.02 (dd, J=10.1, 1.1 Hz, 1H). LC/MS calcd.for C₂₅H₂₀ClN₃O₅S [(M+H)⁺] 510, obsd. 510.

Example FF Synthesis of[(3S,3aR,6S,6aR)-3-[2-[(1-methylsulfonyl-4-piperidyl)amino]pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

Step 1: Preparation of(3S,3aR,6S,6aR)-6-(2-methylsulfanylpyrimidin-4-yl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol

To a solution of triphenylphosphine (3.94 g, 15 mmol) in THF (60 mL) ina 250 mL 2-neck RB flask was added di-isopropylazodicarboxylate (3.04 g,2.96 mL, 15 mmol) at 0-5° C. (ice+water) for 5 minutes under an argonatmosphere. The resulting light yellow suspension was stirred for 10-15minutes at this temperature. A solution of 2-methylthiopyrimidin-4-ol(1.42 g, 10 mmol) in THF (80 mL, heated to dissolve) was added drop-wiseover 5 minutes which resulted in the formation of a very thicksuspension. After 2 minutes, the cooling bath was removed to allow thereaction mixture to warm to room temperature and it was stirred for 10minutes.

Then, a solution of isosorbide (1.75 g, 12 mmol) in THF (50 mL) wasslowly added followed by the neat DIPEA (1.94 g, 2.62 mL, 15 mmol) atroom temperature. The resulting light yellow suspension was stirred for48 h. During this period (after 15 h), it turned into a light brownsolution and after 48 h TLC (1:1, Hex:EA) analysis of the reactionmixture indicated the appearance of a new spot. The solvent was removedunder vacuum and the LCMS analysis of the reaction mixture indicated thepresence of the desired mass. The crude residue was purified using anISCO (220 g) column chromatography to obtain 2.43 g (90%) of(3S,3aR,6S,6aR)-6-(2-methylsulfanylpyrimidin-4-yl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-olas a white low melting solid (paste). ¹H-NMR (DMSO-d6): δ 8.15 (d, J=5.7Hz, 1H), 6.02 (d, J=5.6 Hz, 1H), 5.30 (d, J=3.4 Hz, 1H), 5.16 (d, 3.9Hz, 1H), 4.64 (d, J=3.7 Hz, 1H), 4.48 (d, J=3.4 Hz, 1H), 4.15 (br, s,1H), 4.02 (dd, J=10.1, 3.4 Hz, 1H), 3.93 (d, J=9.8 Hz, 1H), 3.81 (dd,J=10.0, 3.4 Hz, 1H), 3.74 (d, J=9.9 Hz, 1H), 2.56 (s, 3H). LC/MS calcd.for C₁₁H₁₄N₂O₄S [(M+H)⁺] 271, obsd. 271.

Step 2: Preparation of[(3S,3aR,6S,6aR)-3-(2-methylsulfanylpyrimidin-4-yl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

To a colorless solution of(3S,3aR,6S,6aR)-6-(2-methylsulfanylpyrimidin-4-yl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol(2.4 g, 8.8 mmol) in dichloromethane (80 mL) in a 250 mL 2-neck RB flaskwere added first acetyl chloride (902 mg, 817 uL, 11.5 mmol) followed byan excess of triethylamine (2.32 g, 3.2 mL, 23 mmol) at 0-5° C. under anargon atmosphere. The resulting light brown solution was warmed to roomtemperature without removing cooling bath and then stirred for 15 h atwhich time TLC (1:1, Hex:EA) analysis of the reaction mixture indicatedthe appearance of a new spot.

Then, it was diluted with water and the organic compound was extractedinto dichloromethane (2×100 mL). The combined organic extracts werewashed with brine solution and dried over anhydrous MgSO₄. Filtrationand concentration yielded crude light brown oil which was purified usingan ISCO (220 g) column chromatography to obtain 2.61 g (95%) of[(3S,3aR,6S,6aR)-3-(2-methylsulfanylpyrimidin-4-yl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate as a viscous light yellow oil.

Step 3: Preparation of[(3S,3aR,6S,6aR)-3-(2-methylsulfinylpyrimidin-4-yl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]acetate

To a solution of[(3S,3aR,6S,6aR)-3-(2-methylsulfanylpyrimidin-4-yl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]acetate (2.6 g, 8.3 mmol) in dichloromethane (100 mL) in a 250 mL 2-neckRB flask was added mcpba (2.24 g, 13 mmol, 77%) at 0-5° C. (ice+water)in one portion under an argon atmosphere. The resulting colorlesssolution was stirred for 4 h at 0° C. to r.t. (the cooling bath was notremoved) at which time TLC analysis of the mixture indicated thepresence of two polar spots and the disappearance of starting material.

Then, the reaction mixture was diluted with water and the two layerswere separated and the aqueous layer was extracted one more time withdichloromethane. The combined extracts were washed with saturated sodiumbicarbonate solution (2×150 mL) followed by water and brine solution.The organic layer was dried over anhydrous MgSO₄, filtered andconcentrated to obtain 2.9 g of paste which was purified using an ISCO(220 g) column chromatography to obtain 1.59 g (58%) of[(3S,3aR,6S,6aR)-3-(2-methylsulfinylpyrimidin-4-yl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]acetate (more polar) as a white solid and 437 mg of[(3S,3aR,6S,6aR)-3-(2-methylsulfonylpyrimidin-4-yl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]acetate (less polar) as a white solid.

Step 4: Preparation oftert-butyl-4-[[4-[[(3S,3aR,6S,6aR)-6-acetoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furane-3-yl]oxy]pyrimidine-2-yl]amino]piperidine-1-carboxylate

To a solution of[(3S,3aR,6S,6aR)-3-(2-methylsulfinylpyrimidin-4-yl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]acetate (1.59 g, 4.8 mmol) in NMP (20 mL) in a 100 mL 2-neck RB flaskwere added 4-aminopiperidine-1-carboxylic acid tert-butyl ester (1.94 g,9.68 mmol) followed by DIPEA (1.25 g, 1.68 mL, 9.68 mmol) at roomtemperature under an argon atmosphere. The resulting cloudy solution washeated to 120° C. (bath temperature) which gave a clear solution(slightly yellowish). Then, the reaction mixture was stirred for 3 h atthis temperature by which time it turned into a brown solution whichindicated that the reaction was complete. Also, TLC (1:1, Hex:EA)analysis of the mixture indicated the presence of a new spot anddisappearance of the starting material. The reaction mixture was cooledto room temperature and diluted with water. After water addition, awhite precipitate formed, but it completely dissolved after stirring for15 minutes.

Then, the organic compound was extracted into EA (3×100 mL). Thecombined extracts were washed with water (2×200 mL, to remove NMP) andbrine solution. The organic layer was dried over anhydrous MgSO₄,filtered and concentrated to obtain the crude white paste which waspurified using an ISCO (220 g) column chromatography to afford 2.0 g(90%) oftert-butyl-4-[[4-[[(3S,3aR,6S,6aR)-6-acetoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furane-3-yl]oxy]pyrimidine-2-yl]amino]piperidine-1-carboxylateas a white amorphous solid.

Step 5: Preparation of[(3S,3aR,6S,6aR)-3-[2-(4-piperidylamino)pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

To a solution oftert-butyl-4-[[4-[[(3S,3aR,6S,6aR)-6-acetoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furane-3-yl]oxy]pyrimidine-2-yl]amino]piperidine-1-carboxylate(2.0 g, 4.3 mmol) in dichloromethane (40 mL) in a 100 mL 2-neck RB flaskwas added TFA (10 mL) at room temperature under an argon atmosphere. Theresulting light brown solution was stirred for 5 h at room temperatureby which time TLC analysis of the reaction mixture indicated the absenceof starting material. The solvent was removed under vacuum and theresidue was dissolved again in minimal amount of dichloromethane anddiluted with hexanes.

Then, the solvent was removed under vacuum and the residue was driedunder high vacuum to obtain 3.5 g (more than theoretical yield) of[(3S,3aR,6S,6aR)-3-[2-(4-piperidylamino)pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate as a viscous light brown oil.

Step 6: Preparation of[(3S,3aR,6S,6aR)-3-[2-[(1-methylsulfonyl-4-piperidyl)amino]pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

To a solution of[(3S,3aR,6S,6aR)-3-[2-(4-piperidylamino)pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate (3.5 mmol) in THF (57 mL) in a 100 mL 2-neck RB flask were addedmethanesulfonyl chloride (618 mg, 418 uL, 5.4 mmol) followed by an largeexcess of DIPEA (4.39 g, 5.92 mL, 34 mmol) at 0-5° C. under an argonatmosphere. The resulting light brown solution was warmed to roomtemperature without removing the cooling bath. The reaction mixture wasstirred for 6 h by which time TLC analysis of the mixture indicated thepresence of a new spot.

Then, the reaction mixture was quenched with water and the organiccompound was extracted into EA (2×100 mL). The combined extracts werewashed with brine solution and dried over anhydrous MgSO₄. Filtrationand concentration gave the crude product which completely dissolved inEA (˜5 mL) under hot conditions and then diluted with hexanes (˜10 mL).A precipitation developed at room temperature. After 15 h, the solidswere collected by filtration and washed with EA. After air drying, 1.18g of (76%) of[(3S,3aR,6S,6aR)-3-[2-[(1-methylsulfonyl-4-piperidyl)amino]pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate was isolated as an off-white solid. ¹H-NMR (DMSO-d6): δ 8.05 (d,J=6.4 Hz, 1H), 7.02 (br, s, 1H), 6.02 (d, J=6.2 Hz, 1H), 5.32 (s, 1H),5.12 (d, J=3.4 Hz, 1H), 4.68 (d, J=3.4 Hz, 1H), 4.54 (d, J=3.4 Hz, 1H),4.06-3.71 (m, 5H), 3.6-3.5 (m, 2H), 2.92 (s, 3H), 2.9-2.81 (m, 2H), 2.03(s, 3H), 2.01-1.89 (m, 2H), 1.6-1.45 (m, 2H). LC/MS calcd. forC₁₈H₂₆N₄O₇S [(M+H)^(+])443, obsd. 443.

Example GG Preparation of[(3S,3aR,6S,6aR)-3-[2-[(1-tolylsulfonyl-4-piperidvl)amino]pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

To a light brown solution of[(3S,3aR,6S,6aR)-3-[2-(4-piperidylamino)pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate (0.5 mmol) in THF (5 mL) in a 25 mL 2-neck RB flask was added anexcess of DIPEA (610 mg, 822 uL, 4.7 mmol) at 0-5° C. under an argonatmosphere. After 5 minutes, the cooling bath was removed and the lightbrown mixture was warmed to room temperature. After 30 minutes stirringat room temperature, solid p-toluenesulfonyl chloride (142 mg, 0.75mmol) was added. It slowly became a clear and light brown solution andit was stirred for 15 h by which time TLC analysis (1:1, Hex:EA) of thereaction mixture indicated the presence of new spot.

The reaction mixture was quenched with water and the organic compoundwas extracted into EA (2×50 mL). The combined extracts were washed withbrine solution and dried over anhydrous MgSO₄. Filtration andconcentration gave the crude product which was purified using an ISCO(80 g) column chromatography to afford 220 mg (85%) of[(3S,3aR,6S,6aR)-3-[2-[(1-tolylsulfonyl-4-piperidyl)amino]pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate as an off-white solid. ¹H-NMR (CDCl₃): δ 8.0 (d, J=6.3 Hz, 1H),7.75 (d, J=8.2 Hz, 2H), 7.45 (d, J=8.0 Hz, 2H), 6.02 (d, J=6.4 Hz, 1H),5.35 (s, 1H), 5.25 (s, 1H), 4.75 (s, 1H), 4.65 (s, 1H), 4.06-3.81 (m,5H), 3.8-3.62 (m, 4H), 2.65-2.43 (m, 5H), 2.14 (s, 3H), 1.7-1.55 (m,2H). LC/MS calcd. for C₂₄H₃₀N₄O₇S [(M+H)⁺] 519, obsd. 519.

Example HH Preparation of[(3S,3aR,6S,6aR)-3-[2-[[1-(2,2-dimethylpropanoyl)-4-piperidyl]amino]pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

To a solution of[(3S,3aR,6S,6aR)-3-[2-(4-piperidylamino)pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate (218 mg, 0.6 mmol) in dichloromethane (10 mL) in a 25 mL 2-neckRB flask were added first an excess of DIPEA (387 mg, 523 uL, 3.0 mmol)and then pivaloyl chloride (85 mg, 0.7 mmol) at room temperature underan argon atmosphere. The resulting light yellow solution was stirred for15 h at room temperature by which time TLC analysis of the reactionmixture indicated the presence of a new spot. Then, the reaction mixturewas diluted with water and dichloromethane and the two layers separated.The aqueous layer was extracted with dichloromethane (50 mL).

The combined extracts were washed with brine solution. The organic layerwas dried over anhydrous MgSO₄, filtered and concentrated to obtain thecrude oil which was purified using an ISCO (40 g) column chromatographyto obtain 111 mg (41%) of[(3S,3aR,6S,6aR)-3-[2-[[1-(2,2-dimethylpropanoyl)-4-piperidyl]amino]pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate as a white solid. ¹H-NMR (CDCl₃): δ 8.15 (d, J=6.5 Hz, 1H), 6.05(d, J=6.6 Hz, 1H), 5.48 (s, 1H), 5.23 (d, J=3.4 Hz, 1H), 4.74 (d, J=3.4Hz, 1H), 4.6 (d, J=3.5 Hz, 1H), 4.4-4.28 (m, 2H), 4.12-3.81 (m, 5H),3.18-3.05 (m, 2H), 2.24-2.02 (m, 5H), 1.5-1.25 (m, 11H). LC/MS calcd.for C₂₂H₃₂N₄O₆ [(M+H)⁺] 449, obsd. 449.

Example II Preparation of[(3S,3aR,6S,6aR)-3-[2-[(4-fluorophenyl)methylamino]pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate

To a solution of[(3S,3aR,6S,6aR)-3-(2-methylsulfinylpyrimidin-4-yl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]acetate (240 mg, 0.73 mmol) in NMP (5 mL) in a 25 mL 2-neck RB flaskwere added 4-fluorobenzylamine (188 mg, 1.5 mmol) followed by DIPEA (194mg, 261 uL, 1.5 mmol) at room temperature under an argon atmosphere. Theresulting colorless solution was heated to 120° C. (bath temperature)and stirred for 2 h. During this period, it slowly turned into a lightbrown solution. LCMS analysis of the reaction mixture indicated thepresence of a new peak and disappearance of the starting material peak.

Then, the reaction mixture was cooled to room temperature and dilutedwith water and then, the organic compound was extracted into EA (2×50mL). The combined extracts were washed with water (2×100 mL, to removeNMP) and brine solution. The organic layer was dried over anhydrousMgSO₄, filtered and concentrated to obtain a crude white paste that waspurified using an ISCO (40 g) column chromatography to isolate 210 mg(74%) of[(3S,3aR,6S,6aR)-3-[2-[(4-fluorophenyl)methylamino]pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]acetate as a light brown paste. ¹H-NMR (CDCl₃): δ 8.13 (d, J=6.5 Hz,1H), 7.42-7.23 (m, 2H), 7.12-6.98 (m, 2H), 6.11 (d, J=6.4 Hz, 1H), 5.48(s, 1H), 5.23 (d, J=3.4 Hz, 1H), 4.69 (d, J=3.9 Hz, 1H), 4.61 (d, J=3.5Hz, 1H), 4.51-4.50 (m, 2H), 4.12-3.82 (m, 4H), 2.05 (s, 3H). LC/MScalcd. for C₁₉H₂₀FN₃O₅ [(M+H)⁺] 390, obsd. 390.

Example JJ Synthesis of[(3S,3aR,6S,6aR)-3-[2-[(1-methylsulfonyl-4-piperidyl)amino]pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate

Step 1: Preparation of[(3S,3aR,6S,6aR)-3-(2-methylsulfanylpyrimidin-4-yl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate

To a colorless solution of(3S,3aR,6S,6aR)-6-(2-methylsulfanylpyrimidin-4-yl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol(1.72 g, 6.4 mmol) in dichloromethane (60 mL) in a 100 mL 2-neck RBflask were added first benzoyl chloride (1.4 g, 1.16 mL, 10 mmol)followed by an excess of triethylamine (2.02 g, 2.78 mL, 20 mmol) at0-5° C. under an argon atmosphere. The resulting colorless solution waswarmed to room temperature without removing cooling bath and thenstirred for 15 h at room temperature by which time TLC (1:1, Hex:EA)analysis of the reaction mixture indicated the appearance of a new spot.

Then, it was diluted with water and the organic compound was extractedinto dichloromethane (2×100 mL). The combined organic extracts werewashed with brine solution and dried over anhydrous MgSO₄. Filtrationand concentration yielded a crude light brown oil that was purifiedusing an ISCO (220 g) column chromatography to obtain 1.91 g (80%) of[(3S,3aR,6S,6aR)-3-(2-methylsulfanylpyrimidin-4-yl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate as a white paste.

Step 2: Preparation of[(3S,3aR,6S,6aR)-3-(2-methylsulfonylpyrimidin-4-yl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]benzoate

To a solution of[(3S,3aR,6S,6aR)-3-(2-methylsulfanylpyrimidin-4-yl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]benzoate (1.12 g, 3 mmol) in dichloromethane (40 mL) in a 100 mL 2-neckRB flask was added mcpba (1.38 g, 8 mmol, 77%) at 0-5° C. (ice+water) inone portion under an argon atmosphere. The resulting colorless solutionwas stirred for 4 h at 0° C. to r.t. (cooling bath was warmed to r.t.)by which time TLC analysis of the mixture indicated the presence of twopolar spots and the disappearance of starting material.

Then, the reaction mixture was diluted with water and the two layersseparated while aqueous layer extracted again with dichloromethane. Thecombined extracts were washed with saturated sodium bicarbonate solution(2×150 mL) followed by water and brine solution. The organic layer wasdried over anhydrous MgSO₄, filtered and concentrated to obtain crudeoil that was purified using an ISCO (220 g) column chromatography toobtain 644 mg (53%) of[(3S,3aR,6S,6aR)-3-(2-methylsulfonylpyrimidin-4-yl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]benzoate as a white solid.

Step 3: Preparation oftert-butyl-4-[[4-[[(3S,3aR,6S,6aR)-6-benzoyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furane-3-yl]oxy]pyrimidine-2-yl]amino]piperidine-1-carboxylate

To a solution of[(3S,3aR,6S,6aR)-3-(2-methylsulfonylpyrimidin-4-yl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]benzoate (102 mg, 0.25 mmol) in DMF (3 mL) in a 25 mL sealed tube wereadded 4-aminopiperidine-1-carboxylic acid tert-butyl ester (103 mg, 0.5mmol) followed by an excess of triethylamine (101 mg, 139 uL, 1.0 mmol)at room temperature under an argon atmosphere. The rubber septum wasreplaced with a screw cap and the light cloudy solution was heated to140° C. (bath temperature).

Then, the reaction mixture was stirred for 3 h at this temperature bywhich time it turned into a brown solution. TLC (1:1, Hex:EA) analysisof the aliquot, which was hydrolyzed with water and EA indicated thepresence of a new spot. The reaction mixture was cooled to roomtemperature and diluted with water. Then, the organic compound wasextracted into EA (3×30 mL). The combined extracts were washed withwater (2×100 mL) and brine solution. The organic layer was dried overanhydrous MgSO₄, filtered and concentrated to obtain the crude whitecompound which was purified using an ISCO (120 g) column chromatographyto obtain 117 mg (88%) oftert-butyl-4-[[4-[[(3S,3aR,6S,6aR)-6-benzoyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furane-3-yl]oxy]pyrimidine-2-yl]amino]piperidine-1-carboxylateas a white amorphous solid.

Step 4: Preparation of[(3S,3aR,6S,6aR)-3-[2-(4-piperidylamino)pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate

To a solution oftert-butyl-4-[[4-[[(3S,3aR,6S,6aR)-6-benzoyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furane-3-yl]oxy]pyrimidine-2-yl]amino]piperidine-1-carboxylate(117 mg, 0.22 mmol) in dichloromethane (10 mL) in a 50 mL 2-neck RBflask was added TFA (1 mL) at room temperature under an argonatmosphere. The resulting light yellow solution was stirred for 4 h atroom temperature by which time TLC analysis of the reaction mixtureindicated the absence of the starting material.

Then, the solvent was removed under vacuum and the residue was dissolvedagain in minimal amount of dichloromethane and diluted with toluene. Thesolvent was removed under vacuum and the residue was dried under highvacuum to obtain the crude[(3S,3aR,6S,6aR)-3-[2-(4-piperidylamino)pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate as a viscous light brown oil.

Step 5: Preparation of[(3S,3aR,6S,6aR)-3-[2-[(1-methylsulfonyl-4-piperidyl)amino]pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate

To a solution of[(3S,3aR,6S,6aR)-3-[2-(4-piperidylamino)pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate (0.22 mmol) in THF (10 mL) in a 50 mL 2-neck RB flask wereadded methanesulfonyl chloride (38 mg, 26 uL, 0.33 mmol) followed by alarge excess of triethylamine (101 mg, 139 uL, 1.0 mmol) at 0-5° C.under an argon atmosphere. Within 5 minutes, a white precipitate formedwhich was warmed to room temperature without removing the cooling bathand the reaction mixture was stirred for 15 h at room temperature.

Then, the reaction mixture was diluted with water and the organiccompound was extracted into EA (2×20 mL). The combined extracts werewashed with brine solution and dried over anhydrous MgSO₄. Filtrationand concentration produced a crude product that was purified using anISCO (80 g) column chromatography to afford 89 mg (80%) of[(3S,3aR,6S,6aR)-3-[2-[(1-methylsulfonyl-4-piperidyl)amino]pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]benzoate as a white solid. ¹H-NMR (DMSO-d6): δ 8.06 (d, J=5.6 Hz, 1H),7.98 (dd, J=7.8, 1.1 Hz, 2H), 7.69 (m, 1H), 7.54 (t, J=6.7 Hz, 2H), 7.02(br, d, 1H), 6.05 (d, J=2.8 Hz, 1H), 5.45 (s, 1H), 5.34 (d, J=2.8 Hz,1H), 4.79-4.77 (m, 2H), 4.07-4.05 (m, 2H), 4.02 (d, J=10.1 Hz, 1H),3.96-3.95 (m, 1H), 3.82-3.75 (m, 1H), 3.54-3.52 (m, 2H), 2.92-2.84 (m,5H), 1.95-1.93 (m, 2H), 1.55-1.53 (m, 2H). LC/MS calcd. for C₂₃H₂₈N₄O₇S[(M+H)⁺] 505, obsd. 505.

Example KK Preparation of[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]5-bromo-2-methylsulfanyl-pyrimidine-4-carboxylate

To a solution of triphenylphosphine (577 mg, 2.2 mmol) in THF (15 mL) ina 100 mL 2-neck RB flask was added di-isopropylazodicarboxylate (445 mg,433 uL, 2.2 mmol) at 0-5° C. (ice+water) for 5 minutes under an argonatmosphere. The resulting light yellow suspension was stirred for 10-15minutes at this temperature. Then, a solution of5-bromo-2-methylsulfanyl-pyrimidine-4-carboxylic acid (360 mg, 1.45mmol) in THF (12 mL) was added drop-wise over 3 minutes. After 2minutes, the cooling bath was removed to allow the reaction mixture towarm to room temperature and it was stirred for 10-15 minutes.

Then, a solution of isosorbide (254 mg, 1.74 mmol) in THF (10 mL) wasslowly added followed by the neat DIPEA (284 mg, 383 uL, 2.2 mmol) atroom temperature. It became a clear solution within 5 minutes afterwhich it was stirred for 36 h. TLC (1:1, Hex:EA) analysis of thereaction mixture indicated the appearance of a new spot. The solvent wasremoved under vacuum and the crude residue was purified using an ISCO(220 g) column chromatography to obtain 409 mg (75%) of[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]5-bromo-2-methylsulfanyl-pyrimidine-4-carboxylate as a light yellowsolid. ¹H-NMR (DMSO-d6): δ 8.86 (s, 1H), 5.37 (s, 1H), 5.28 (d, J=3.9Hz, 1H), 4.65 (d, J=3.9 Hz, 1H), 4.44 (d, J=2.8, 1H), 4.12 (br, s, 1H),3.94 (d, J=1.7 Hz, 1H), 3.77 (dd, J=8.4, 2.8 Hz, 1H), 3.71 (d, J=8.4 Hz,1H), 3.31 (d, J=12.9S Hz, 1H), 2.53 (s, 3H). LC/MS calcd. forC₁₂H₁₃BrN₂O₅S [(M+H)^(+])377, obsd. 377.

Example LL Preparation of[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl](2S)-2-[(2-chloro-6-methyl-benzoyl)amino]-3-[4-[(2,6dichlorobenzoyl)amino]phenyl]propanoate

To a solution of triphenylphosphine (393 mg, 1.5 mmol) in THF (5 mL) ina 25 mL 2-neck RB flask was added di-isopropylazodicarboxylate (303 mg,295 uL, 1.5 mmol) at 0-5° C. (ice+water) for 2-3 minutes under an argonatmosphere. The resulting light yellow suspension was stirred for 10minutes at this temperature. Then, a solution of(2S)-2-[(2-chloro-5-methyl-benzoyl)amino]-3-[4-[(2,6-dichlorobenzoyl)amino]phenyl]propanoicacid (200 mg, 0.5 mmol) (for preparation, see WO1999/10312) in THF (3mL) was added drop-wise for 5 minutes. After 2 minutes, the cooling bathwas removed to allow the reaction mixture to warm to room temperaturewhere it was stirred for 10 minutes.

Then, a solution of isosorbide (88 mg, 0.6 mmol) in THF (2 mL) was addedslowly followed by the neat DIPEA (194 mg, 261 uL, 1.5 mmol) at roomtemperature. The resulting orange color suspension was stirred for 48 h.During this period, it turned to a light yellow solution and after 48 h,TLC analysis of the reaction mixture indicated the appearance of a newand less polar spot, but it was close to triphenylphosphine oxide.

Then, the solvent was removed under vacuum and the crude residue waspurified using an ISCO (120 g) column chromatography to obtain 284 mg(90%) of[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl](2S)-2-[(2-chloro-6-methyl-benzoyl)amino]-3-[4-[(2,6-dichlorobenzoyl)amino]phenyl]propanoateas a white solid. ¹H-NMR (CDCl₃): δ 7.63 (d, J=8.6 Hz, 2H), 7.4-7.2 (m,7H), 7.1-7.02 (m, 1H), 6.25 (d, J=7.8 Hz, 1H), 5.25-5.1 (m, 3H), 4.55(d, J=3.4 Hz, 2H), 4.0-3.92 (m, 4H), 3.2 (d, J=7.5 Hz, 2H), 2.05 (s,3H). LC/MS calcd. for C₃₀H₂₇C₁₃N₂O₇ [(M+H)⁺] 633, obsd. 633.

Example MM Preparation of[(3S,3aR,6S,6aR)-3-acetoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl](2S)-2-[(2-chloro-6-methyl-benzoyl)amino]-3-[4-[(2,6-dichlorobenzoyl)amino]phenyl]propanoate

To a solution of triphenylphosphine (1.57 g, 6.0 mmol) in THF (50 mL) ina 250 mL 3-neck RB flask was added di-isopropylazodicarboxylate (1.21 g,1.18 mL, 6.0 mmol) at 0-5° C. (ice+water) for 4-5 minutes under an argonatmosphere. The resulting light yellow suspension was stirred for 10minutes at this temperature. Then, a solution of(2S)-2-[(2-chloro-5-methyl-benzoyl)amino]-3-[4-[(2,6-dichlorobenzoyl)amino]phenyl]propanoicacid (2.02 g, 4.0 mmol) (for preparation, see WO1999/10312) in THF (50mL) was added drop-wise for 5 minutes. After 2 minutes, the cooling bathwas removed to allow the reaction mixture to warm to room temperaturewhere it was stirred for 10 minutes.

Then, a solution of isosorbide 2-acetate (for preparation, see referenceSynthesis, 1987, 174) (903 mg, 4.8 mmol) in THF (40 mL) was added slowlyfollowed by the neat DIPEA (775 mg, 1.05 mL, 6.0 mmol) at roomtemperature. The resulting orange color solution was stirred for 48 h bywhich time it turned to a clear light brown solution and TLC analysis ofthe reaction mixture indicated the appearance of a new spot. Then, thesolvent was removed under vacuum and the crude residue was purifiedusing an ISCO (220 g) column chromatography to obtain 2.16 g (80%) of[(3S,3aR,6S,6aR)-3-acetoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl](2S)-2-[(2-chloro-6-methyl-benzoyl)amino]-3-[4-[(2,6-dichlorobenzoyl)amino]phenyl]propanoateas a white solid. ¹H-NMR (CDCl₃): δ 7.65 (d, J=8.5 Hz, 2H), 7.4-7.2 (m,7H), 7.1-7.02 (m, 1H), 6.24 (d, J=7.8 Hz, 1H), 5.25-5.1 (m, 2H), 4.6 (d,J=3.4 Hz, 2H), 4.0-3.92 (m, 4H), 3.2 (d, J=7.5 Hz, 2H), 2.15 (s, 3H),2.05 (s, 3H). LC/MS calcd. for C₃₂H₂₉Cl₃N₂O₈ [(M+H)⁺] 675, obsd. 675.

Example NN Preparation of[(3S,3aR,6S,6aR)-3-benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl](2S)-2-[(2-chloro-6-methyl-benzoyl)amino]-3-[4-[(2,6-dichlorobenzoyl)amino]phenyl]propanoate

To a solution of triphenylphosphine (1.18 g, 4.5 mmol) in THF (3 mL) ina 250 mL 3-necked RB flask was added di-isopropylazodicarboxylate (910mg, 886 uL, 4.5 mmol) at 0-5° C. (ice+water) for 4-5 minutes under anargon atmosphere. The resulting light yellow suspension was stirred for10 minutes at this temperature. Then, a solution of(2S)-2-[(2-chloro-5-methyl-benzoyl)amino]-3-[4-[(2,6-dichlorobenzoyl)amino]phenyl]propanoicacid (1.52 g, 3.0 mmol) (for preparation, see WO1999/10312) in THF (30mL) was added drop-wise for 5 minutes. After 2 minutes, the cooling bathwas removed to allow the reaction mixture to warm to room temperaturewhere it was stirred for 10 minutes.

Then, a solution of isosorbide 2-benzyl ether (851 mg, 3.6 mmol) in THF(20 mL) was added slowly followed by the neat DIPEA (582 mg, 784 uL, 4.5mmol) at room temperature. The resulting light brown suspension wasstirred for 36 h by this time it gave a clear light brown solution andTLC analysis of the reaction mixture indicated the appearance of a newand less polar spot. Then, the reaction mixture was diluted with water(100 mL) and the organic compound was extracted into EA (75 mL). Theorganic extracts were washed with 4:1 ratio of water and methanolmixture to remove the triphenylphosphine oxide. The organic layer waswashed with brine solution and dried over anhydrous MgSO₄, filtrationand concentration gave the crude amorphous solid which was purifiedusing an ISCO (220 g) column chromatography to afford 1.86 g (86%) of[(3S,3aR,6S,6aR)-3-benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl](2S)-2-[(2-chloro-6-methyl-benzoyl)amino]-3-[4-[(2,6-dichlorobenzoyl)amino]phenyl]propanoateas a white solid. ¹H-NMR (CDCl₃): δ 7.51 (d, J=8.6 Hz, 2H), 7.4-7.2 (m,12H), 7.1-7.02 (m, 1H), 6.25 (d, J=7.8 Hz, 1H), 5.25-5.15 (m, 2H),4.51-4.49 (m, 4H), 4.1 (d, J=3.4 Hz, 1H), 4.0-3.75 (m, 4H), 3.25-3.2 (m,1H), 2.2 (s, 3H). LC/MS calcd. for C₃₇H₃₃C₁₃N₂O₇ [(M+H)⁺] 723, obsd.723.

Example 00 Preparation of[(3S,3aR,6S,6aR)-3-acetoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl](2S)-2-[(2-chloro-6-methyl-benzoyl)amino]-3-[4-(1,3,4-trimethyl-2,6-dioxo-pyrimidin-5-yl)phenyl]propanoate

To a solution of triphenylphosphine (1.97 g, 7.5 mmol) in THF (50 mL) ina 250 mL 3-neck RB flask was added di-isopropylazodicarboxylate (1.52 g,1.48 mL, 7.5 mmol) at 0-5° C. (ice+water) for 5 minutes under an argonatmosphere. The resulting light yellow suspension was stirred for 10-15minutes at this temperature. Then, a solution of(2S)-2-[(2-chloro-6-methyl-benzoyl)amino]-3-[4-(1,3,4-trimethyl-2,6-dioxo-pyrimidin-5-yl)phenyl]propanoicacid (2.35 g, 5 mmol) (For preparation, see U.S. Ser. No.00/638,0387B 1) in THF (70 mL, heated to dissolve) was added drop-wisefor 5 minutes. After 2 minutes, the cooling bath was removed to allowthe reaction mixture to warm to room temperature where it was stirredfor 10-15 minutes.

Then, a solution of isosorbide 2-acetate (1.13 g, 5 mmol) in THF (40 mL)was added followed by the neat DIPEA (969 mg, 1.3 mL, 7.5 mmol) at roomtemperature. The resulting light yellow solution was stirred for 48 h bywhich time it turned to a clear colorless solution and TLC analysis ofthe reaction mixture indicated the appearance of a new spot. Then, thesolvent was removed under vacuum and the crude residue was purifiedusing an ISCO (220 g) column chromatography to obtain 2.53 g (79%) of[(3S,3aR,6S,6aR)-3-acetoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl](2S)-2-[(2-chloro-6-methyl-benzoyl)amino]-3-[4-(1,3,4-trimethyl-2,6-dioxo-pyrimidin-5-yl)phenyl]propanoateas a white solid. ¹H-NMR (DMSO-d6): δ 9.08 (d, J=7.8 Hz, 1H), 7.34 (d,J=7.8 Hz, 2H), 7.28-7.24 (m, 2H), 7.17 (d, J=6.6 Hz, 1H), 7.12 (d, J=7.8Hz, 2H), 5.13 (d, J=3.6 Hz, 1H), 5.04 (d, J=3.4 Hz, 1H), 4.779-4.76 (m,1H), 4.49 (d, J=4.1 Hz, 1H), 4.46 (d, J=3.9 Hz, 1H), 3.95 (dd, J=10.8,3.6 Hz, 1H), 3.91 (dd, J=10.8, 3.6 Hz, 1H), 3.85 (t, J=9.6 Hz, 1H), 3.41(s, 3H), 3.32 (d, J=13.8 Hz, 1H), 3.22 (s, 3H), 3.21 (dd, J=13.4, 5.4Hz, 1H), 3.01 (dd, J=13.8, 10.2 Hz, 1H), 2.11 (s, 3H), 2.06 (s, 3H),2.02 (s, 3H). LC/MS calcd. for C₃₂H₃₄ClN₃O₉ [(M+H)⁺] 640, obsd. 640.

Example PP Preparation of[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl](2S)-2-[(2-chloro-6-methyl-benzoyl)amino]-3-[4-(1,3,4-trimethyl-2,6-dioxo-pyrimidin-5-yl)phenyl]propanoate

To a solution of triphenylphosphine (787 mg, 3 mmol) in THF (20 mL) in a100 mL 3-neck RB flask was added di-isopropylazodicarboxylate (606 mg,591 uL, 3 mmol) at 0-5° C. (ice+water) for 5 minutes under an argonatmosphere. The resulting light yellow suspension was stirred for 10-15minutes at this temperature. Then, a solution of(2S)-2-[(2-chloro-6-methyl-benzoyl)amino]-3-[4-(1,3,4-trimethyl-2,6-dioxo-pyrimidin-5-yl)phenyl]propanoicacid (940 mg, 2 mmol) (For preparation, see U.S. Ser. No.00/638,0387B 1) in THF (30 mL, heated to dissolve) was added drop-wisefor 5 minutes. After 2 minutes, the cooling bath was removed to allowthe reaction mixture to warm to room temperature where it was stirredfor 10-15 minutes.

Then, a solution of isosorbide (351 mg, 2.4 mmol) in THF (15 mL) wasadded followed by the neat DIPEA (388 mg, 523 uL, 3 mmol) at roomtemperature. The resulting light yellow solution was stirred for 48 h bywhich time it turned to a clear colorless solution and TLC analysis ofthe reaction mixture indicated the appearance of a new spot. Then, thesolvent was removed under vacuum and the crude residue was dissolved inethyl acetate at hot condition and then diluted with hexanes. Theresulting solution was stored in the freezer for 15 h. The white solidswere collected by filtration and washed with hexanes. This solid residue(1.5 g) was then purified using an ISCO (80 g) column chromatography toobtain 950 mg (80%) of[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl](2S)-2-[(2-chloro-6-methyl-benzoyl)amino]-3-[4-(1,3,4-trimethyl-2,6-dioxo-pyrimidin-5-yl)phenyl]propanoateas a white solid. ¹H-NMR (DMSO-d6): δ 9.07 (d, J=7.8 Hz, 1H), 7.33 (d,J=7.3 Hz, 2H), 7.28-7.24 (m, 2H), 7.16 (d, J=6.6 Hz, 1H), 7.11 (d, J=7.8Hz, 2H), 5.25 (d, J=4.2 Hz, 1H), 5.09 (d, J=3.6 Hz, 1H), 4.82-4.79 (m,1H), 4.45 (d, J=3.6 Hz, 1H), 4.36 (d, J=3.6 Hz, 1H), 4.1 (br, s, 1H),3.88 (dd, J=11.4, 4.2 Hz, 1H), 3.79 (d, J=10.8 Hz, 1H), 3.73 (dd, J=8.9,2.9 Hz, 1H), 3.67 (d, J=9.6 Hz, 1H), 3.41 (s, 3H), 3.33 (s, 3H), 3.21(dd, J=13.4, 5.4 Hz, 1H), 3.01 (dd, J=13.8, 10.2 Hz, 1H), 2.11 (s, 3H),2.02 (s, 3H). LC/MS calcd. for C₃₀H₃₂ClN₃O₈ [(M+H)⁺] 598, obsd. 598.

Example QQ: Macrophage Migration Inhibitory Factor (MIF) as a DrugTarget Assay Conditions

a) PBMC Isolation:

-   -   Heparinized blood (10 ml) was diluted with equal volume of        phosphate buffer saline (PBS). To the Ficoll solution (5 ml) add        5 ml of blood:PBS mixture and centrifuge at 1600 rpm for 30        minutes. Take the buffy coat and wash with PBS at 1200 rpm for 5        minutes (twice). After two wash with PBS, the PBMCs were washed        with RPMI medium. The PBMC were counted and plated in 96 well        plates (1×10⁶ cells/well).

b) Expression of TNF-α and IL-113 in PBMCs in the Presence of MIFInhibitors:

-   -   After overnight incubation, the cells were treated with        different concentration of MIF inhibitors. After 6 hr, cells        were treated with LPS (10 ng/ml) and LPS+MIF combination (10        ng/ml) and further incubated for overnight. PBMCs treated with        10 ng/ml of LPS and MIF in the presence of different        concentrations of test compounds. After the incubation period,        the supernatant were collected and human TNF-α and IL-1β were        determined using the ELISA kits (R&D Systems).

TABLE 1 Inhibition and IC₅₀ values of TNF-α and IL-1β (LPS-stimulatedPBMCs) TNF-α IC₅₀ IL-1β Example (uM) IC₅₀ (uM) A >1.0 >1.0 B >10 >10C >0.5 >0.5 D >10 >10 E >0.5 >0.5 F >10 >10 G >0.1 >0.1 H >10 >10I >0.5 >0.5 J >0.1 >0.1 K >0.1 >0.1 L >1.0 >1.0 M >0.5 >0.5 N >0.1 >10O >0.1 >10 P >10 >10 Q >0.1 >0.1 R >0.1 >0.1 S >0.5 >0.5

Example RR: EGFR as a Drug Target Assay Conditions

The IC50s of the compounds on EGFR activity were determined using theLuminescent ATP/ADP detection assay system. Briefly, the assay methodmeasures ADP formed from EGFR kinase activity using luminescence derivedfrom ATP-Luciferase detection system. Purified EGFR kinase was incubatedwith different concentrations of test compound in the kinase reactionbuffer for 10 min. The reaction was stopped by depleting the unused ATPin the kinase reaction buffer using the depletion buffer for 40 min. Thelevels of ADP generated during the kinase reaction was detected bymeasuring the luminescence using the Luciferase system.

TABLE 2 Inhibitory effect of new compounds against EGFR kinase ExampleEGFR IC₅₀ (uM) T >0.1 U >0.1 V Inactive W Inactive X >0.5 Y >1.0 Z >0.1AA >0.1 BB >0.5 CC >0.5 DD >0.1 EE >0.5 FF Inactive GG Inactive HHInactive II Inactive JJ Inactive KK Inactive

The compounds of the present invention are indicated for the inhibition,treatment or prevention of diseases mediated by MIF. MIF is aproinflammatory cytokine as a result several diseases mediated by MIF,e.g., inflammatory diseases, autoimmune diseases, neuropathic disorders,neurodegenerative diseases, cerebrovascular diseases, central nervousinfections, traumatic diseases, colitis, heart and vascular conditions,liver and kidney diseases, respiratory diseases, allergic diseases,fibrotic diseases, metabolic disorders, infectious diseases, nephritis,sarcoidosis, transplantation, angiogenesis and cancers. Particularlyarthritis, rheumatoid arthritis, osteoarthritis, psoriatic arthritis,lupus syndromes, systemic lupus erythematosus, sclerosis, multiplesclerosis, atherosclerosis, arteriosclerosis, systemic sclerosis,reactive arthritis, osteoporosis, brain disorders, Alzheimer's disease,colitis, inflammatory bowel disease, Crohn's disease, ulcerativedisease, peptic ulceration, gastritis, oseophagitis, ischaemia,ischaemic heart disease, myocardial infraction, stroke, pulmonaryhypertension, cirrhosis, chronic pulmonary disease, acute respiratorydistress syndrome, asthma, asthma bronchitis, psoriasis,dermatomyositis, allergic rhinitis, diabetes, diabetic retinopathy,insulin-dependent diabetes, diabetes mellitus, obesity, endometriosis,testicular dysfunction, Lyme disease, viral diseases, parasiticdiseases, fungal diseases, malaria, sepsis, septic shock, interstitialnephritis, angiogenesis, multiple myeloma, leukemia, non-small cell lungcancer, breast cancer, brain cancer, prostate cancer, pancreas cancer,skin cancer, metastatic bone disease and other forms of metastasis.

The compounds of the present invention are also indicated for theinhibition, treatment or prevention of diseases mediated by the EGFR.Diseases mediated by EGFR are primary or metastatic cancers, cervicalcancer, solid tumors, tumor growth, lymphoma, B-cell lymphoma, T-celllymphoma, premalignant conditions, benign tumors, benigndysproliferative disorders, renal carcinoma, esophageal cancer, stomachcancer, colon cancer, lung cancer, non-small cell lung cancer, melanoma,nasopharyngeal cancer, osteocarcinoma, ovarian cancer, breast cancer,brain cancer, renal carcinoma, bladder carcinoma, uterine cancer,prostate cancer, pancreas cancer, skin cancer, leukemia, tumorneovascularization, angiomas, myelodysplastic diseases, and metastaticbone disease and other forms of metastasis.

The compounds of the present invention are also useful for theinhibition, treatment or prevention of diseases that mediated by thekinases. Diseases mediated by kinases are primary or metastatic cancers,cervical cancer, solid tumors, tumor growth, lymphoma, B-cell lymphoma,T-cell lymphoma, premalignant conditions, benign tumors, benigndysproliferative disorders, renal carcinoma, esophageal cancer, stomachcancer, colon cancer, lung cancer, small cell lung cancer, melanoma,nasopharyngeal cancer, osteocarcinoma, ovarian cancer, breast cancer,renal carcinoma, bladder carcinoma, uterine cancer, prostate cancer,skin cancer, leukemia, tumor neovascularization, angiomas,myelodysplastic diseases.

The prodrug compounds of the alpha4 beta1 and alpha4 beta7 integrinantagonists of the present invention are indicated for the inhibition,treatment or prevention of diseases mediated by integrin receptors.Integrins, especially alpha4 beta1 and alpha4 beta7, are cell surfacereceptors as a result several diseases mediated by these integrinreceptors, e.g., inflammatory diseases, autoimmune diseases, respiratorydiseases, allergic diseases, fibrotic diseases, angiogenesis andcancers. Particularly arthritis, rheumatoid arthritis, osteoarthritis,sclerosis, multiple sclerosis, atherosclerosis, inflammatory boweldisease, Crohn's disease, ulcerative disease, asthma, asthma bronchitis,breast cancer, brain cancer, metastatic bone disease and other forms ofmetastasis.

Although this invention has been described with a certain degree ofparticularity, it is to be understood that the present disclosure hasbeen made only by way of illustration and that numerous changes in thedetails of construction and arrangement of parts may be resorted towithout departing from the spirit and the scope of the invention.

What is claimed is:
 1. A compound according to Formula II

wherein: R₂ is hydrogen, hydroxyl, or a group substituted ornon-substituted and straight or branched selected from -oxy(alkyl),-oxy(alkene), alkyl, -alkenyl, -alkynyl, —OC(O)(alkyl),—OC(O)(haloalkyl), and —OC(O)(aryl); R₄ is cyano, amino, aminoalkyl-,alkyl, -alkyl(aryl), substituted or non-substituted aryl, if substitutedthen substituted with 1, 2, 3, 4 or 5 substituents which can be the sameor different and are independently selected from the group consisting ofhalo, hydroxyl, cyano, oxo, amino, aminoalkyl-, alkyl(arylhalide),(amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy,-alkylhydroxy, -alkyl(aryl), aryloxy-, -alkyl(aryl),(alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, C(O)OC_(n),—NR^(a)R^(b); deuterium, hydroxyl-alkyl-, hydroxyl-aryl-, amino,aminoalkyl; R₅ is C(O)R^(c) or cyano; R^(a) is an alkyl, alkoxy(alkyl),substituted or unsubstituted monocyclic or bicyclic aryl or heteroaryl,or alkyl(aryl), the substituted or unsubstituted monocyclic or bicyclicheteroaryl having 0, 1, 2 or 3 heteroatoms independently selected fromN, O, or S; R^(b) is hydrogen or halo; R^(c) is hydrogen, or a group,substituted or unsubstituted, selected from straight or branched C₁ toC₃ alkyl, CF₃, alkoxy, cyano, aryl, and monocyclic or bicyclicheteroaryl having one to three heteroatoms independently selected fromO, S, and N and if substituted then substituted with 1, 2, 3, 4 or 5substituents which can be the same or different and are independentlyselected from the group consisting of halo, hydroxyl, cyano, oxo, amino,aminoalkyl-, ethoxy, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl,alkoxy-, hydroxy, -alkylhydroxy, -alkyl(aryl), aryloxy-, -alkyl(aryl),(alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, C(O)OC_(n),—NR^(a)R^(b); deuterium, hydroxyl-alkyl-, hydroxyl-aryl-, amino,aminoalkyl; Y is S or O; and n is 0, 1, 2, or
 3. 2. The compound ofclaim 5 wherein R₄ is selected from the group consisting of:


3. The compound of claim 5 wherein, R₄ is alkyl(aryl); R₅ is C(O)OC_(n);and n is 0, 1, 2, or
 3. 4. The compound of claim 5 wherein R₅ is:


5. A compound selected from the group consisting of: Name Ethyl4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-ethyl-2-oxo-1,2-dihydroquinoline-3-carboxylate Ethyl4-[[(3S,3aR,6S,6aR)-6-acetoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]oxy]-1-ethyl-2-oxo-1,2-dihydroquinoline-3-carboxylate Ethyl4-[[(3S,3aR,6S,6aR)-6-(2-chloroacetyl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]oxy]-1-ethyl-2-oxo-1,2-dihydroquinoline-3-carboxylate Ethyl4-[[(3S,3aS,6aR)-2,3,3a,6a-tetrahydrofuro[3,2-b]furan-3-yl]oxy]-1-ethyl-2-oxo-1,2-dihydroquinoline-3-carboxylate Ethyl4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylate Ethyl4-[[(3S,3aR,6S,6aR)-6-acetoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylate Ethyl4-[[(3S,3aR,6S,6aR)-6-(2-chloroacetyl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylateEthyl4-[[(3S,3aS,6aR)-2,3,3a,6a-tetrahydrofuro[3,2-b]furan-3-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylate Ethyl4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-[(4-fluorophenyl)methyl]-2-oxo-1,2-dihydroquinoline-3-carboxylateEthyl4-[[(3S,3aR,6S,6aR)-6-(2-chloroacetyl)oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]oxy]-1-[(4-fluorophenyl)methyl]-2-oxo-1,2-dihydroquinoline-3-carboxylate4-[[(3S,3aR,6S,6aR)-3-Hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile[(3S,3aR,6S,6aR)-3-[(1-Benzyl-3-cyano-2-oxo-4-quinolyl)oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] acetate[(3S,3aR,6S,6aR)-3-[(1-Benzyl-3-cyano-2-oxo-4-quinolyl)oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] 2-chloroacetate4-[[(3S,3aR,6S,6aR)-3-Hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-1-[(4-fluorophenyl)methyl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile[(3S,3aR,6S,6aR)-3-[[3-Cyano-1-[(4-fluorophenyl)methyl]-2-oxo-4-quinolyl]oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] acetate[(3S,3aR,6S,6aR)-3-[[3-Cyano-1-[(4-fluorophenyl)methyl]-2-oxo-4-quinolyl]oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] benzoate[(3S,3aR,6S,6aR)-3-[[3-Cyano-1-[(4-fluorophenyl)methyl]-2-oxo-4-quinolyl]oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] 2-chloroacetate4-[4-[[(3S,3aR,6S,6aR)-3-Hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-3-chloro-anilino]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carbonitrileEthyl4-[4-[[(3S,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-3-chloro-anilino]-1-benzyl-2-oxo-1,2-dihydroquinoline-3-carboxylate[(3S,3aR,6S,6aR)-3-[4-[(6,7-Dimethoxyquinazolin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] acetateN-[4-[[(3S,3aR,6S,6aR)-3-benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]phenyl]-6,7-dimethoxy-quinazolin-4-amineN-[4-[[(3S,3aR,6S,6aR)-3-benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-3-chloro-phenyl]-6,7-dimethoxy-quinazolin-4-amine(3S,3aR,6S,6aR)-6-[2-Chloro-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol[(3S,3aR,6S,6aR)-3-[2-Chloro-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] acetate[(3S,3aR,6S,6aR)-3-[2-Chloro-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] benzoate[(3S,3aR,6S,6aR)-3-[4-(Thieno[3,2-d]pyrimidin-4-ylamino)phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] acetate(3S,3aR,6S,6aR)-6-[2-Chloro-4-(thieno[3,2-d]pyrimidin-4-ylamino)phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol[(3S,3aR,6S,6aR)-3-[2-Chloro-4-(thieno[3,2-d]pyrimidin-4-ylamino)phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] acetate[(3S,3aR,6S,6aR)-3-[2-Chloro-4-(thieno[3,2-d]pyrimidin-4-ylamino)phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] benzoate(3S,3aR,6S,6aR)-6-[2-Chloro-4-[(2-methylsulfanylpyrimidin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol[(3S,3aR,6S,6aR)-3-[2-[(1-Methylsulfonyl-4-piperidyl)amino]pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] acetate[(3S,3aR,6S,6aR)-3-[2-[(1-Tolylsulfonyl-4-piperidyl)amino]pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] acetate[(3S,3aR,6S,6aR)-3-[2-[[1-(2,2-Dimethylpropanoyl)-4-piperidyl]amino]pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] acetate[(3S,3aR,6S,6aR)-3-[2-[(4-Fluorophenyl)methylamino]pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] acetate[(3S,3aR,6S,6aR)-3-[2-[(1-Methylsulfonyl-4-piperidyl)amino]pyrimidin-4-yl]oxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] benzoate[(3S,3aR,6S,6aR)-3-Acetoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]5-bromo-2-[(1- methylsulfonyl-4-piperidyl)amino]pyrimidine-4-carboxylate(3S,3aR,6S,6aR)-6-[4-[[2-[4-[[(3S,3aR,6S,6aR)-3-Hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-3-chloro-anilino]pyrimidin-4-yl]amino]-2-chloro-phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol[(3S,3aR,6S,6aR)-3-Hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl](2S)-2-[(2-chloro-6-methyl-benzoyl)amino]-3-[4-[(2,6-dichlorobenzoyl)amino]phenyl]propanoate[(3S,3aR,6S,6aR)-3-Acetoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl](2S)-2-[(2-chloro-6-methyl-benzoyl)amino]-3-[4-[(2,6-dichlorobenzoyl)amino]phenyl]propanoate[(3S,3aR,6S,6aR)-3-Benzyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl](2S)-2-[(2-chloro-6-methyl-benzoyl)amino]-3-[4-[(2,6-dichlorobenzoyl)amino]phenyl]propanoate[(3S,3aR,6S,6aR)-3-Acetoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl](2S)-2-[(2-chloro-6-methyl-benzoyl)amino]-3-[4-(1,3,4-trimethyl-2,6-dioxo-pyrimidin-5-yl)phenyl]propanoate[(3S,3aR,6S,6aR)-3-Hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl](2S)-2-[(2-chloro-6-methyl-benzoyl)amino]-3-[4-(1,3,4-trimethyl-2,6-dioxo-pyrimidin-5-yl)phenyl]propanoate


6. A pharmaceutical composition comprising therapeutically effectiveamounts of at least one compound of claim 1, or a pharmaceuticallyacceptable salt thereof, and at least one pharmaceutically acceptablecarrier.
 7. The pharmaceutical composition of claim 6, furthercomprising therapeutically effective amounts of one or more additionaltherapeutic agents.